cenb20190331

0001437749-19-010466.txt : 20190520 0001437749-19-010466.hdr.sgml : 20190520 20190520124716 ACCESSION NUMBER: 0001437749-19-010466 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 80 CONFORMED PERIOD OF REPORT: 20190331 FILED AS OF DATE: 20190520 DATE AS OF CHANGE: 20190520 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CEN BIOTECH INC CENTRAL INDEX KEY: 0001653821 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: Z4 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-55557 FILM NUMBER: 19838071 BUSINESS ADDRESS: STREET 1: 7405 TECUMSEH ROAD EAST STREET 2: SUITE 300 CITY: WINDSOR STATE: A6 ZIP: N8T 1G2 BUSINESS PHONE: 226-344-0660 MAIL ADDRESS: STREET 1: 7405 TECUMSEH ROAD EAST STREET 2: SUITE 300 CITY: WINDSOR STATE: A6 ZIP: N8T 1G2 10-Q 1 cenb20190331_10q.htm FORM 10-Q cenb20190331_10q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

FORM 10-Q

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2019

[ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from ___________ to ___________

Commission File Number 000-55557

CEN BIOTECH, INC.

(Exact name of registrant as specified in its charter)

Ontario, Canada	-
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
7405 Tecumseh Road East Suite 300 Windsor, Ontario Canada	N8T 1G2
(Address of principal executive offices)	(Zip code)

(519) 419-4958

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer [ ]	Accelerated filer [ ]
Non-accelerated filer [X]	Smaller reporting company [X]
Emerging growth company [X]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2 of the Exchange Act): Yes [ ] No [X]

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on

which registered

None

N/A

As of May 20, 2019, there were 25,548,363, shares of common stock, no par value per share (“common stock”), of the registrant outstanding.

TABLE OF CONTENTS

PART I

ITEM 1	CONDENSED CONSOLIDATED FINANCIAL STATEMENTS	3

ITEM 2	MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	4

ITEM 3	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	8

ITEM 4	CONTROLS AND PROCEDURES	8

PART II

ITEM 1	LEGAL PROCEEDINGS	9

ITEM 1A	RISK FACTORS	9

ITEM 2	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	10

ITEM 3	DEFAULTS UPON SENIOR SECURITIES	10

ITEM 4	MINE SAFETY DISCLOSURE	10

ITEM 5	OTHER INFORMATION	10

ITEM 6	EXHIBITS	11

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report includes “forward-looking statements” that represent our beliefs, projections and predictions about future events. There are statements in this quarterly report that are not historical facts. All statements other than statements of historical fact are “forward-looking statements,” including any projections of earnings, revenue or other financial items, any statements of the plans, strategies and objectives of management for future operations, any statements concerning proposed new projects or other developments, any statements regarding future economic conditions or performance, any statements of management’s beliefs, goals, strategies, intentions and objectives, and any statements of assumptions underlying any of the foregoing. These “forward-looking statements” can be identified by use of terminology such as “anticipate,” “believe,” “estimate,” “expect,” “hope,” “intend,” “may,” “plan,” “positioned,” “project,” “propose,” “should,” “strategy,” “will,” or any similar expressions, as well as statements in the future tense. These statements are necessarily subjective and involve known and unknown risks, uncertainties and other important factors that could cause our actual results, performance or achievements, or industry results, to differ materially from any future results, performance or achievements described in or implied by such statements.

Forward-looking statements are based on information available at the time those statements are made and management’s belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Although we believe that our assumptions underlying such forward-looking statements are reasonable, we do not guarantee our future performance, and our actual results may differ materially from those contemplated by these forward-looking statements. Our assumptions used for the purposes of the forward-looking statements made in the following information represent estimates of future events and are subject to uncertainty as to possible changes in economic, legislative, industry, and other circumstances, including the development of our lines of business and any products that we may manufacture or sell and our ability to raise additional funding sufficient to implement our strategy, as well as assumptions regarding Canadian and U.S. laws regarding the consumer or retail sale of marijuana products and accessories and the manufacture and distribution of such products and accessories, including zoning and banking regulations. We also assume that we will be able to raise additional capital to fund our operations while we develop a line of business to generate net revenues. As a result, the identification and interpretation of data and other information and their use in developing and selecting assumptions from and among reasonable alternatives require the exercise of judgment. In light of these numerous risks and uncertainties, we cannot provide any assurance that the results and events contemplated by our forward-looking statements contained in this quarterly report will in fact transpire. These forward-looking statements are not guarantees of future performance. You are cautioned to not place undue reliance on these forward-looking statements. We do not undertake any obligation to update or revise any forward-looking statements.

PART I

ITEM 1.

FINANCIAL STATEMENTS

Contents
	Page
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS:

Unaudited condensed consolidated balance sheets	F-1

Unaudited condensed consolidated statements of operations	F-2

Unaudited condensed consolidated statements of shareholders’ deficit	F-3

Unaudited condensed consolidated statements of cash flows	F-4

Notes to the unaudited condensed consolidated financial statements	F-5

CEN BIOTECH, INC. AND SUBSIDIARY

Condensed Consolidated Balance Sheets

(Unaudited)

	March 31, 2019			December 31, 2018
ASSETS
Current assets
Cash and cash equivalents	$	39,752		$	3,193

Property, plant and improvements
Property and equipment, net		161,913			166,509
Other assets
Operating lease right-of-use assets		251,110			-
Other receivable		417,904			418,905
Note receivable – related party		44,859			44,859
Advances to CEN Biotech Ukraine LLC – related party		905,328			875,328
Intangible assets, net		5,699,568			5,805,771

Total assets	$	7,520,434		$	7,314,565

LIABILITIES AND SHAREHOLDERS’ DEFICIT
Current liabilities
Accounts payable	$	206,521		$	206,521
Loans payable		10,113,095			10,107,205
Loans payable – related parties		1,361,550			1,360,806
Convertible notes payable		4,190,461			3,597,760
Convertible notes payable – related parties		926,368			926,368
Accrued interest		7,544,199			6,860,494
Accrued interest – related parties		1,032,171			946,227
Operating lease liabilities		40,683			-
Accrued expenses		446,432			402,377

Total current liabilities		25,861,480			24,407,758

Operating lease liabilities, less current portion		210,838			-
Patent acquisition liability		1,010,000			1,010,000
Convertible notes, less current portion		1,117,123			1,545,887
Convertible notes – related parties, less current portion		1,612,313			1,612,313

Total liabilities		29,811,754			28,575,958

Commitments and contingencies

Shareholders’ deficit
Common stock; unlimited authorized shares; 25,518,363 and 25,473,363 issued and outstanding as of March 31, 2019 and December 31, 2018, respectively. No par value.		-			-
Additional paid-in capital		14,606,510			14,393,660
Accumulated deficit		(36,897,830	)		(35,655,053	)
Total shareholders’ deficit		(22,291,320	)		(21,261,393	)

Total liabilities and shareholders’ deficit	$	7,520,434		$	7,314,565

See accompanying notes to financial statements.

F-1

CEN BIOTECH, INC. AND SUBSIDIARY

Condensed Consolidated Statements of Operations

(Unaudited)

	For the three months ended March 31,
	2019			2018

Operating expenses
Consulting fees	$	18,942		$	11,985
Consulting fees – related parties		31,200			31,200
Stock based compensation		167,400			167,400
General and administrative		187,685			441,839

Total operating expenses		405,227			652,424

Loss from operations		(405,227	)		(652,424	)

Other (expense) income
Interest expense		(701,888	)		(594,503	)
Interest expense – related parties		(113,213	)		(104,286	)
Interest income		2,045			-
Foreign exchange (loss) gain		(24,494	)		30,443

Other expense, net		(837,550	)		(668,346	)

Net loss	$	(1,242,777	)	$	(1,320,770	)

Net Loss Per Share:
Basic and diluted	$	(0.05	)	$	(0.05	)

Weighted Average Number of Shares Outstanding
Basic and diluted		25,495,863			25,153,061

See accompanying notes to financial statements.

F-2

CEN BIOTECH, INC. AND SUBSIDIARY

Condensed Consolidated Statements of Shareholders’ Deficit

(Unaudited)

			Common		Additional					Total
	Common		Shares		Paid-in		Accumulated			Shareholders’
	Shares		Amount		Capital		Deficit			Deficit

Balances, January 1, 2018		25,131,843	$	-	$	9,110,041	$	(28,124,692	)	$	(19,014,651	)

Patent acquisition liability modification		-		-		4,380,000		-			4,380,000

Stock-based compensation		-		-		167,400		-			167,400

Issuance of common stock – interest shares		43,400		-		26,908		-			26,908

Net loss		-		-		-		(1,320,770	)		(1,320,770	)

Balances, March 31, 2018		25,175,243	$	-	$	13,684,349	$	(29,445,462	)	$	(15,761,113	)

Balances, January 1, 2019		25,473,363	$	-	$	14,393,660	$	(35,655,053	)	$	(21,261,393	)

Stock-based compensation		-		-		167,400		-			167,400

Issuance of common stock – interest shares		45,000		-		45,450		-			45,450

Net loss		-		-		-		(1,242,777	)		(1,242,777	)

Balances, March 31, 2019		25,518,363	$	-	$	14,606,510	$	(36,897,830	)	$	(22,291,320	)

See accompanying notes to financial statements.

F-3

CEN BIOTECH, INC. AND SUBSIDIARY

Condensed Consolidated Statements of Cash Flows

(Unaudited)

	For the three months ended March 31,
	2019			2018
Cash flows from operating activities
Net loss	$	(1,242,777	)	$	(1,320,770	)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation		4,596			442
Amortization		106,203			106,203
Stock-based compensation – employees		167,400			167,400
Non-cash interest expense		701,885			561,910
Non-cash interest expense – related parties		113,214			104,286
Deferred lease expense		-			13,576
Foreign exchange loss (gain)		24,494			(30,443	)
Changes in operating assets and liabilities which provided (used) cash
Operating lease right-of-use assets		5,216			-
Other receivable		1,001			(146,018	)
Accounts payable		(957	)		14,770
Accounts payable – related parties		-			(7,585	)
Operating lease liabilities		(4,805	)		-
Accrued expenses		44,055			12,903
Net cash used in operating activities		(80,475	)		(523,326	)
Cash flows from investing activities
Advance on business acquisition		(30,000	)		-
Leasehold improvements in progress		-			(5,439	)
Net cash used in investing activities		(30,000	)		(5,439	)

Cash flows from financing activities
Issuance of loans payable		-			180,000
Repayment of loans payable		-			(130,000	)
Issuance of loans payable – related parties		-			225,000
Issuance of convertible notes		147,034			595,800

Net cash provided by financing activities		147,034			870,800

Net increase in cash and cash equivalents		36,559			342,035

Cash and cash equivalents, beginning of period		3,193			84,978

Cash and cash equivalents, end of period	$	39,752		$	427,013

Supplemental cash flows disclosures
Cash paid for interest	$	-		$	32,593

Non-cash transactions - investing and financing activities
Patent acquisition liability modification	$	-		$	4,380,000

See accompanying notes to financial statements.

F-4

CEN BIOTECH, INC. AND SUBSIDIARY

Notes to the Condensed Consolidated Financial Statements (Unaudited)

(All amounts are in US dollars unless otherwise stated.)

NOTE 1 – BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The accompanying unaudited interim condensed consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and with the rules and regulations of the United States Securities and Exchange Commission (the “SEC”) set forth in Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) which are, in the opinion of management, necessary to a fair statement of the results for the interim periods presented. Unaudited interim results are not necessarily indicative of the results for the full fiscal year. These financial statements should be read in conjunction with the condensed consolidated financial statements of the Company for the year ended December 31, 2018 and notes thereto.

There have been no material changes in the Company’s significant accounting policies as compared to the significant accounting policies described in the Company’s annual report on Form 10-K for the year ended December 31, 2018.

Loss per Share

Net loss per common share is computed pursuant to ASC 260-10-45. Basic loss per share is computed based on the weighted average number of common shares outstanding during the period. Diluted net loss per share is calculated by dividing net loss by the diluted weighted average common shares outstanding, which includes the effect of potentially dilutive securities. During periods when there is a net loss, all potentially dilutive shares are anti-dilutive and are excluded from the calculation of net loss per share. Diluted earnings per share is similarly computed except that the denominator includes the effect, using the treasury stock method, of unvested restricted stock and convertible notes, if including such potential shares of common stock is dilutive. For the three-months ended March 31, 2019 and 2018, the common stock equivalents of the convertible note agreements were not included in diluted earnings per share computations because their effect was antidilutive.

Share Purchase Agreement

On July 31, 2018, the Company entered into a Share Purchase Agreement with AstralENERGY Solar Manufacturing Corporation, LTD. (“AstralENERGY”) to acquire 70% of the outstanding common stock of AstralENERGY. The Company will issue an aggregate 2,500,000 shares of common stock of the Company as consideration for the acquisition. AstralENERGY is a manufacturer of architecturally designed solar panels for residential and commercial solar production and has also developed integrated multi-function LED street lighting systems. Consummation of the acquisition is subject to the completion of certain conditions specified in the agreement. As of May 20, 2019, this transaction has not closed.

F-5

NOTE 2 – NEW ACCOUNTING STANDARD

Adoption of New Accounting Standard

The Company adopted Accounting Standards Codification (ASC) 842, “Leases” using the modified retrospective approach, effective January 1, 2019, on its condensed consolidated financial statements. The comparative information has not been restated and continues to be reported under the lease accounting standard in effect for those periods.

The new lease standard requires all leases to be reported on the balance sheet as right-of-use assets and lease obligations. We elected the practical expedients permitted under the transition guidance of the new standard.

NOTE 3 – GOING CONCERN UNCERTAINTY / MANAGEMENT PLANS

The accompanying condensed consolidated financial statements have been prepared in contemplating continuation of the Company as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. However, a substantial doubt has been raised with regard to the ability of the Company to continue as a going concern. The Company has incurred significant operating losses and negative cash flows from operations since inception. The Company had an accumulated deficit of $36,897,830 at March 31, 2019 and had no committed source of additional debt or equity financing. The Company has not had any operating revenue and does not foresee any operating revenue in the near term. The Company has relied on the issuance of loans payable and convertible debt instruments to finance its expenses, including notes that are in default, as described in Notes 7, 8, 9, and 10. The Company will be dependent upon raising additional capital through placement of our common stock, notes or other securities in order to implement its business plan or additional borrowings, including from related parties. There can be no assurance that the Company will be successful in either situation in order to continue as a going concern. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.

The Company’s cash position may not be sufficient to support the Company’s daily operations or its ability to undertake any business activity that will generate net revenue.

NOTE 4 – PROPERTY, PLANT AND IMPROVEMENTS, NET

Property and equipment, net consists of the following as of:

	March 31, 2019			December 31, 2018
Leasehold improvements	$	166,163		$	166,163
Furniture and equipment		17,668			17,668
Accumulated depreciation and amortization		(21,918	)		(17,322	)

Net property, plant and improvements	$	161,913		$	166,509

Depreciation and amortization expense was $4,596 and $442 for the three-months ended March 31, 2019 and 2018, respectively.

F-6

NOTE 5 – ADVANCES TO CEN BIOTECH UKRAINE

At March 31, 2019 and December 31, 2018, the Company had advances of $905,328 and $875,328, respectively, to CEN Biotech Ukraine, LLC, a related party, (see Note 13). The advances were for the purpose of funding the operations of CEN Biotech Ukraine, LLC and are unsecured, non-interest bearing, and are due on demand.

NOTE 6 – INTANGIBLE ASSETS

On September 12, 2016, the Company executed an agreement dated August 31, 2016, to acquire assets, including a patent related to LED Lighting, from Tesla Digital, Inc., a Canadian Corporation, and Stevan (Steve) Pokrajac (the “Sellers”).

Material consideration given by Company was: (a) Shares of CEN common stock equal to $5 million upon commencement of public trading (b) The transfer of real properties located at 135 North Rear Road, Lakeshore, Ontario, Canada having a fair value of $2,161,467 and 1517-1525 Ridge Road having a purchase cost (including other related disbursements) to the Company of $202,666.

The patent remains in the name of Tesla Digital, Inc. until full settlement of the terms of the agreement. In the interim, pursuant to an updated agreement executed on April 15, 2019 between the Company and the Sellers, CEN has reaffirmed the rights to use the patented technology.

In addition, the Company agreed to employ Stevan Pokrajac, by an LED subsidiary that the Company plans to form, but which has not yet been formed, in connection with the development of the acquired technology with compensation equal to $200,000 per year, commencing with the start of operations of the planned subsidiary after the acquisition is completed.

In March 2018, the Tesla agreement was amended to replace the $5 million stock consideration commitment with a commitment to issue one million registered shares of CEN common stock with a closing date of September 30, 2018. On October 4, 2018, this agreement was amended to extend the closing date to December 15, 2018. On April 3, 2019, the Company entered into an amendment which extended the closing date of the agreement to December 31, 2019. The modification of the agreement converted a fixed value of shares to a fixed number of shares. Accordingly, the liability was reduced and additional paid in capital was increased by $4,380,000 to reflect the fair value of the shares committed at the date of the amendment. As of March 31, 2019 and December 31, 2018, the fair value of this liability was $1,010,000. This liability will be remeasured at each reporting date using the current fair value of CEN’s common shares.

The Company intends to explore using the patented LED Lighting Technology across manufacturing operations and licensing opportunities across multiple industries such as horticultural, automotive, industrial and commercial lighting. The assets acquired, other than the patent, included certain machinery and raw materials, which were old and non-functioning and accordingly, had no fair value.

The intangible assets consists of the following as of:

	March 31, 2019			December 31, 2018

Lighting patent	$	6,797,000		$	6,797,000
Accumulated amortization		(1,097,432	)		(991,229	)

Net	$	5,699,568		$	5,805,771

As of March 31, 2019 and December 31, 2018, there is no impairment expense recognized based on the Company’s expectations that it will be able to monetize the patent.

The lighting patent is being amortized straight-line over 16 years. Expected amortization expense is $424,812 per year through 2031, with the remaining $283,215 to be amortized in 2032.

F-7

NOTE 7 – LOANS PAYABLE

Loans payable consist of the following at:

	March 31, 2019		December 31, 2018
Loan payable to Global Holdings International, LLC, which bears interest at 15% per annum after defaulting on the maturity date of June 30, 2016. This note is secured by the Company's equipment.	$	9,675,000	$	9,675,000

Mortgage payable in default to ARG & Pals, Inc., for the original amount of CAD $385,000. The mortgage bears interest at 22% per annum, and matured on November 21, 2018.		288,095		282,205

Loan payable in default to an individual, issued January 17, 2018 with a 30-day maturity, bearing share interest of 2,000 common shares per 30-day period. This is an unsecured loan which matured on April 16, 2019.		50,000		50,000

Loan payable in default to an individual, issued April 13, 2018, with a 30-day maturity, bearing share interest of 4,000 common shares per 30-day period. This is an unsecured loan which matured on April 16, 2019.		100,000		100,000

Total loans payable (all current)	$	10,113,095	$	10,107,205

We are in default of $9,675,000 of debt that is secured by certain equipment that we value at approximately $9,000. The remainder of our debt that is in default is not secured.

During the three-month periods ended March 31, 2019 and 2018, 18,000 and 16,400 common shares were issued to individuals for loans made to CEN, respectively. Accordingly, during the three-month periods ended March 31, 2019 and 2018, $18,180 and $10,168 in interest expense and additional paid-in capital was recorded, respectively.

F-8

NOTE 8 – LOANS PAYABLE- RELATED PARTY

Loans payable - related party consists of the following at:

	March 31, 2019		December 31, 2018
Loan payable in default to the spouse of Bill Chaaban, President of CEN, bears an interest at 10% per annum. This is an unsecured loan that matured on December 31, 2018.	$	235,050	$	234,306

Loan payable in default to a former director of Creative, former parent company, bears interest at 10% per annum. This is an unsecured loan that matured on December 31, 2018.		601,500		601,500

Loan payable to R&D Labs Canada, Inc., whose president is Bill Chaaban, also the President of CEN, bearing interest at 8% per annum. This is an unsecured loan with a maturity date of October 2, 2019. R&D Labs Canada is a company owned by Bill Chaaban’s spouse.		300,000		300,000

Loan payable in default to the spouse of Joseph Byrne, CEO of CEN, issued January 12, 2018 with a 30-day maturity, bearing share interest of 4,000 common shares per 30-day period. This is an unsecured loan that matured on May 16, 2019.		100,000		100,000

Loan payable in default to Alex Tarrabain, a Director of CEN, issued January 17, 2018 with a 30-day maturity, bearing share interest of 3,000 common shares per 30-day period. This is an unsecured loan that matured on May 16, 2019.		75,000		75,000

Loan payable in default to Joseph Byrne, CEO of CEN, issued January 24, 2018 with a 30-day maturity, bearing share interest of 2,000 common shares per 30-day period. This is an unsecured loan that matured on May 16, 2019.		50,000		50,000

Total loans payable - related party		1,361,550		1,360,806
Less: current portion		1,361,550		1,360,806

Long-term portion loans payable - related party	$	-	$	-

Attributable related party accrued interest was $384,187 and $357,373 as of March 31, 2019 and December 31, 2018, respectively. Interest expense attributable to related party loans was $26,814 and $43,042 for the three-months ended March 31, 2019 and 2018, respectively.

During both three-month periods ended March 31, 2019 and 2018, 27,000 common shares were issued to related parties in connection with interest terms of the above loans made to CEN. Accordingly, during the three-month periods ended March 31, 2019 and 2018, $27,270 and $16,740 in related party interest expense, which is included above, and additional paid-in capital was recorded, respectively.

F-9

NOTE 9 – CONVERTIBLE NOTES

Convertible notes payable consists of the following at:

	March 31, 2019		December 31, 2018

Convertible note payable, due on demand, bearing interest at 7% per annum with conversion rights for 335,833 common shares.	$	826,657	$	809,755

Convertible notes payable to multiple private investors, including certain notes in default, bearing interest at 5% per annum with conversion rights for 2,775,690 common shares, maturing at various dates between May 2018 and March 2021.		4,480,927		4,333,892

Total convertible notes payable		5,307,584		5,143,647
Less current portion		4,190,461		3,597,760

Convertible notes payable, less current portion	$	1,117,123	$	1,545,887

These notes may be converted at the option of the note holder at any time after registration of CEN’s common stock upon written notice by the note holder. These notes are convertible into a total of 3,111,523 common shares.

As of May 20, 2019, we are currently in default of $1,329,287 of convertible notes payable, which are convertible into 834,277 shares of common stock.

NOTE 10 – CONVERTIBLE NOTES - RELATED PARTY

Convertible notes - related party consists of the following at:

	March 31, 2019		December 31, 2018
Convertible note due to the spouse of Bill Chaaban, President of CEN, which bears an interest at 12% per annum. This note is convertible to 867,576 common shares with a maturity date of August 17, 2020.	$	1,388,122	$	1,388,122

Convertible notes in default due to Harold Aubrey de Lavenu, a Director of CEN, bearing interest at 5% per annum. These notes are convertible to 548,980 common shares with maturity dates of March 31, 2019.		878,368		878,368

Convertible note in default due to Alex Tarrabain, a Director of CEN, bearing interest at 5% per annum. This note is convertible to 30,000 common shares with a maturity date of March 31, 2019.		48,000		48,000

Convertible notes due to Joseph Byrne, CEO of CEN, bearing interest at 12% per annum. This note is convertible to 140,120 common shares with a maturity date of August 17, 2020.		224,191		224,191

Total convertible notes payable - related party		2,538,681		2,538,681
Less current portion		926,368		926,368

Convertible notes payable - related party, less current portion	$	1,612,313	$	1,612,313

Attributable related party accrued interest was $647,984 and $588,854 as of March 31, 2019 and December 31, 2018, respectively. Interest expense attributable to related party convertible notes was $59,129 and $61,244 for the three-months ended March 31, 2019 and 2018, respectively.

As of May 20, 2019, we are currently in default of $926,368 of convertible notes payable, which are convertible into 578,980 shares of common stock.

F-10

NOTE 11 – INCOME TAXES

A reconciliation of the effective tax rate of the income tax benefit and the statutory income tax rates applied to the loss before income taxes is as follows for the three-months ended March 31:

	2019			2018

Income tax benefit at Canadian statutory rate		26.5	%		26.5	%
Valuation allowance		(26.5	%)		(26.5	%)

Effective income tax rate		0	%		0	%

As of March 31, 2019, the Company has net operating loss carry forwards of approximately $37,800,000 that may be available to reduce future years’ taxable income. Such carry forwards typically expire after 20 years. The Company currently has carry forwards that begin to expire in 2034. Future tax benefits which may arise as a result of these losses have not been recognized in these condensed consolidated financial statements, because the Company believes that it is more likely than not that the carryforwards will expire unused and accordingly, the Company has recorded a valuation allowance for the deferred tax asset relating to these tax loss carry-forwards. The deferred tax asset and associated valuation allowance are as follows for the period ended March 31, 2019 and the year ended December 31, 2018:

	2019			2018

Deferred tax asset - net operating losses	$	10,000,000		$	9,700,000
Deferred tax asset valuation allowance		(10,000,000	)		(9,700,000	)

Net deferred tax asset	$	-		$	-

The change in the valuation allowance amounted to $300,000 and $400,000 for the three-months ended March 31, 2019 and 2018, respectively. All other temporary differences are immaterial both individually and in the aggregate to the condensed consolidated financial statements.

Company management analyzes its income tax filing positions in Canadian federal and provincial jurisdictions where it is required to file income tax returns, for all open tax years in these jurisdictions, to identify potential uncertain tax positions. As of March 31, 2019, there are no uncertain income tax positions taken or expected to be taken that would require recognition of a liability or disclosure in the condensed consolidated financial statements. The Company is subject to routing audits by taxing jurisdictions; however, there are currently no audits for any tax periods in progress. Generally, the Company is no longer subject to income tax examinations for years prior to 2015.

NOTE 12 – SHAREHOLDERS’ DEFICIT / STOCK ACTIVITY

The Company is authorized to issue an unlimited number of common shares and an unlimited number of special voting shares. Common shares have no stated par value.

As of March 31, 2019, 4,698,199 shares of common stock are committed to the holders of the convertible notes.

F-11

NOTE 13 – RELATED PARTY TRANSACTIONS

The Company has received loans from several related parties, as described above in Notes 8 and 10.

There are advances of $905,328 and $875,328 to CEN Ukraine as of March 31, 2019 and December 31, 2018, respectively, which such advances were made for the purpose of funding the operations of CEN Ukraine. CEN Ukraine was founded by Bill Chaaban. Prior to December 3, 2017, Bill Chaaban directly owned 51% of CEN Ukraine. Subsequent to December 3, 2017, Mr. Chaaban directly owned 25.5% of CEN Ukraine. CEN Ukraine was founded to seek agricultural and pharmaceutical opportunities in Ukraine. Bill Chaaban personally funded the establishment and initial phases of CEN Ukraine. On December 14, 2017, the Company entered into a controlling interest purchase agreement with Bill Chaaban and another shareholder of CEN Ukraine for 51% of the outstanding equity interests of CEN Ukraine. The consideration will be paid by issuing common shares of the Company. The agreement, which is subject to certain conditions, has not closed as of May 20, 2019, as the Company needs to raise additional funds in order to proceed with the closing.

On July 12, 2017, the Company’s Shareholders elected individuals to serve as Directors on the Board. These individuals hold long-term convertible notes payable issued prior to the election. All notes payable bear interest at 5% per annum and are convertible to common shares with various maturity dates. They became related parties when they were elected.

During each of the three-months ended March 31, 2019 and 2018, the Company incurred payroll expenses with certain Board Members and Officers totaling $31,200. As of March 31, 2019 and December 31, 2018, $156,000 and $124,800, respectively, were payable for such services.

During 2017, the Company purchased equipment from R&D Labs Canada, Inc., whose president is Bill Chaaban, in exchange for a $300,000 note payable. This equipment was then sold to CEN Ukraine for a loss of $255,141 in exchange for a $44,859 note receivable, payable in 10 equal installments beginning in 2017 through 2026. No payments have been received as of March 31, 2019, however, management expects this balance to be collectible.

The Company leases 20 North Rear Road, a 10.4 acre site of land in Canada, through a sublease from a relative of the Company’s President. There are two buildings on the site – one of 27,000 square feet and one of 53,000 square feet. There is also a 4,000 square foot vault for security purposes. The Company constructed improvements to this property, including structures and equipment for growing marijuana, security fencing required for licensing as a marijuana producer, and other infrastructure. These improvements were fully impaired during the 4^th quarter of 2018.

The 20 North Rear Road lease agreement began on September 1, 2013 and required annual rent payments of CAD $339,000, including tax. At December 31, 2016, the balance sheet included accrued rent of $552,934, owed to Jamaal Shaban (“Lessor”), cousin of Bill Chaaban. Concurrently, the Lessor had fallen behind on a mortgage payable on the property. Effective January 2017, the Company entered into agreements to terminate the initial lease, enter into a convertible debt note with the Lessor’s creditor, and begin a new lease agreement for the same property. The new lease agreement calls for monthly rental payments of CAD $4,000 plus taxes for a period of five years. In exchange, the Company issued convertible notes payable of $824,446 in satisfaction of the accrued rent and future rent. The lease has been accounted for as an operating lease, and the amount of the note in excess of the accrued rent was treated as a deferred lease asset amortized over the 5-year lease. However, in conjunction with the impairment in the 4^th quarter of 2018, the remaining deferred lease asset was fully expensed. As of March 31, 2019, the operating right of use asset was $88,992 and the associated liability was $85,998, utilizing an 8% discount rate. During the three-months ended March 31, 2019 and 2018, lease expenses of $19,562 and $22,883 related to this agreement were recognized within general and administrative expenses.

F-12

The Company also leases office space in Windsor, Ontario from R&D Labs Canada, Inc., whose president is Bill Chaaban. Under the lease agreement effective October 1, 2017, monthly rents of CAD $2,608 are due through September 2022, at which point monthly rents of CAD $3,390 are due. As of March 31, 2019, the operating right of use asset was $162,118 and the associated liability was $165,523, utilizing an 8% discount rate. During the three-months ended March 31, 2019 and 2018, lease expenses of $9,259 and $6,068 related to this agreement were recognized within general and administrative expenses.

As of March 31, 2019, the weighted average remaining lease term was approximately 6.8 years and the weighted average discount rate used to determine operating lease liabilities was 8%.

NOTE 14 – STOCK BASED COMPENSATION

Adoption of Equity Compensation Plan

On November 29, 2017, the Board adopted the 2017 Equity Compensation Plan (the “Plan”) providing for the granting of options to purchase shares of common stock, restricted stock awards and other stock-based awards to directors, officers, employees, advisors and consultants. The Company reserved 20,000,000 shares of common stock for issuance under the Plan. The Plan is intended to provide equity incentives to persons retained by our Company.

Equity Compensation Grants

On November 30, 2017, the Company granted a one-time equity award (“Equity Award”) of 20,000 restricted shares of the Company’s common stock pursuant to a Restricted Stock Agreement, to each of the following executives and directors of the Company: Bahige “Bill” Chaaban, Chairman of the Board and President of the Company; Joseph Byrne, Chief Executive Officer and Director; Richard Boswell, Senior Executive Vice President, Chief Financial Officer and Director; Brian Payne, Vice President and Director; Donald Strilchuck, Director; Harold Aubrey de Lavenu, Director; Alex Tarrabain, Director; and Ameen Ferris, Director. The Equity Awards vested immediately.

In addition, as part of this one-time equity award, Donald Strilchuck, Director, received an additional 1,000,000 restricted shares of the Company's common stock for security consulting services, of which 550,000 vested immediately and the remaining vesting ratably each month over the next 36 months. Other individuals received a total of 1,870,000 restricted shares of the Company's common stock for consulting services performed, of which 1,330,000 vested immediately and the remaining vesting ratably each month over the next 36 months. The expense related to the restricted stock awarded to non-employees for services rendered was recognized on the grant date.

On June 7, 2018, the Company elected Dr. Usamakh Saadikh to serve as a director of the Company. As compensation for his role as a Director, the company granted a one-time equity award of 20,000 shares of the Company’s common stock. This award vested immediately.

F-13

On June 19, 2018, the Company entered into an agreement with a law firm for the payment of its services under which the Company issued 125,000 shares of its common stock. This award vested immediately. The expense related to the restricted stock awarded to non-employees for services rendered was recognized on the grant date.

On December 31, 2018, the Company issued 12,120 shares of its common stock to individuals for the payment of their services. These awards vested immediately. The expense related to the stock awarded to non-employees for services rendered was recognized on the grant date.

Employment Agreements

On November 30, 2017, employment agreements were entered into with four key members of management:

•

Under the Employment Agreement with Bahige (Bill) Chaaban, President of the Company, Mr. Chaaban will receive compensation in the form of a base annual salary of $31,200 and a grant of 8,750,000 shares of restricted stock of the Company, of which 7,400,000 vested immediately and the remaining vesting ratably each month over the next 36 months.

•

Under the Employment Agreement with Joseph Byrne, Chief Executive Officer of the Company, Mr. Byrne will receive compensation in the form of a base annual salary of $31,200 and a grant of 1,250,000 shares of restricted stock of the Company, of which 325,000 vested immediately and the remaining vesting ratably each month over the next 36 months.

•

Under the Employment Agreement with Richard Boswell, Senior Executive Vice President and Chief Financial Officer of the Company, Mr. Boswell will receive compensation in the form of a base annual salary of $31,200 and a grant of 4,500,000 shares of restricted stock of the Company, of which 4,140,000 vested immediately and the remaining vesting ratably each month over the next 36 months.

•

Under the Employment Agreement with Brian Payne, Vice President of the Company, Mr. Payne will receive compensation in the form of a base annual salary of $31,200 and a grant of 750,000 shares of restricted stock of the Company, of which 300,000 vested immediately and the remaining vesting ratably each month over the next 36 months.

Restricted Stock Awards

The grant-date fair value of the restricted shares noted in the employment agreements and equity compensation grants sections above was $11,435,741 in 2018 and prior. No such grants were made during the three-month periods ended March 31, 2019 and 2018. The grant-date fair value is calculated utilizing an enterprise valuation model as of the date the awards are granted. During 2017, 14,317,500 of these shares vested, with the remaining restricted stock units of 3,962,500 shares vesting pro-rata over the requisite service period, which is generally three years from the grant-date. During each of the three-months ended March 31, 2019 and 2018, an additional 337,500 of these shares vested. Non-vested restricted stock awards participate in dividends and recipients are entitled to vote these restricted shares during the vesting period.

Compensation expense recognized in connection with the restricted stock awards was $167,400 for each of the three-months ended March 31, 2019 and 2018. The fair value of the restricted stock which vested amounted to $340,875 and $209,250 for the three-months ended March 31, 2019 and 2018, respectively.

F-14

Non-vested restricted stock award activity for the three-months ended March 31, 2019 and 2018 are as follows:

	Number of Shares			Weighted- Average Grant Date Fair Value per Share		Weighted- Average Remaining Contractual Term (Years)
Non-vested at January 1, 2018		3,962,500		$	0.62		2.92
Granted		-			-		-
Vested		(337,500	)		0.62		-
Forfeited		-			-		-
Non-vested at March 31, 2018		3,625,000		$	0.62		2.75

Non-vested at December 31, 2018		2,612,500		$	0.62		2.00
Granted		-			-		-
Vested		(337,500	)		0.62		-
Forfeited		-			-		-
Non-vested at March 31, 2019		2,275,000		$	0.62		1.75

The fair value of the restricted stock grants was based on the valuation of a third-party specialist. Unrecognized compensation expense related to restricted stock amounted to approximately $1,131,500 as of March 31, 2019. This expense will be recognized over vesting period of the respective awards.

NOTE 15 – NET LOSS PER SHARE

During periods when there is a net loss, all potentially dilutive shares are anti-dilutive and are excluded from the calculation of diluted net loss per share. Based on the Company’s application of the as-converted and treasury stock methods, all common stock equivalents were excluded from the computation of diluted earnings per share due to net losses as of March 31, 2019 and 2018. Common stock equivalents that were excluded for the three-month periods ended March 31, 2019 and 2018 are as follows:

		2019				2018
Convertible debt			4,628,234				3,919,160

NOTE 16 – CONTINGENCY

In connection with the distribution by Creative of CEN’s common stock on February 29, 2016 and the Form 10 registration statement filed by CEN to register its shares of common stock under the Exchange Act, CEN received comments by the Staff of the Securities and Exchange Commission, including a letter dated May 4, 2016 in which the Staff noted that they “…continue to question the absence of Securities Act registration of the spin-off distribution”. In the event that the distribution of shares of CEN’s common stock was a distribution that required registration under the Securities Act, then the Company could be subject to enforcement action by the SEC that claims a violation of Section 5 of the Securities Act and could be subject to a private right of action for rescission or damages. Based on management’s estimate, any potential liability related to this matter would not be material.

F-15

NOTE 17 – FAIR VALUE DISCLOSURES

Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework that prioritizes and ranks the level of observability of inputs used in measuring fair value.

The fair value of the Company’s financial instruments are as follows:

			Fair Value Measured at Reporting Date Using
	Carrying Amount		Level 1		Level 2		Level 3		Fair Value
At March 31, 2019:
Cash and cash equivalents	$	39,752	$	-	$	39,752	$	-	$	39,752
Other receivables	$	417,904	$	-	$	-	$	417,904	$	417,904
Note receivable - related party	$	44,859	$	-	$	-	$	44,859	$	44,859
Advances to CEN Biotech Ukraine, LLC - related party	$	905,328	$	-	$	-	$	905,328	$	905,328
Loans payable	$	10,113,095	$	-	$	-	$	10,113,095	$	10,113,095
Loans payable - related parties	$	1,361,550	$	-	$	-	$	-	$	-
Patent acquisition liability	$	1,010,000	$	-	$	-	$	1,010,000	$	1,010,000
Convertible notes payable	$	5,307,584	$	-	$	-	$	5,768,525	$	5,768,525
Convertible notes payable - related parties	$	2,538,681	$	-	$	-	$	-	$	-

	Carrying Amount		Level 1		Level 2		Level 3		Fair Value
At December 31, 2018:
Cash and cash equivalents	$	3,193	$	-	$	3,193	$	-	$	3,193
Other receivables	$	418,905	$	-	$	-	$	418,905	$	418,905
Note receivable - related party	$	44,859	$	-	$	-	$	44,859	$	44,859
Advances to CEN Biotech Ukraine, LLC - related party	$	875,328	$	-	$	-	$	875,328	$	875,328
Loans payable	$	10,107,205	$	-	$	-	$	10,107,205	$	10,107,205
Loans payable - related parties	$	1,360,806	$	-	$	-	$	-	$	-
Patent acquisition liability	$	1,010,000	$	-	$	-	$	1,010,000	$	1,010,000
Convertible notes payable	$	5,143,647	$	-	$	-	$	5,534,810	$	5,534,810
Convertible notes payable - related parties	$	2,538,681	$	-	$	-	$	-	$	-

The fair values of other receivables (including related accrued interest), note receivable - related party, and advances to CEN Biotech Ukraine, LLC approximates carrying value due to the terms of the instruments.

The fair value of the loans payable approximates carrying value due to the terms of such instruments and applicable interest rates.

The fair value of convertible notes payable is based on the par value plus accrued interest through the date of reporting due to the terms of such instruments and interest rates.

It is not practicable to estimate the fair value of loans payable – related parties and convertible notes payable – related parties due to their related party nature.

The fair value of the patent acquisition liability is based upon a valuation report obtained from a 3^rd party valuation specialist. This valuation report utilized a cash-free asset value model to estimate enterprise value based upon similar companies.

F-16

NOTE 18 – SUBSEQUENT EVENT.

On April 3, 2019, the Company entered into an amendment to the Share Purchase Agreement dated August 31, 2016, and executed September 12, 2016, as amended, between CEN Biotech, Inc. and Stevan Pokrajac and Tesla Digital Inc. and Tesla Digital Global Group Inc., which extended the closing date of the agreement to December 31, 2019.

On May 15, 2019, the Company entered into a Non-Binding (other than as set forth therein) Term Sheet (the “Term Sheet”) with Caduceus Software Systems Corp., a Wyoming corporation (“CSOC”), which was reviewed and approved by the Board of Directors of the Company (the “Board”) on May 15, 2019. Pursuant to the Term Sheet, the Company and CSOC agreed to undertake a merger transaction to combine the two companies’ operations and negotiate and enter into a definite agreement to effect the transaction.

On May 16, 2019, the Board appointed Alex Tarrabain, one of the members of the Company’s Board to serve as the Company’s Chief Financial Officer and as one of the Vice Presidents of the Company effective May 21, 2019 (the “Effective Date”). Richard Boswell, who served as the Company’s Chief Financial Officer since July 2017, resigned from his position as the Company’s Chief Financial Officer as of the Effective Date, and will continue to serve in his position as the Company’s Senior Executive Vice President going forward focusing on the Company’s strategic activities and will also continue to serve as a member of the Company’s Board.

In connection with the foregoing, on May 16, 2019, the Company entered into an Executive Employment Agreement (the “Employment Agreement”) with Mr. Tarrabain pursuant to which Mr. Tarrabain agreed to serve as the Company’s Vice President and Chief Financial Officer and the Company agreed to issue to Mr. Tarrabain 1,250,000 shares (the “Shares’) of the Company’s common stock in accordance with a Restricted Stock Agreement (the “RSA”). The Employment Agreement has an indefinite term. Additionally, pursuant to the Employment Agreement, the Company agreed to pay Mr. Tarrabain an annual base salary of $31,200. Further, pursuant to the Employment Agreement in the event of an occurrence of a “Change in Control” (as defined in the Employment Agreement) or a strategic transaction, the Board may, but is not obligated to, provide Mr. Tarrabain with additional compensation, including additional stock options or restricted stock, for services outside of his general scope of duties and responsibilities.

Pursuant to the RSA, entered into by Mr. Tarrabain and the Company on May 16, 2019, 350,000 of the Shares will vest immediately (the “Grant Date”) and the balance 900,000 of the Shares will vest over a three (3) year period with 25,000 of the Shares versing on the one (1) month anniversary of the Grant Date and an additional 25,000 of the Shares vesting at the end of each one (1) month anniversary of the Grant Date thereafter, provided that Mr. Tarrabain continues to be an employee of the Company.

F-17

ITEM 2

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION

Background and Overview

CEN Biotech, Inc. (“CEN” or the “Company”) is a Canadian holding company, incorporated in Canada on August 4, 2013 as a subsidiary of Creative Edge Nutrition, Inc. (“Creative”), a Nevada corporation. Creative separated its planned specialty pharmaceutical business located in Canada by transferring substantially all of the assets and liabilities of the planned specialty pharmaceutical business to CEN and effecting a distribution (the “Spin-Off Distribution”) of CEN common stock to Creative shareholders on February 29, 2016. The Spin-Off Distribution was intended to be tax free for U.S. federal income tax purposes.

Prior to the Spin-Off Distribution, CEN initially pursued the cannabis business in Canada and obtained funding to build the initial phase of its comprehensive seed-to-sale facility and applied to obtain a license in Canada to begin operating its state-of-the-art medical marijuana cultivation, processing, and distribution facility in Lakeshore, Ontario. On March 11, 2015, the Company’s application for a license to produce marijuana for medical purposes was formally rejected by Canadian regulatory authority. On February 1, 2016 the Company commenced legal action against the Attorney General of Canada in the Ontario Superior Court of Justice for damages for detrimental reliance, economic loss, and prejudgment and post judgment interest, costs of the proceeding and other relief that the court may seem just. As of May 20, 2019 the action in the Ontario Superior Court of Justice is still ongoing. After evaluating this action, the Company decided to not pursue the development of its medical marijuana business and instead to seek to develop and pursue other businesses that are related to the cannabis and other industries, including Light Emitting Diode (“LED”) lighting and hemp-based industrial, medical and food products that have a tetrahydrocannabinol (“THC”) that is below 0.3%.

We are currently focused on the manufacturing, production and development of products within the cannabis industry, including LED lighting technology and hemp-based products. The Company intends to continue to explore the usage of hemp, which it now intends to cultivate for usage in industrial, medical and food products.

At present we are not able to estimate if or when we will be able to generate any revenues. Our condensed consolidated financial statements have been prepared assuming that we will continue as a going concern; however, given our recurring losses from operations, management has determined there is substantial doubt about our ability to continue as a going concern.

Near Term Operating Plan

Our near-term operating plans are based on us obtaining financing through debt or equity raises of approximately $50,000,000 USD. Generally, the funds are planned to be invested as follows: $25 million in hemp activities, $20 million in LED lighting manufacturing and $5 million in general operating costs. There can be no assurance that the Company will be able to raise the foregoing funds or proceed as planned.

Results of Operations

We have incurred recurring losses and have not commenced revenue generating operations to date. Our expenses to date are primarily our general and administrative expenses and fees, costs and expenses related to acquisitions and operations. Our condensed consolidated financial statements have been prepared assuming that we will continue as a going concern and, accordingly, do not include adjustments relating to the recoverability and realization of assets and classification of liabilities that might be necessary should we be unable to continue in operation.

The accompanying condensed consolidated financial statements have been prepared in contemplating continuation of the Company as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. However, a substantial doubt has been raised with regard to the ability of the Company to continue as a going concern. The Company has incurred significant operating losses and negative cash flows from operations since inception. The Company had an accumulated deficit of $36,897,830 at March 31, 2019 and had no committed source of debt or equity financing. The Company has not had any operating revenue and does not foresee any operating revenue in the near term. The Company has relied on the issuance of loans payable and convertible debt instruments to finance its expenses, including a note that is in default and is secured by the Company’s equipment and certain unsecured convertible notes payable. The Company will be dependent upon raising additional capital through placement of our common stock, notes or other securities in order to implement its business plan or additional borrowings, including from related parties. There can be no assurance that the Company will be successful in either situation in order to continue as a going concern. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.

The Company’s cash position may not be sufficient to support the Company’s daily operations or its ability to undertake any business activity that will generate net revenue.

Results of Operations for the Three-Months Ended March 31, 2019 and 2018:

The following tables reflect our operating results for the three-months ended March 31, 2019 and 2018, respectively:

Operating Summary	Three-months ended March 31, 2019		Three-months ended March 31, 2018		Change
Revenues, net	$	-	$	-		-
Cost of Goods Sold		-		-		-
Gross Profit		-		-		-
Operating Expenses		405,227		652,424		37.9	%
Loss from Operations		405,227		652,424		37.9	%
Other Expense		837,550		668,346		(25.3	%)
Net Loss	$	1,242,777	$	1,320,770		5.9	%

Revenue

We have not recognized revenue during the three-months ended March 31, 2019 and 2018, as we have not commenced revenue generating operations to date.

Operating Expenses

During the three months ended March 31, 2019, our operating expenses were $405,227 compared to $652,424 during the three months ended March 31, 2018. During the three months ended March 31, 2019, our operating expenses were comprised of salary and consulting fees of $50,142, stock-based compensation expense of $167,400, and general and administrative expenses of $187,685. By comparison, during the three months ended March 31, 2018, our operating expenses were comprised of salary and consulting fees of $43,185, stock-based compensation expense of $167,400, and general and administrative expenses of $441,839. Expenses incurred during the three months ended March 31, 2019 compared to three months ended March 31, 2018 decreased primarily due to decreases in general and administrative expenses related to travel, legal, and other professional fees.

Other Income and Expense Items

During the three months ended March 31, 2019, our other income and expense, net was $837,550 compared to $668,346 during the three months ended March 31, 2018. During the three months ended March 31, 2019, our other income and expense items were comprised of interest expense of $815,101, interest income of $2,045, and foreign exchange loss of $24,494. By comparison, during the three months ended March 31, 2018, our other income and expense items were comprised of interest expense of $698,789, and foreign exchange gain of $30,443. The increase during the period is due to interest expense on additional notes and loans issued to fund operations.

Income Taxes

As of March 31, 2019, the Company has net operating loss carryforwards of approximately $37,800,000 that may be available to reduce future years’ taxable income. As of March 31, 2019, the Company has a deferred tax asset of approximately $10,000,000 which has been completely offset by a valuation allowance. The Company believes that it is more likely than not that the carryforwards will expire unused as the Company has not been able to commence revenue generating activities to date.

Net Loss

Our net loss during the three months ended March 31, 2019 was $1,242,777 compared to a net loss of $1,320,770 during the three months ended March 31, 2018 due to the factors discussed above.

Liquidity and Capital Resources

As of March 31, 2019 and 2018, our liquid assets consisted of cash of $39,752 and $3,193, respectively.

Our indebtedness includes a patent acquisition liability of $1,010,000, accrued interest of $7,544,199, accrued interest to related parties of $1,032,171, as well as loans payable, loans payable to related parties, loans payable share interest, loans payable share interest to related parties, convertible notes and convertible notes to related parties totaling $19,320,910, with maturity dates as outlined below. The convertible notes are due 2 years from issuance with notes maturing in 2018 through 2021. We are in default of $9,675,000 of debt that is secured by certain equipment that we value at approximately $11,000. We are also currently in default of $3,755,300 of unsecured debt. We expect our operating and administrative expenses to be at least $2,400,000 annually.

Description	Maturity Date		Amount
Loan Payable		6/30/2016	$	9,675,000
Loan Payable		11/21/2018		288,095
Loan Payable – Related Party		12/31/2018		836,550
Loan Payable – Related Party		10/2/2019		300,000
Loan Payable – Share Interest		4/16/2019		150,000
Loan Payable – Share Interest – Related Party		5/16/2019		225,000
Convertible Notes		On Demand		826,657
Convertible Notes	Q2 2018			14,000
Convertible Notes	Q4 2018			74,000
Convertible Notes	Q1 2019			1,04,6287
Convertible Notes	Q2 2019			405,000
Convertible Notes	Q3 2019			791,017
Convertible Notes	Q4 2019			457,701
Convertible Notes	Q1 2020			575,800
Convertible Notes	Q2 2020			117,000
Convertible Notes	Q3 2020			514,264
Convertible Notes	Q4 2020			338,823
Convertible Notes	Q1 2021			147,035
Convertible Notes Related Party	Q1 2019			926,368
Convertible Notes Related Party	Q3 2020			161,2313

Total			$	19,320,910

We intend to fund our expenses through the issuance and sale of additional securities. We do not have any commitments from any persons to purchase any securities and there can be no assurance that we will be able to raise sufficient funds to pay our liabilities as they become due and payable.

Three months ended March 31, 2019 and 2018

Cash Flows from Operating Activities

We have not generated positive cash flows from operating activities. During the three months ended March 31, 2019, we used $80,475 in operating activities compared to $523,326 used in operating activities during the three months ended March 31, 2018. The decrease in the use of operating cash between the two periods related primarily to a decrease in the extensions of credit under the other receivables category.

Cash Flows from Investing Activities

Our use of cash flow for investing activities during the three months ended March 31, 2019 was $30,000 compared to $5,439 during the three months ended March 31, 2018. During the three months ended March 31, 2019, our use of cash flows for investing activities were comprised of advances to CEN Ukraine of $30,000. By comparison, during the three months ended March 31, 2018, our use of cash flows for investing activities was comprised of leasehold improvements of $5,439.

Cash Flows from Financing Activities

During the three months ended March 31, 2019, we received $147,034 through issuance of convertible notes to investors to fund our working capital requirements. During the three months ended March 31, 2018, we received $1,000,800 through issuance of convertible notes and share interest loans to investors to fund our working capital requirements. During the three months ended March 31, 2018, $130,000 of the share interest loans payable were repaid.

CEN has no committed source of debt or equity financing. Our Executive team and Board are seeking additional financing from their business contacts, but no assurances can be given that such financing will be obtained or, if obtained, on what terms.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements, as defined in Item 303(a)(4)(ii) of Regulation S-K, obligations under any guarantee contracts or contingent obligations. We also have no other commitments, other than the costs of being a reporting company that will increase our operating costs or cash requirements in the future.

Jumpstart Our Business Startups Act of 2012

The Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) provides that an emerging growth company can take advantage of certain exemptions from various reporting and other requirements that are applicable to public companies that are not emerging growth companies. We currently take advantage of some, but not all, of the reduced regulatory and reporting requirements that are available to us for as long as we qualify as an emerging growth company. Our independent registered public accounting firm will not be required to provide an attestation report on the effectiveness of our internal control over financial reporting for as long as we qualify as an emerging growth company.

Recent Accounting Pronouncements

Adoption of New Accounting Standard

The Company adopted Accounting Standards Codification (ASC) 842, “Leases” using the modified retrospective approach, effective January 1, 2019, on its condensed consolidated financial statements. The comparative information has not been restated and continues to be reported under the lease accounting standard in effect for those periods.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

As a smaller reporting company, we are not required to provide the information called for by this Item.

Item 4. Controls and Procedures.

(a) Evaluation of disclosure and controls and procedures.

As of March 31, 2019, our management, with the participation of our Chief Executive Officer and Chief Financial Officer, conducted an assessment and evaluated the effectiveness of the Company's disclosure controls and procedures pursuant to Rule 13a-15 under the Exchange Act. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.

Management, with the participation of our Chief Executive Officer and Chief Financial Officer, performed an evaluation of the effectiveness of our disclosure controls and procedures as of March 31, 2019. Based on this evaluation, management concluded that the Company’s internal control over financial reporting was effective as of March 31, 2019.

Management recognized the need for additional resources in the area of accounting and financial reporting controls and procedures. As a result, we have outsourced the accounting and financial reporting oversight roles to a qualified accounting firm with public company reporting expertise.

(b) Changes in internal control over financial reporting.

There were no changes in our internal control over financial reporting that occurred during the quarter ended March 31, 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

From time to time, we may become party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of our business. We are not currently a party, as plaintiff or defendant, to any legal proceedings that we believe to be material or which, individually or in the aggregate, would be expected to have a material effect on our business, financial condition or results of operation if determined adversely to us.

Item 1A. Risk Factors.

As a smaller reporting company, we are not required to provide the information called for by this Item.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

During the three-months ended March 31, 2019, CEN entered into loans and associated extension agreements with various parties. In consideration for such loans and associated extensions, CEN granted various individuals total aggregate amount of 45,000 unregistered shares of common stock of CEN during the three-months ended March 31, 2019.

The above issuances of shares of common stock were issued in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended and the provisions of Regulation D promulgated thereunder or in reliance on the provisions of Regulation S promulgated thereunder.

During the three months ended March 31, 2019, we issued $147,034 of convertible notes to investors to fund our working capital requirements. These notes bear interest at 5% per year and are convertible at the option of the holder into 91,672 common shares.

The above issuances of convertible notes were issued in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended and the provisions of Regulation D promulgated thereunder or in reliance on the provisions of Regulation S promulgated thereunder.

Item 3. Defaults Upon Senior Securities.

CEN has a payment default with respect to the term loan payable to Global Holdings International, LLC, in the principal amount of $9,675,000 and which bears compound interest at 15% per annum which was due on September 30, 2016. The aggregate amount due under this loan as of May 20, 2019 is approximately $17,000,000. Interest and default interest and related fees currently accrue at approximately $600,000 per quarter. This note is secured by some of the Company's equipment which we value at approximately $9,000.

CEN has a payment default with respect to certain unsecured convertible loans payable to private investors and related parties, in the principal amount of $2,255,655 and which bear interest at 5% per annum which were due prior to May 20, 2019. The aggregate amounts due under these loans as of May 20, 2019, including accrued interest, is approximately $3,300,000. Interest and default interest and related fees currently accrue at approximately $40,000 per quarter.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

Item 6. Exhibits.

Exhibit No.

Description

The financial statement schedules and exhibits filed as part of this Quarterly Report on Form 10-Q are as follows:

a. Exhibits

Exhibit No.		Description

	3.1	Articles of Incorporation of Cen Biotech, Inc. (Incorporated by reference to Exhibit 3.1 to the Company’s Registration Statement (Commission file number 000-55557) on Form 10 filed with the SEC January 4, 2016.)

	3.2	By-Laws of Cen Biotech, Inc. (Incorporated by reference to Exhibit 3.2 to the Company’s Registration Statement (Commission file number 000-55557) on Form 10 filed with the SEC January 4, 2016.)

	10.1	Amendment dated April 3, 2019, to Share Purchase Agreement dated August 31, 2016, and executed September 12, 2016, as amended, between CEN Biotech, Inc. and Stevan Pokrajac and Tesla Digital Inc. and Tesla Digital Global Group Inc. (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC April 8, 2019).

	10.2	Term Sheet dated May 15, 2019, between CEN Biotech, Inc. and Caduceus Software Systems Corp. (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC May 16, 2019).

	10.3	Executive Employment Agreement dated May 16, 2019, between CEN Biotech, Inc. and Alex Tarrabain. (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC May 16, 2019).

	10.4	Restricted Stock Agreement dated May 16, 2019, between CEN Biotech, Inc. and Alex Tarrabain. (Incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the SEC May 16, 2019).

	31.1	Certification of Chief Executive Officer pursuant to Exchange Act Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*

	31.2	Certification of the Chief Financial Officer pursuant to Exchange Act Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*

	32.1	Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**

	32.2	Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**

	101.INS	XBRL Instance*
	101.SCH	XBRL Taxonomy Extension Schema*
	101.CAL	XBRL Taxonomy Extension Calculation*
	101.DEF	XBRL Taxonomy Extension Definition*
	101.LAB	XBRL Taxonomy Extension Labels*
	101.PRE	XBRL Taxonomy Extension Presentation*

* Filed herein.

** Furnished herewith.

b. Financial Statement Schedules

None

SIGNATURES

Pursuant to the requirements of Section 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: May 20, 2019

	CEN BIOTECH, INC.

	By:	/s/ Joseph Byrne
	Name:	Joseph Byrne
	Title:	Chief Executive Officer (Principal Executive Officer)

Dated: May 20, 2019	/s/ Richard Boswell
	Name: Richard Boswell
	Title: Chief Financial Officer (Principal Financial and Accounting Officer)

EX-31.1 2 ex_145140.htm EXHIBIT 31.1 ex_145140.htm

Exhibit 31.1

CERTIFICATIONS

I, Joseph Byrne, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, of CEN Biotech Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 20, 2019	/s/ Joseph Byrne
	Joseph Byrne
	Chief Executive Officer (Principal Executive Officer)

EX-31.2 3 ex_145141.htm EXHIBIT 31.2 ex_145141.htm

Exhibit 31.2

CERTIFICATIONS

I, Richard Boswell, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, of CEN Biotech Inc.;

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 20, 2019

/s/ Richard Boswell

Richard Boswell

Chief Financial Officer (Principal Financial and Accounting Officer)

EX-32.1 4 ex_145142.htm EXHIBIT 32.1 ex_145142.htm

Exhibit 32.1

Section 1350 Certification

In connection with the Quarterly Report on Form 10-Q of CEN Biotech Inc. (the “Company”) for the quarter ended March 31, 2019 as filed with the Securities and Exchange Commission (the “Report”), I Joseph Byrne, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: May 20, 2019

/s/ Joseph Byrne

Joseph Byrne

Chief Executive Officer

(Principal Executive Officer )

EX-32.2 5 ex_145143.htm EXHIBIT 32.2 ex_145143.htm

Exhibit 32.2

Section 1350 Certification

In connection with the Quarterly Report on Form 10-Q of CEN Biotech Inc. (the “Company”) for the quarter ended March 31, 2019, as filed with the Securities and Exchange Commission (the “Report”), I Richard Boswell, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: May 20, 2019

/s/ Richard Boswell

Richard Boswell,

Chief Financial Officer

(Principal Financial and Accounting Officer)

EX-101.INS 6 cenb-20190331.xml XBRL INSTANCE DOCUMENT 1010000 1010000 4380000 4380000 4380000 905328 875328 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><div style="display: inline; font-weight: bold;">NOTE <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5</div> – ADVANCES TO CEN BIOTECH UKRAINE</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018, </div>the Company had advances of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$905,328</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$875,328,</div> respectively, to CEN Biotech Ukraine, LLC, a related party, (see Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13</div>). The advances were for the purpose of funding the operations of CEN Biotech Ukraine, LLC and are unsecured, non-interest bearing, and are due on demand.</div></div> 905328 905328 905328 875328 875328 875328 31200 31200 2538681 2538681 926368 926368 1612313 1612313 May 2018 and March 2021 May 2018 and March 2021 2000 2000 4000 4000 4000 4000 3000 3000 2000 2000 13576 200000 0.265 0.265 31200 31200 31200 31200 31200 1250000 8750000 7400000 1250000 325000 4500000 4140000 750000 300000 350000 900000 25000 25000 9000 283215 -5216 384187 357373 647984 588854 1032171 946227 1361550 1360806 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><div style="display: inline; font-weight: bold;">NOTE </div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8</div></div><div style="display: inline; font-weight: bold;"> – LOANS PAYABLE- RELATED PARTY</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><div style="display: inline; font-weight: bold;"> </div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Loans payable - related party consists of the following at:</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div> <table style="margin-right: 20%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">March 31,</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">2019</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">December 31,</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">2018</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loan payable in default to the spouse of Bill Chaaban, President of CEN, bears an interest at 10% per annum. This is an unsecured loan that matured on December 31, 2018.</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">235,050</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">234,306</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loan payable in default to a former director of Creative, former parent company, bears interest at 10% per annum. This is an unsecured loan that matured on December 31, 2018.</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">601,500</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">601,500</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loan payable to R&D Labs Canada, Inc., whose president is Bill Chaaban, also the President of CEN, bearing interest at 8% per annum. This is an unsecured loan with a maturity date of October 2, 2019. R&D Labs Canada is a company owned by Bill Chaaban’s spouse.</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">300,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">300,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loan payable in default to the spouse of Joseph Byrne, CEO of CEN, issued January 12, 2018 with a 30-day maturity, bearing share interest of 4,000 common shares per 30-day period. This is an unsecured loan that matured on May 16, 2019.</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">100,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">100,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loan payable in default to Alex Tarrabain, a Director of CEN, issued January 17, 2018 with a 30-day maturity, bearing share interest of 3,000 common shares per 30-day period. This is an unsecured loan that matured on May 16, 2019.</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">75,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">75,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loan payable in default to Joseph Byrne, CEO of CEN, issued January 24, 2018 with a 30-day maturity, bearing share interest of 2,000 common shares per 30-day period. This is an unsecured loan that matured on May 16, 2019.</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total loans payable - related party</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,361,550</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,360,806</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less: current portion</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,361,550</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,360,806</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Long-term portion loans payable - related party</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Attributable related party accrued interest was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$384,187</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$357,373</div> as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018, </div>respectively. Interest expense attributable to related party loans was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$26,814</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$43,042</div> for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>-months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> respectively.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">During both <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>-month periods ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">27,000</div></div> common shares were issued to related parties in connection with interest terms of the above loans made to CEN. Accordingly, during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>-month periods ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$27,270</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$16,740</div> in related party interest expense, which is included above, and additional paid-in capital was recorded, respectively.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><div style="display: inline; font-weight: bold;">NOTE <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0</div></div><div style="display: inline; font-weight: bold;"> – CONVERTIBLE NOTES - RELATED PARTY</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><div style="display: inline; font-weight: bold;"> </div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Convertible notes - related party consists of the following at:</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div> <table style="margin-right: 20%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">March 31,</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">2019</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">December 31,</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">2018</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible note due to the spouse of Bill Chaaban, President of CEN, which bears an interest at 12% per annum. This note is convertible to 867,576 common shares with a maturity date of August 17, 2020.</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,388,122</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,388,122</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible notes in default due to Harold Aubrey de Lavenu, a Director of CEN, bearing interest at 5% per annum. These notes are convertible to 548,980 common shares with maturity dates of March 31, 2019.</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">878,368</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">878,368</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible note in default due to Alex Tarrabain, a Director of CEN, bearing interest at 5% per annum. This note is convertible to 30,000 common shares with a maturity date of March 31, 2019.</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">48,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">48,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible notes due to Joseph Byrne, CEO of CEN, bearing interest at 12% per annum. This note is convertible to 140,120 common shares with a maturity date of August 17, 2020.</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">224,191</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">224,191</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total convertible notes payable - related party</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,538,681</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,538,681</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less current portion</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">926,368</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">926,368</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible notes payable - related party, less current portion</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,612,313</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,612,313</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Attributable related party accrued interest was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$647,984</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$588,854</div> as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018, </div>respectively. Interest expense attributable to related party convertible notes was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$59,129</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$61,244</div> for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>-months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> respectively.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">These notes <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be converted at the option of the note holder at any time after registration of CEN’s common stock upon written notice by the note holder. These notes are convertible into a total of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,586,676</div> common shares.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 20, 2019, </div>we are currently in default of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$926,368</div> of convertible notes payable, which are convertible into <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">578,980</div> shares of common stock.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div></div> 113214 104286 2161467 4380000 4380000 202666 44859 44859 44859 44859 44859 44859 339000 -4805 4000 2608 3390 417904 418905 1010000 1010000 1010000 1010000 1010000 1010000 0.51 0.255 225000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 20%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">March 31,</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">2019</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">December 31,</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">2018</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible note due to the spouse of Bill Chaaban, President of CEN, which bears an interest at 12% per annum. This note is convertible to 867,576 common shares with a maturity date of August 17, 2020.</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,388,122</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,388,122</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible notes in default due to Harold Aubrey de Lavenu, a Director of CEN, bearing interest at 5% per annum. These notes are convertible to 548,980 common shares with maturity dates of March 31, 2019.</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">878,368</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">878,368</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible note in default due to Alex Tarrabain, a Director of CEN, bearing interest at 5% per annum. This note is convertible to 30,000 common shares with a maturity date of March 31, 2019.</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">48,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">48,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible notes due to Joseph Byrne, CEO of CEN, bearing interest at 12% per annum. This note is convertible to 140,120 common shares with a maturity date of August 17, 2020.</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">224,191</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">224,191</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total convertible notes payable - related party</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,538,681</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,538,681</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less current portion</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">926,368</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">926,368</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible notes payable - related party, less current portion</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,612,313</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,612,313</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 20%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">March 31,</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">2019</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">December 31,</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">2018</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loan payable in default to the spouse of Bill Chaaban, President of CEN, bears an interest at 10% per annum. This is an unsecured loan that matured on December 31, 2018.</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">235,050</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">234,306</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loan payable in default to a former director of Creative, former parent company, bears interest at 10% per annum. This is an unsecured loan that matured on December 31, 2018.</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">601,500</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">601,500</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loan payable to R&D Labs Canada, Inc., whose president is Bill Chaaban, also the President of CEN, bearing interest at 8% per annum. This is an unsecured loan with a maturity date of October 2, 2019. R&D Labs Canada is a company owned by Bill Chaaban’s spouse.</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">300,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">300,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loan payable in default to the spouse of Joseph Byrne, CEO of CEN, issued January 12, 2018 with a 30-day maturity, bearing share interest of 4,000 common shares per 30-day period. This is an unsecured loan that matured on May 16, 2019.</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">100,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">100,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loan payable in default to Alex Tarrabain, a Director of CEN, issued January 17, 2018 with a 30-day maturity, bearing share interest of 3,000 common shares per 30-day period. This is an unsecured loan that matured on May 16, 2019.</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">75,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">75,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loan payable in default to Joseph Byrne, CEO of CEN, issued January 24, 2018 with a 30-day maturity, bearing share interest of 2,000 common shares per 30-day period. This is an unsecured loan that matured on May 16, 2019.</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total loans payable - related party</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,361,550</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,360,806</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less: current portion</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,361,550</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,360,806</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Long-term portion loans payable - related party</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div> 11435741 false --12-31 Q1 2019 2019-03-31 10-Q 0001653821 25548363 Yes true false Non-accelerated Filer CEN BIOTECH INC true cenb

206521

446432

402377

552934

21918

17322

14606510

14393660

106203

255141

167400

4628234

3919160

10.4

7520434

7314565

2500000

0.51

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Share Purchase Agreement</div></div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> July 31, 2018, </div>the Company entered into a Share Purchase Agreement with AstralENERGY Solar Manufacturing Corporation, LTD. (“AstralENERGY”) to acquire <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">70%</div> of the outstanding common stock of AstralENERGY. The Company will issue an aggregate <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,500,000</div> shares of common stock of the Company as consideration for the acquisition. AstralENERGY is a manufacturer of architecturally designed solar panels for residential and commercial solar production and has also developed integrated multi-function LED street lighting systems. Consummation of the acquisition is subject to the completion of certain conditions specified in the agreement. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 20, 2019, </div>this transaction has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> closed.</div></div></div></div></div></div></div></div></div></div></div></div>

39752

3193

84978

427013

39752

3193

36559

342035

4698199

20000000

Unlimited

25518363

25473363

25518363

25473363

1010000

1329287

926368

824446

5307584

5768525

5143647

5534810

1117123

1545887

4190461

3597760

9675000

3111523

834277

1586676

578980

867576

548980

30000

140120

335833

2775690

385000

0.05

0.15

0.22

0.1

0.08

0.12

0.05

0.12

0.07

0.05

2016-06-30

2018-11-21

2019-04-16

2018-12-31

2019-10-02

2019-03-16

2019-05-16

2020-08-17

2019-03-31

2020-08-17

10000000

9700000

10000000

9700000

4596

442

905328

875328

156000

124800

-0.05

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Loss per Share</div></div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Net loss per common share is computed pursuant to ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">260</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">45.</div> Basic loss per share is computed based on the weighted average number of common shares outstanding during the period. Diluted net loss per share is calculated by dividing net loss by the diluted weighted average common shares outstanding, which includes the effect of potentially dilutive securities. During periods when there is a net loss, all potentially dilutive shares are anti-dilutive and are excluded from the calculation of net loss per share. Diluted earnings per share is similarly computed except that the denominator includes the effect, using the treasury stock method, of unvested restricted stock and convertible notes, if including such potential shares of common stock is dilutive. For the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>-months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> the common stock equivalents of the convertible note agreements were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> included in diluted earnings per share computations because their effect was antidilutive.</div></div></div></div></div></div></div></div></div></div></div></div>

-0.265

1131500

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0pt" cellspacing="0pt" style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 9%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 25%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Fair Value Measured at Reporting Date Using</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 9%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Carrying</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Amount</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Level 1</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Level 2</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Level 3</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Fair Value</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">At March 31, 2019:</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 9%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 9%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 9%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 9%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 9%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">39,752</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">39,752</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">39,752</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other receivables</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">417,904</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">417,904</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">417,904</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Note receivable - related party</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">44,859</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">44,859</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">44,859</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Advances to CEN Biotech Ukraine, LLC - related party</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">905,328</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">905,328</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">905,328</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loans payable</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,113,095</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,113,095</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,113,095</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loans payable - related parties</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,361,550</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Patent acquisition liability</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,010,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,010,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,010,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible notes payable</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,307,584</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,768,525</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,768,525</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible notes payable - related parties</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,538,681</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Carrying</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Amount</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Level 1</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Level 2</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Level 3</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Fair Value</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">At December 31, 2018:</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,193</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,193</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,193</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other receivables</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">418,905</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">418,905</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">418,905</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Note receivable - related party</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">44,859</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">44,859</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">44,859</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Advances to CEN Biotech Ukraine, LLC - related party</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">875,328</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">875,328</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">875,328</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loans payable</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,107,205</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,107,205</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,107,205</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loans payable - related parties</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,360,806</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Patent acquisition liability</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,010,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,010,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,010,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible notes payable</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,143,647</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,534,810</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,534,810</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible notes payable - related parties</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,538,681</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><div style="display: inline; font-weight: bold;">NOTE </div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17</div> </div><div style="display: inline; font-weight: bold;">– FAIR VALUE DISCLOSURES</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework that prioritizes and ranks the level of observability of inputs used in measuring fair value.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The fair value of the Company’s financial instruments are as follows:</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div> <table style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0pt" cellpadding="0pt"> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 9%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 25%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Fair Value Measured at Reporting Date Using</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 9%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Carrying</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Amount</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Level 1</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Level 2</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Level 3</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Fair Value</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">At March 31, 2019:</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 9%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 9%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 9%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 9%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 9%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">39,752</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">39,752</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">39,752</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other receivables</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">417,904</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">417,904</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">417,904</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Note receivable - related party</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">44,859</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">44,859</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">44,859</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Advances to CEN Biotech Ukraine, LLC - related party</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">905,328</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">905,328</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">905,328</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loans payable</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,113,095</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,113,095</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,113,095</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loans payable - related parties</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,361,550</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Patent acquisition liability</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,010,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,010,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,010,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible notes payable</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,307,584</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,768,525</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,768,525</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible notes payable - related parties</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,538,681</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" margin: 0pt;"> </div> <div style=" margin: 0pt;"> </div> <div> <table style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Carrying</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Amount</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Level 1</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Level 2</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Level 3</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Fair Value</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 40%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">At December 31, 2018:</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,193</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,193</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,193</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other receivables</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">418,905</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">418,905</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">418,905</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Note receivable - related party</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">44,859</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">44,859</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">44,859</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Advances to CEN Biotech Ukraine, LLC - related party</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">875,328</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">875,328</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">875,328</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loans payable</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,107,205</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,107,205</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,107,205</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loans payable - related parties</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,360,806</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Patent acquisition liability</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,010,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,010,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,010,000</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible notes payable</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,143,647</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,534,810</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,534,810</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible notes payable - related parties</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,538,681</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The fair values of other receivables (including related accrued interest), note receivable - related party, and advances to CEN Biotech Ukraine, LLC approximates carrying value due to the terms of the instruments.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The fair value of the loans payable approximates carrying value due to the terms of such instruments and applicable interest rates.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The fair value of convertible notes payable is based on the par value plus accrued interest through the date of reporting due to the terms of such instruments and interest rates.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">It is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> practicable to estimate the fair value of loans payable – related parties and convertible notes payable – related parties due to their related party nature.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The fair value of the patent acquisition liability is based upon a valuation report obtained from a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div><div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;">rd</div> party valuation specialist. This valuation report utilized a cash-free asset value model to estimate enterprise value based upon similar companies.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </div></div>

P16Y

1097432

991229

424812

6797000

5699568

5805771

-24494

30443

-24494

30443

187685

441839

-957

14770

-7585

44055

12903

-1001

146018

5699568

5805771

701888

594503

26814

43042

59129

61244

113213

104286

2045

32593

7544199

6860494

18942

11985

0.08

P5Y

29811754

28575958

7520434

7314565

25861480

24407758

10113095

10107205

10113095

10107205

417904

418905

235050

234306

601500

300000

100000

75000

50000

1361550

1360806

1388122

878368

48000

224191

2538681

826657

809755

4480927

4333892

5307584

5143647

1361550

1360806

926368

4190461

3597760

1612313

1117123

1545887

147034

870800

-30000

-5439

-80475

-523326

-1242777

-1320770

-1242777

-837550

-668346

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Number of</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Shares</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Weighted-</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Average Grant</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Date Fair Value</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">per Share</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Weighted-</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Average</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Remaining</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Contractual</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Term</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">(Years)</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 49%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Non-vested at January 1, 2018</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,962,500</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.62</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.92</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Granted</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Vested</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(337,500</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.62</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Forfeited</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Non-vested at March 31, 2018</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,625,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.62</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.75</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Non-vested at December 31, 2018</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,612,500</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.62</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.00</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Granted</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Vested</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(337,500</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.62</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Forfeited</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Non-vested at March 31, 2019</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,275,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.62</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.75</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>

1361550

1360806

300000

44859

2015 2016 2017 2018

405227

652424

-405227

-652424

19562

22883

9259

6068

85998

165523

40683

210838

88992

162118

251110

0.08

P6Y292D

37800000

701885

561910

5439

30000

905328

875328

147034

595800

180000

166163

17668

161913

166509

31200

130000

-36897830

-35655053

0.7

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0pt" cellspacing="0pt" style="margin: 0pt auto 0pt 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">2019</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">2018</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 66%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible debt</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,628,234</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,919,160</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 20%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">March 31,</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">2019</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">December 31,</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">2018</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible note payable, due on demand, bearing interest at 7% per annum with conversion rights for 335,833 common shares.</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">826,657</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">809,755</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible notes payable to multiple private investors, including certain notes in default, bearing interest at 5% per annum with conversion rights for 2,775,690 common shares, maturing at various dates between May 2018 and March 2021.</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,480,927</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,333,892</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total convertible notes payable</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,307,584</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,143,647</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less current portion</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,190,461</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,597,760</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible notes payable, less current portion</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,117,123</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,545,887</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 20%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">March 31,</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">2019</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: justify; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">December 31,</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">2018</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loan payable to Global Holdings International, LLC, which bears interest at 15% per annum after defaulting on the maturity date of June 30, 2016. This note is secured by the Company's equipment.</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,675,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,675,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Mortgage payable in default to ARG & Pals, Inc., for the original amount of CAD $385,000. The mortgage bears interest at 22% per annum, and matured on November 21, 2018.</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">288,095</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">282,205</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loan payable in default to an individual, issued January 17, 2018 with a 30-day maturity, bearing share interest of 2,000 common shares per 30-day period. This is an unsecured loan which matured on April 16, 2019.</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loan payable in default to an individual, issued April 13, 2018, with a 30-day maturity, bearing share interest of 4,000 common shares per 30-day period. This is an unsecured loan which matured on April 16, 2019.</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">100,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">100,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total loans payable (all current)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,113,095</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,107,205</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>

167400

P3Y

P30D

20000

1000000

1870000

20000

3962500

3625000

2612500

2275000

0.62

P2Y335D

P2Y273D

P2Y

P1Y273D

550000

1330000

14317500

337500

340875

209250

0.62

25131843

25175243

25473363

25518363

9675000

288095

282205

50000

100000

10113095

10107205

125000

12120

18000

16400

27000

43400

45000

1000000

18180

10168

27270

16740

26908

45450

5000000

167400

-22291320

-21261393

9110041

-28124692

-19014651

13684349

-29445462

-15761113

14393660

-35655053

14606510

-36897830

300000

400000

25495863

25153061

xbrli:shares xbrli:pure utr:acre iso4217:USD iso4217:CAD iso4217:USD xbrli:shares 0001653821 cenb:LeaseArrangement20NorthRearRoadMember 2013-09-01 2013-09-01 0001653821 2016-09-12 2016-09-12 0001653821 us-gaap:PatentedTechnologyMember 2016-09-12 2016-09-12 0001653821 cenb:LeaseArrangement20NorthRearRoadMember 2017-01-01 2017-01-31 0001653821 us-gaap:RestrictedStockMember 2017-01-01 2017-12-31 0001653821 cenb:EquipmentSoldToRelatedPartyInExchangeForNoteReceivableMember cenb:CENBiotechUkraineMember 2017-01-01 2017-12-31 0001653821 us-gaap:RestrictedStockMember 2017-01-01 2018-12-31 0001653821 cenb:LeasesOfficeSpaceFromRdLabsCanadaIncMember 2017-10-01 2017-10-01 0001653821 cenb:RestrictedSharesIssuedForSecurityConsultingServicesMember 2017-11-30 2017-11-30 0001653821 cenb:RestrictedSharesIssuedForSecurityConsultingServicesMember cenb:DirectorDonaldStrilchuckMember 2017-11-30 2017-11-30 0001653821 us-gaap:RestrictedStockMember srt:ChiefExecutiveOfficerMember 2017-11-30 2017-11-30 0001653821 us-gaap:RestrictedStockMember cenb:DirectorAlexTarrabainMember 2017-11-30 2017-11-30 0001653821 us-gaap:RestrictedStockMember cenb:DirectorAmeenFerrisMember 2017-11-30 2017-11-30 0001653821 us-gaap:RestrictedStockMember cenb:DirectorDonaldStrilchuckMember 2017-11-30 2017-11-30 0001653821 us-gaap:RestrictedStockMember cenb:DirectorHaroldAubreyDeLavenuMember 2017-11-30 2017-11-30 0001653821 us-gaap:RestrictedStockMember srt:PresidentMember 2017-11-30 2017-11-30 0001653821 us-gaap:RestrictedStockMember cenb:SeniorExecutiveVicePresidentAndChiefFinancialOfficerMember 2017-11-30 2017-11-30 0001653821 us-gaap:RestrictedStockMember srt:VicePresidentMember 2017-11-30 2017-11-30 0001653821 srt:ChiefExecutiveOfficerMember 2017-11-30 2017-11-30 0001653821 srt:ChiefExecutiveOfficerMember cenb:VestedImmediatelyMember 2017-11-30 2017-11-30 0001653821 srt:PresidentMember 2017-11-30 2017-11-30 0001653821 srt:PresidentMember cenb:VestedImmediatelyMember 2017-11-30 2017-11-30 0001653821 cenb:SeniorExecutiveVicePresidentAndChiefFinancialOfficerMember 2017-11-30 2017-11-30 0001653821 cenb:SeniorExecutiveVicePresidentAndChiefFinancialOfficerMember cenb:VestedImmediatelyMember 2017-11-30 2017-11-30 0001653821 srt:VicePresidentMember 2017-11-30 2017-11-30 0001653821 srt:VicePresidentMember cenb:VestedImmediatelyMember 2017-11-30 2017-11-30 0001653821 2018-01-01 2018-03-31 0001653821 us-gaap:ConvertibleDebtSecuritiesMember 2018-01-01 2018-03-31 0001653821 us-gaap:RestrictedStockMember 2018-01-01 2018-03-31 0001653821 cenb:IndividualLendersMember 2018-01-01 2018-03-31 0001653821 cenb:RelatedPartiesLendersMember 2018-01-01 2018-03-31 0001653821 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-03-31 0001653821 cenb:ConvertibleDebtPayableToRelatedPartyMember 2018-01-01 2018-03-31 0001653821 cenb:LeasesOfficeSpaceFromRdLabsCanadaIncMember 2018-01-01 2018-03-31 0001653821 cenb:ConsultingFeesMember cenb:BoardMembersAndOfficersMember 2018-01-01 2018-03-31 0001653821 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0001653821 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0001653821 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0001653821 2018-01-01 2018-12-31 0001653821 us-gaap:RestrictedStockMember 2018-01-01 2018-12-31 0001653821 cenb:ConvertibleNotes1Member 2018-01-01 2018-12-31 0001653821 cenb:ConvertibleNotes2Member 2018-01-01 2018-12-31 0001653821 cenb:ConvertibleDebtPayableToRelatedPartyMember cenb:BillChaabanPresidentOfCenBiotechMember 2018-01-01 2018-12-31 0001653821 cenb:ConvertibleDebtPayableToRelatedPartyMember cenb:DirectorAlexTarrabainMember 2018-01-01 2018-12-31 0001653821 cenb:ConvertibleDebtPayableToRelatedPartyMember cenb:DirectorHaroldAubreyDeLavenuMember 2018-01-01 2018-12-31 0001653821 cenb:ConvertibleDebtPayableToRelatedPartyMember cenb:JosephByrneMember 2018-01-01 2018-12-31 0001653821 cenb:LoansPayableToRelatedPartyMember 2018-01-01 2018-12-31 0001653821 cenb:LoansPayableToRelatedPartyMember cenb:BillChaabanPresidentOfCenBiotechMember 2018-01-01 2018-12-31 0001653821 cenb:LoansPayableToRelatedPartyMember cenb:CreativeEdgeMember 2018-01-01 2018-12-31 0001653821 cenb:LoansPayableToRelatedPartyMember cenb:DirectorAlexTarrabainMember 2018-01-01 2018-12-31 0001653821 cenb:LoansPayableToRelatedPartyMember cenb:JosephByrneMember 2018-01-01 2018-12-31 0001653821 cenb:LoansPayableToRelatedPartyMember cenb:RDLabsCanadaIncMember 2018-01-01 2018-12-31 0001653821 cenb:LoansPayableToRelatedPartyMember cenb:SpouseOfJosephByrneCEOOfCENBiotechMember 2018-01-01 2018-12-31 0001653821 cenb:CENBiotechUkraineMember 2018-01-01 2018-12-31 0001653821 cenb:SecondShortTermLoanPayableToAnIndividualMember 2018-01-01 2018-12-31 0001653821 cenb:ShortTermLoanPayableToAnIndividualMember 2018-01-01 2018-12-31 0001653821 cenb:ShortTermLoanPayableToGlobalHoldingsInternationalLLCMember 2018-01-01 2018-12-31 0001653821 cenb:ShortTermMortgagePayableToARGPalsIncMember 2018-01-01 2018-12-31 0001653821 2018-03-01 2018-03-31 0001653821 cenb:TeslaDigitalMember 2018-03-01 2018-09-30 0001653821 us-gaap:RestrictedStockMember cenb:DirectorUsamakhSaadikhMember 2018-06-07 2018-06-07 0001653821 2018-06-19 2018-06-19 0001653821 cenb:AstraleENERGYMember 2018-07-31 2018-07-31 0001653821 2018-12-31 2018-12-31 0001653821 2019-01-01 2019-03-31 0001653821 us-gaap:ConvertibleDebtSecuritiesMember 2019-01-01 2019-03-31 0001653821 us-gaap:RestrictedStockMember 2019-01-01 2019-03-31 0001653821 cenb:IndividualLendersMember 2019-01-01 2019-03-31 0001653821 cenb:RelatedPartiesLendersMember 2019-01-01 2019-03-31 0001653821 cenb:ConvertibleNotes1Member 2019-01-01 2019-03-31 0001653821 cenb:ConvertibleNotes2Member 2019-01-01 2019-03-31 0001653821 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-03-31 0001653821 us-gaap:DomesticCountryMember us-gaap:CanadaRevenueAgencyMember 2019-01-01 2019-03-31 0001653821 us-gaap:ConvertibleDebtMember 2019-01-01 2019-03-31 0001653821 cenb:ConvertibleDebtPayableToRelatedPartyMember 2019-01-01 2019-03-31 0001653821 cenb:ConvertibleDebtPayableToRelatedPartyMember cenb:BillChaabanPresidentOfCenBiotechMember 2019-01-01 2019-03-31 0001653821 cenb:ConvertibleDebtPayableToRelatedPartyMember cenb:DirectorAlexTarrabainMember 2019-01-01 2019-03-31 0001653821 cenb:ConvertibleDebtPayableToRelatedPartyMember cenb:DirectorHaroldAubreyDeLavenuMember 2019-01-01 2019-03-31 0001653821 cenb:ConvertibleDebtPayableToRelatedPartyMember cenb:JosephByrneMember 2019-01-01 2019-03-31 0001653821 cenb:LoansPayableToRelatedPartyMember 2019-01-01 2019-03-31 0001653821 cenb:LoansPayableToRelatedPartyMember cenb:BillChaabanPresidentOfCenBiotechMember 2019-01-01 2019-03-31 0001653821 cenb:LoansPayableToRelatedPartyMember cenb:CreativeEdgeMember 2019-01-01 2019-03-31 0001653821 cenb:LoansPayableToRelatedPartyMember cenb:DirectorAlexTarrabainMember 2019-01-01 2019-03-31 0001653821 cenb:LoansPayableToRelatedPartyMember cenb:JosephByrneMember 2019-01-01 2019-03-31 0001653821 cenb:LoansPayableToRelatedPartyMember cenb:RDLabsCanadaIncMember 2019-01-01 2019-03-31 0001653821 cenb:LoansPayableToRelatedPartyMember cenb:SpouseOfJosephByrneCEOOfCENBiotechMember 2019-01-01 2019-03-31 0001653821 cenb:LeasesOfficeSpaceFromRdLabsCanadaIncMember 2019-01-01 2019-03-31 0001653821 cenb:ConsultingFeesMember cenb:BoardMembersAndOfficersMember 2019-01-01 2019-03-31 0001653821 cenb:CENBiotechUkraineMember 2019-01-01 2019-03-31 0001653821 cenb:SecondShortTermLoanPayableToAnIndividualMember 2019-01-01 2019-03-31 0001653821 cenb:ShortTermLoanPayableToAnIndividualMember 2019-01-01 2019-03-31 0001653821 cenb:ShortTermLoanPayableToGlobalHoldingsInternationalLLCMember 2019-01-01 2019-03-31 0001653821 cenb:ShortTermMortgagePayableToARGPalsIncMember 2019-01-01 2019-03-31 0001653821 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001653821 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001653821 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001653821 us-gaap:RestrictedStockMember us-gaap:SubsequentEventMember cenb:VicePresidentAndChiefFinancialOfficerMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2019-05-16 2019-05-16 0001653821 us-gaap:RestrictedStockMember us-gaap:SubsequentEventMember cenb:VicePresidentAndChiefFinancialOfficerMember cenb:VestingOneMonthAfterGrantMember 2019-05-16 2019-05-16 0001653821 us-gaap:SubsequentEventMember cenb:VicePresidentAndChiefFinancialOfficerMember 2019-05-16 2019-05-16 0001653821 us-gaap:SubsequentEventMember cenb:VicePresidentAndChiefFinancialOfficerMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2019-05-16 2019-05-16 0001653821 us-gaap:SubsequentEventMember cenb:VicePresidentAndChiefFinancialOfficerMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2019-05-16 2019-05-16 0001653821 us-gaap:SubsequentEventMember cenb:VicePresidentAndChiefFinancialOfficerMember cenb:VestingAtTheEndOfEachOneMonthAnniversaryOfRantDateMember 2019-05-16 2019-05-16 0001653821 us-gaap:SubsequentEventMember cenb:VicePresidentAndChiefFinancialOfficerMember cenb:VestingOneMonthAfterGrantMember 2019-05-16 2019-05-16 0001653821 cenb:ConvertibleDebtInDefaultMember us-gaap:SubsequentEventMember 2019-05-20 2019-05-20 0001653821 cenb:ConvertibleDebtToRelatedPartyInDefaultMember us-gaap:SubsequentEventMember 2019-05-20 2019-05-20 0001653821 cenb:LeasesOfficeSpaceFromRdLabsCanadaIncMember 2022-09-01 2022-09-01 0001653821 cenb:LeaseArrangement20NorthRearRoadMember 2016-12-31 0001653821 cenb:ConvertibleDebtIssuedToLessorsCreditorMember 2017-01-31 0001653821 cenb:LeaseArrangement20NorthRearRoadMember 2017-01-31 0001653821 cenb:LongTermConvertibleNotesPayableToMultiplePrivateInvestorsMember 2017-07-12 0001653821 cenb:EquityCompensation2017PlanMember 2017-11-29 0001653821 cenb:CENBiotechUkraineMember 2017-12-02 0001653821 cenb:CENBiotechUkraineMember 2017-12-03 0001653821 2017-12-31 0001653821 us-gaap:RestrictedStockMember 2017-12-31 0001653821 us-gaap:RestrictedStockMember cenb:VestingProrateOverTheRequisiteServicePeriodMember 2017-12-31 0001653821 cenb:EquipmentSoldToRelatedPartyInExchangeForNoteReceivableMember cenb:CENBiotechUkraineMember 2017-12-31 0001653821 cenb:PurchasedEquipmentInExchangeForNotePayableMember cenb:RDLabsCanadaIncMember 2017-12-31 0001653821 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001653821 us-gaap:CommonStockMember 2017-12-31 0001653821 us-gaap:RetainedEarningsMember 2017-12-31 0001653821 2018-03-31 0001653821 us-gaap:RestrictedStockMember 2018-03-31 0001653821 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0001653821 us-gaap:CommonStockMember 2018-03-31 0001653821 us-gaap:RetainedEarningsMember 2018-03-31 0001653821 2018-12-31 0001653821 us-gaap:RestrictedStockMember 2018-12-31 0001653821 cenb:ConvertibleNotes1Member 2018-12-31 0001653821 cenb:ConvertibleNotes1Member us-gaap:ConvertibleDebtMember 2018-12-31 0001653821 cenb:ConvertibleNotes2Member 2018-12-31 0001653821 cenb:ConvertibleNotes2Member us-gaap:ConvertibleDebtMember 2018-12-31 0001653821 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-12-31 0001653821 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-12-31 0001653821 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-12-31 0001653821 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2018-12-31 0001653821 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-12-31 0001653821 us-gaap:ConvertibleDebtMember 2018-12-31 0001653821 cenb:ConvertibleDebtPayableToRelatedPartyMember 2018-12-31 0001653821 cenb:ConvertibleDebtPayableToRelatedPartyMember cenb:BillChaabanPresidentOfCenBiotechMember 2018-12-31 0001653821 cenb:ConvertibleDebtPayableToRelatedPartyMember cenb:DirectorAlexTarrabainMember 2018-12-31 0001653821 cenb:ConvertibleDebtPayableToRelatedPartyMember cenb:DirectorHaroldAubreyDeLavenuMember 2018-12-31 0001653821 cenb:ConvertibleDebtPayableToRelatedPartyMember cenb:JosephByrneMember 2018-12-31 0001653821 cenb:LoansPayableToRelatedPartyMember 2018-12-31 0001653821 cenb:LoansPayableToRelatedPartyMember cenb:BillChaabanPresidentOfCenBiotechMember 2018-12-31 0001653821 cenb:LoansPayableToRelatedPartyMember cenb:CreativeEdgeMember 2018-12-31 0001653821 cenb:LoansPayableToRelatedPartyMember cenb:DirectorAlexTarrabainMember 2018-12-31 0001653821 cenb:LoansPayableToRelatedPartyMember cenb:JosephByrneMember 2018-12-31 0001653821 cenb:LoansPayableToRelatedPartyMember cenb:RDLabsCanadaIncMember 2018-12-31 0001653821 cenb:LoansPayableToRelatedPartyMember cenb:SpouseOfJosephByrneCEOOfCENBiotechMember 2018-12-31 0001653821 cenb:FurnitureAndEquipmentMember 2018-12-31 0001653821 us-gaap:LeaseholdImprovementsMember 2018-12-31 0001653821 cenb:ConsultingFeesMember cenb:BoardMembersAndOfficersMember 2018-12-31 0001653821 cenb:CENBiotechUkraineMember 2018-12-31 0001653821 cenb:SecondShortTermLoanPayableToAnIndividualMember 2018-12-31 0001653821 cenb:ShortTermLoanPayableToAnIndividualMember 2018-12-31 0001653821 cenb:ShortTermLoanPayableToGlobalHoldingsInternationalLLCMember 2018-12-31 0001653821 cenb:ShortTermMortgagePayableToARGPalsIncMember 2018-12-31 0001653821 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001653821 us-gaap:CommonStockMember 2018-12-31 0001653821 us-gaap:RetainedEarningsMember 2018-12-31 0001653821 2019-03-31 0001653821 us-gaap:RestrictedStockMember 2019-03-31 0001653821 cenb:ConvertibleNotes1Member 2019-03-31 0001653821 cenb:ConvertibleNotes1Member us-gaap:ConvertibleDebtMember 2019-03-31 0001653821 cenb:ConvertibleNotes2Member 2019-03-31 0001653821 cenb:ConvertibleNotes2Member us-gaap:ConvertibleDebtMember 2019-03-31 0001653821 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-03-31 0001653821 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-03-31 0001653821 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-03-31 0001653821 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-03-31 0001653821 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-03-31 0001653821 us-gaap:ConvertibleDebtMember 2019-03-31 0001653821 cenb:ConvertibleDebtPayableToRelatedPartyMember 2019-03-31 0001653821 cenb:ConvertibleDebtPayableToRelatedPartyMember cenb:BillChaabanPresidentOfCenBiotechMember 2019-03-31 0001653821 cenb:ConvertibleDebtPayableToRelatedPartyMember cenb:DirectorAlexTarrabainMember 2019-03-31 0001653821 cenb:ConvertibleDebtPayableToRelatedPartyMember cenb:DirectorHaroldAubreyDeLavenuMember 2019-03-31 0001653821 cenb:ConvertibleDebtPayableToRelatedPartyMember cenb:JosephByrneMember 2019-03-31 0001653821 cenb:LoansPayableToRelatedPartyMember 2019-03-31 0001653821 cenb:LoansPayableToRelatedPartyMember cenb:BillChaabanPresidentOfCenBiotechMember 2019-03-31 0001653821 cenb:LoansPayableToRelatedPartyMember cenb:CreativeEdgeMember 2019-03-31 0001653821 cenb:LoansPayableToRelatedPartyMember cenb:DirectorAlexTarrabainMember 2019-03-31 0001653821 cenb:LoansPayableToRelatedPartyMember cenb:JosephByrneMember 2019-03-31 0001653821 cenb:LoansPayableToRelatedPartyMember cenb:RDLabsCanadaIncMember 2019-03-31 0001653821 cenb:LoansPayableToRelatedPartyMember cenb:SpouseOfJosephByrneCEOOfCENBiotechMember 2019-03-31 0001653821 cenb:FurnitureAndEquipmentMember 2019-03-31 0001653821 us-gaap:LeaseholdImprovementsMember 2019-03-31 0001653821 cenb:LeaseArrangement20NorthRearRoadMember 2019-03-31 0001653821 cenb:LeasesOfficeSpaceFromRdLabsCanadaIncMember 2019-03-31 0001653821 cenb:ConsultingFeesMember cenb:BoardMembersAndOfficersMember 2019-03-31 0001653821 cenb:CENBiotechUkraineMember 2019-03-31 0001653821 cenb:SecondShortTermLoanPayableToAnIndividualMember 2019-03-31 0001653821 cenb:ShortTermLoanPayableToAnIndividualMember 2019-03-31 0001653821 cenb:ShortTermLoanPayableToGlobalHoldingsInternationalLLCMember 2019-03-31 0001653821 cenb:ShortTermMortgagePayableToARGPalsIncMember 2019-03-31 0001653821 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001653821 us-gaap:CommonStockMember 2019-03-31 0001653821 us-gaap:RetainedEarningsMember 2019-03-31 0001653821 2019-05-20 0001653821 cenb:CENBiotechUkraineMember srt:ScenarioForecastMember 2019-05-20 0001653821 cenb:ConvertibleDebtInDefaultMember us-gaap:SubsequentEventMember 2019-05-20 0001653821 cenb:ConvertibleDebtPayableToRelatedPartyMember us-gaap:SubsequentEventMember 2019-05-20

EX-101.SCH 7 cenb-20190331.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Condensed Consolidated Statements of Shareholders' Deficit (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 006 - Disclosure - Note 1 - Basis of Presentation and Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 2 - New Accounting Standard link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 3 - Going Concern Uncertainty / Management Plans link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 4 - Property, Plant and Improvements, Net link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 5 - Advances to CEN Biotech Ukraine link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 6 - Intangible Assets link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 7 - Loans Payable link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 9 - Convertible Notes link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 11 - Income Taxes link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 12 - Shareholders' Deficit / Stock Activity link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 14 - Stock Based Compensation link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 16 - Contingency link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 17 - Fair Value Disclosures link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 18 - Subsequent Event link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 4 - Property, Plant and Improvements, Net (Tables) link:calculationLink link:definitionLink link:presentationLink 026 - Disclosure - Note 6 - Intangible Assets (Tables) link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 7 - Loans Payable (Tables) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 9 - Convertible Notes (Tables) link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note 11 - Income Taxes (Tables) link:calculationLink link:definitionLink link:presentationLink 032 - Disclosure - Note 14 - Stock Based Compensation (Tables) link:calculationLink link:definitionLink link:presentationLink 034 - Disclosure - Note 17 - Fair Value Disclosures (Tables) link:calculationLink link:definitionLink link:presentationLink 035 - Disclosure - Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 036 - Disclosure - Note 3 - Going Concern Uncertainty / Management Plans (Details Textual) link:calculationLink link:definitionLink link:presentationLink 037 - Disclosure - Note 4 - Property, Plant and Improvements, Net (Details Textual) link:calculationLink link:definitionLink link:presentationLink 038 - Disclosure - Note 4 - Property, Plant and Improvements, Net - Property, Plant and Improvement Placed in Service (Details) link:calculationLink link:definitionLink link:presentationLink 039 - Disclosure - Note 5 - Advances to CEN Biotech Ukraine (Details Textual) link:calculationLink link:definitionLink link:presentationLink 040 - Disclosure - Note 6 - Intangible Assets (Details Textual) link:calculationLink link:definitionLink link:presentationLink 041 - Disclosure - Note 6 - Intangible Assets - Intangible Assets (Details) link:calculationLink link:definitionLink link:presentationLink 042 - Disclosure - Note 7 - Loans Payable (Details Textual) link:calculationLink link:definitionLink link:presentationLink 043 - Disclosure - Note 7 - Loans Payable - Loans Payable (Details) link:calculationLink link:definitionLink link:presentationLink 044 - Disclosure - Note 7 - Loans Payable - Loans Payable (Details) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 048 - Disclosure - Note 9 - Convertible Notes (Details Textual) link:calculationLink link:definitionLink link:presentationLink 049 - Disclosure - Note 9 - Convertible Notes - Convertible Notes (Details) link:calculationLink link:definitionLink link:presentationLink 050 - Disclosure - Note 9 - Convertible Notes - Convertible Notes (Details) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 054 - Disclosure - Note 11 - Income Taxes (Details Textual) link:calculationLink link:definitionLink link:presentationLink 055 - Disclosure - Note 11 - Income Taxes - Reconciliation of Effective Tax Rate (Details) link:calculationLink link:definitionLink link:presentationLink 056 - Disclosure - Note 11 - Income Taxes - Deferred Tax Assets (Details) link:calculationLink link:definitionLink link:presentationLink 057 - Disclosure - Note 12 - Shareholders' Deficit / Stock Activity (Details Textual) link:calculationLink link:definitionLink link:presentationLink 059 - Disclosure - Note 14 - Stock Based Compensation (Details Textual) link:calculationLink link:definitionLink link:presentationLink 060 - Disclosure - Note 14 - Stock Based Compensation - Restricted Stock Award Activity (Details) link:calculationLink link:definitionLink link:presentationLink 062 - Disclosure - Note 17 - Fair Value Disclosures - Fair Value of Financial Instruments (Details) link:calculationLink link:definitionLink link:presentationLink 063 - Disclosure - Note 18 - Subsequent Event (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 8 cenb-20190331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 cenb-20190331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 cenb-20190331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Note To Financial Statement Details Textual cenb_NoncashOrPartNoncashAcquisitionNoncashConsiderationCarryingValueOfPropertiesToBeTransferred Noncash or Part Noncash Acquisition, Noncash Consideration, Carrying Value of Properties to be Transferred The carrying value of the properties to be transferred in a noncash or part noncash consideration for a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Significant Accounting Policies Note 4 - Property, Plant and Improvements, Net Note 6 - Intangible Assets Note 7 - Loans Payable Note 8 - Loans Payable - Related Party us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months Note 9 - Convertible Notes Note 10 - Convertible Notes - Related Party Note 11 - Income Taxes Note 14 - Stock Based Compensation Income Tax Disclosure [Text Block] Note 15 - Net Loss Per Share Note 17 - Fair Value Disclosures Note 4 - Property, Plant and Improvements, Net - Property, Plant and Improvement Placed in Service (Details) Stock based compensation Stock-based compensation – employees Note 6 - Intangible Assets - Intangible Assets (Details) Note 7 - Loans Payable - Loans Payable (Details) us-gaap_LiabilitiesCurrent Total current liabilities Note 7 - Loans Payable - Loans Payable (Details) (Parentheticals) Note 8 - Loans Payable - Related Party - Loans Payable to Related Parties (Details) Business Combinations Policy [Policy Text Block] us-gaap_FiniteLivedIntangibleAssetUsefulLife Finite-Lived Intangible Asset, Useful Life Note 8 - Loans Payable - Related Party - Loans Payable to Related Parties (Details) (Parentheticals) Note 9 - Convertible Notes - Convertible Notes (Details) Earnings Per Share, Policy [Policy Text Block] Note 9 - Convertible Notes - Convertible Notes (Details) (Parentheticals) Note 10 - Convertible Notes - Related Party - Convertible Notes Payable to Related Parties (Details) Note 10 - Convertible Notes - Related Party - Convertible Notes Payable to Related Parties (Details) (Parentheticals) Non-vested, weighted average remaining contractual term (Year) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Note 11 - Income Taxes - Reconciliation of Effective Tax Rate (Details) Amortization Note 11 - Income Taxes - Deferred Tax Assets (Details) Note 14 - Stock Based Compensation - Restricted Stock Award Activity (Details) Note 15 - Net Loss Per Share - Antidilutive Securities (Details) Operating expenses Note 17 - Fair Value Disclosures - Fair Value of Financial Instruments (Details) Notes To Financial Statements Notes To Financial Statements [Abstract] Granted, weighted average grant date fair value (in dollars per share) us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired Business Acquisition, Percentage of Voting Interests Acquired Vested, weighted average grant date fair value (in dollars per share) Forfeited, weighted average grant date fair value (in dollars per share) Schedule of Finite-Lived Intangible Assets [Table Text Block] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Non-vested, weighted average grant date fair value (in dollars per share) Non-vested, weighted average grant date fair value (in dollars per share) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Forfeited, number of share (in shares) us-gaap_LesseeOperatingLeaseTermOfContract Lessee, Operating Lease, Term of Contract us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance Non-vested, number of share (in shares) Non-vested, number of share (in shares) Depreciation Depreciation, Total Granted, number of share (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Vested, number of share (in shares) Intangible Assets Disclosure [Text Block] Nonvested Restricted Stock Shares Activity [Table Text Block] Less: current portion us-gaap_LongTermDebtCurrent Loans payable Cash and cash equivalents us-gaap_CashAndCashEquivalentsFairValueDisclosure Stockholders' Equity Note Disclosure [Text Block] Convertible notes payable Common stock; unlimited authorized shares; 25,518,363 and 25,473,363 issued and outstanding as of March 31, 2019 and December 31, 2018, respectively. No par value. Interest income Adjustments to reconcile net loss to net cash used in operating activities Common stock, shares authorized Common stock, shares issued (in shares) us-gaap_LesseeOperatingLeaseDiscountRate Lessee, Operating Lease, Discount Rate Common stock, par value (in dollars per share) Common Stock, No Par Value us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Accrued expenses us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Common Stock, Capital Shares Reserved for Future Issuance us-gaap_DeferredTaxAssetsValuationAllowance Deferred tax asset valuation allowance us-gaap_InterestPayableCurrent Accrued interest Accounts payable us-gaap_PaymentsForProceedsFromProductiveAssets Leasehold improvements in progress us-gaap_DeferredTaxAssetsNet Net deferred tax asset Cash paid for interest us-gaap_PolicyTextBlockAbstract Accounting Policies Property, Plant and Equipment Disclosure [Text Block] Second Short-term Loan Payable to an Individual [Member] Represents information pertaining to a second short-term loan payable to an individual. Property, Plant and Equipment [Table Text Block] Portion at Fair Value Measurement [Member] [Default] Estimate of Fair Value Measurement [Member] Furniture and Equipment [Member] Represents the information pertaining to furniture and equipment. cenb_FinitelivedIntangibleAssetsAmortizationExpenseAfterYearThirteen Finite-Lived Intangible Assets, Amortization Expense, After Year Thirteen Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the thirteenth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. cenb_IncreaseDecreaseInOperatingLeaseRightOfUseAsset Operating lease right-of-use assets Amount of increase (decrease) in operating lease right-of-use asset. Measurement Basis [Axis] Fair Value, Inputs, Level 3 [Member] Foreign exchange (loss) gain Non-cash transactions - investing and financing activities Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Weighted Average Number of Shares Outstanding Fair Value Hierarchy and NAV [Axis] Patent acquisition liability modification cenb_AdjustmentsToAdditionalPaidInCapitalPatentAcquisitionLiabilityModification Adjustments to Additional Paid in Capital, Patent Acquisition Liability Modification Amount of increase (decrease) to additional paid in capital (APIC) resulting from patent acquisition liability modification. Current liabilities Vesting [Axis] Patented Technology [Member] Vesting [Domain] Share-based Payment Arrangement, Tranche One [Member] Share-based Payment Arrangement, Tranche Two [Member] us-gaap_Assets Total assets Supplemental cash flows disclosures Plan Name [Axis] Plan Name [Domain] us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount us-gaap_OperatingLeaseExpense Operating Lease, Expense Cash flows from operating activities Statement [Line Items] Short-term Loan Payable to an Individual [Member] Represents the information pertaining the short-term loan payable to an individual. cenb_OperatingLeaseLiabilitiesPayments Operating lease liabilities The Cash outflow (inflow) from operating lease liabilities. us-gaap_DebtDefaultLongtermDebtAmount Debt Instrument, Debt Default, Amount Additional paid-in capital Creative Edge [Member] Former parent entity of the company. Share Interest (in shares) Contractual share interest, per 30-day period, for funds borrowed under the debt agreement. Finite-Lived Intangible Assets by Major Class [Axis] Share-based Payment Arrangement [Text Block] Finite-Lived Intangible Assets, Major Class Name [Domain] Shareholders’ deficit cenb_OperatingLeaseAnnualRent Operating Lease Annual Rent Amount of the annual rent required for operating lease. Leasehold Improvements [Member] Property, Plant and Equipment, Type [Axis] us-gaap_NonoperatingIncomeExpense Other expense, net Other receivables us-gaap_LoansReceivableFairValueDisclosure Property, Plant and Equipment, Type [Domain] Award Type [Domain] Spouse of Joseph Byrne, CEO of CEN Biotech [Member] Represents the information pertaining to the spouse of Joseph Bryne, CEO of CEN Biotech. Deferred tax asset - net operating losses Chief Executive Officer [Member] Current assets Fair Value Disclosures [Text Block] Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction Sale of Stock, Percentage of Ownership after Transaction Award Type [Axis] Fair Value, by Balance Sheet Grouping [Table Text Block] Net loss Net loss us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Accumulated amortization us-gaap_FiniteLivedIntangibleAssetsNet Net Intangible assets, net Lighting patent us-gaap_FiniteLivedIntangibleAssetsGross Restricted Stock [Member] Other assets us-gaap_Liabilities Total liabilities us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash provided by financing activities Commitments and contingencies us-gaap_PaymentsToFundLongtermLoansToRelatedParties Payments to Fund Long-term Loans to Related Parties Convertible Debt Securities [Member] us-gaap_OperatingIncomeLoss Loss from operations us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash used in operating activities Other (expense) income us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash used in investing activities Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] cenb_EmploymentAgreementCompensationSharesOfCommonStock Employment Agreement, Compensation, Shares of Common Stock The number of common shares issued to the employee as compensation for service pursuant to the employment agreement. us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease Net increase in cash and cash equivalents Vice President and Chief Financial Officer [Member] Information pertaining to the vice president and chief financial officer. Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Counterparty Name [Axis] Counterparty Name [Domain] us-gaap_DueToRelatedPartiesCurrentAndNoncurrent Due to Related Parties, Total Commitments and Contingencies Disclosure [Text Block] us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated depreciation and amortization Property and equipment, net Net property, plant and improvements us-gaap_PropertyPlantAndEquipmentGross Property, plant and equipment, gross Canada Revenue Agency [Member] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Tesla Digital [Member] Represents the information pertaining to Tesla Digital. us-gaap_DueFromRelatedParties Due from Related Parties, Total Property, plant and improvements Related Parties Lenders [Member] Represents the information pertaining to related-party lenders. Individual Lenders [Member] Represents the information pertaining to the individual lenders. President [Member] us-gaap_AccruedRentCurrentAndNoncurrent Accrued Rent Cash flows from investing activities Scenario [Domain] Forecast [Member] Vesting at The End of Each One Month Anniversary of rant Date [Member] Represents awards vesting at the end of each one (1) month anniversary of the Grant Date. Vesting One Month After Grant [Member] Represents awards vesting one month after grant. Retained Earnings [Member] Earnings Per Share [Text Block] Convertible Debt [Member] Title of Individual [Domain] Title of Individual [Axis] Scenario [Axis] us-gaap_RelatedPartyTransactionAmountsOfTransaction Related Party Transaction, Amounts of Transaction Vice President [Member] Additional Paid-in Capital [Member] Common Stock [Member] EX-101.PRE 11 cenb-20190331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Mar. 31, 2019	May 20, 2019
Document Information [Line Items]
Entity Registrant Name	CEN BIOTECH INC
Entity Central Index Key	0001653821
Trading Symbol	cenb
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		25,548,363
Document Type	10-Q
Document Period End Date	Mar. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1
Amendment Flag	false

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Current assets
Cash and cash equivalents	$ 39,752	$ 3,193
Property, plant and improvements
Property and equipment, net	161,913	166,509
Other assets
Operating lease right-of-use assets	251,110
Other receivable	417,904	418,905
Note receivable – related party	44,859	44,859
Advances to CEN Biotech Ukraine LLC – related party	905,328	875,328
Intangible assets, net	5,699,568	5,805,771
Total assets	7,520,434	7,314,565
Current liabilities
Accounts payable	206,521	206,521
Loans payable	10,113,095	10,107,205
Loans payable – related parties	1,361,550	1,360,806
Convertible notes payable	4,190,461	3,597,760
Convertible notes payable – related parties	926,368	926,368
Accrued interest	7,544,199	6,860,494
Accrued interest – related parties	1,032,171	946,227
Operating lease liabilities	40,683
Accrued expenses	446,432	402,377
Total current liabilities	25,861,480	24,407,758
Operating lease liabilities, less current portion	210,838
Patent acquisition liability	1,010,000	1,010,000
Convertible notes, less current portion	1,117,123	1,545,887
Convertible notes – related parties, less current portion	1,612,313	1,612,313
Total liabilities	29,811,754	28,575,958
Commitments and contingencies	0	0
Shareholders’ deficit
Common stock; unlimited authorized shares; 25,518,363 and 25,473,363 issued and outstanding as of March 31, 2019 and December 31, 2018, respectively. No par value.
Additional paid-in capital	14,606,510	14,393,660
Accumulated deficit	(36,897,830)	(35,655,053)
Total shareholders’ deficit	(22,291,320)	(21,261,393)
Total liabilities and shareholders’ deficit	$ 7,520,434	$ 7,314,565

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares $ / shares in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Common stock, par value (in dollars per share)	$ 0	$ 0
Common stock, shares issued (in shares)	25,518,363	25,473,363
Common stock, shares outstanding (in shares)	25,518,363	25,473,363
Common stock, shares authorized	Unlimited	Unlimited

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Operating expenses
Consulting fees	$ 18,942	$ 11,985
Consulting fees – related parties	31,200	31,200
Stock based compensation	167,400	167,400
General and administrative	187,685	441,839
Total operating expenses	405,227	652,424
Loss from operations	(405,227)	(652,424)
Other (expense) income
Interest expense	(701,888)	(594,503)
Interest expense – related parties	(113,213)	(104,286)
Interest income	2,045	0
Foreign exchange (loss) gain	(24,494)	30,443
Other expense, net	(837,550)	(668,346)
Net loss	$ (1,242,777)	$ (1,320,770)
Net Loss Per Share:
Basic and diluted (in dollars per share)	$ (0.05)	$ (0.05)
Weighted Average Number of Shares Outstanding
Basic and diluted (in shares)	25,495,863	25,153,061

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Shareholders' Deficit (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balances (in shares) at Dec. 31, 2017	25,131,843
Balances at Dec. 31, 2017		$ 9,110,041	$ (28,124,692)	$ (19,014,651)
Patent acquisition liability modification		4,380,000		4,380,000
Stock-based compensation (in shares)
Stock-based compensation		167,400		167,400
Issuance of common stock – interest shares (in shares)	43,400
Issuance of common stock – interest shares		26,908		26,908
Net loss			(1,320,770)	(1,320,770)
Balances (in shares) at Mar. 31, 2018	25,175,243
Balances at Mar. 31, 2018		13,684,349	(29,445,462)	(15,761,113)
Balances (in shares) at Dec. 31, 2018	25,473,363
Balances at Dec. 31, 2018		14,393,660	(35,655,053)	(21,261,393)
Stock-based compensation (in shares)
Stock-based compensation		167,400		167,400
Issuance of common stock – interest shares (in shares)	45,000
Issuance of common stock – interest shares		45,450		45,450
Net loss			(1,242,777)	(1,242,777)
Balances (in shares) at Mar. 31, 2019	25,518,363
Balances at Mar. 31, 2019		$ 14,606,510	$ (36,897,830)	$ (22,291,320)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 17 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cash flows from operating activities
Net loss	$ (1,242,777)	$ (1,320,770)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation	4,596	442
Amortization	106,203	106,203
Stock-based compensation – employees	167,400	167,400
Non-cash interest expense	701,885	561,910
Non-cash interest expense – related parties	113,214	104,286
Deferred lease expense		13,576
Foreign exchange loss (gain)	24,494	(30,443)
Changes in operating assets and liabilities which provided (used) cash
Operating lease right-of-use assets	5,216
Other receivable	1,001	(146,018)
Accounts payable	(957)	14,770
Accounts payable – related parties		(7,585)
Operating lease liabilities	4,805
Accrued expenses	44,055	12,903
Net cash used in operating activities	(80,475)	(523,326)
Cash flows from investing activities
Advance on business acquisition	(30,000)
Leasehold improvements in progress		(5,439)
Net cash used in investing activities	(30,000)	(5,439)
Cash flows from financing activities
Issuance of loans payable		180,000
Repayment of loans payable		(130,000)
Issuance of loans payable – related parties		225,000
Issuance of convertible notes	147,034	595,800
Net cash provided by financing activities	147,034	870,800
Net increase in cash and cash equivalents	36,559	342,035
Cash and cash equivalents, beginning of period	3,193	84,978
Cash and cash equivalents, end of period	39,752	427,013
Supplemental cash flows disclosures
Cash paid for interest		32,593
Non-cash transactions - investing and financing activities
Patent acquisition liability modification		$ 4,380,000

XML 18 R7.htm IDEA: XBRL DOCUMENT

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]	NOTE 1 – BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The accompanying unaudited interim condensed consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and with the rules and regulations of the United States Securities and Exchange Commission (the “SEC”) set forth in Article 8 of Regulation S- X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) which are, in the opinion of management, necessary to a fair statement of the results for the interim periods presented. Unaudited interim results are not necessarily indicative of the results for the full fiscal year. These financial statements should be read in conjunction with the condensed consolidated financial statements of the Company for the year ended December 31, 2018 and notes thereto. There have been no material changes in the Company’s significant accounting policies as compared to the significant accounting policies described in the Company’s annual report on Form 10 -K for the year ended December 31, 2018. Loss per Share Net loss per common share is computed pursuant to ASC 260 - 10 - 45. Basic loss per share is computed based on the weighted average number of common shares outstanding during the period. Diluted net loss per share is calculated by dividing net loss by the diluted weighted average common shares outstanding, which includes the effect of potentially dilutive securities. During periods when there is a net loss, all potentially dilutive shares are anti-dilutive and are excluded from the calculation of net loss per share. Diluted earnings per share is similarly computed except that the denominator includes the effect, using the treasury stock method, of unvested restricted stock and convertible notes, if including such potential shares of common stock is dilutive. For the three -months ended March 31, 2019 and 2018, the common stock equivalents of the convertible note agreements were not included in diluted earnings per share computations because their effect was antidilutive. Share Purchase Agreement On July 31, 2018, the Company entered into a Share Purchase Agreement with AstralENERGY Solar Manufacturing Corporation, LTD. (“AstralENERGY”) to acquire 70% of the outstanding common stock of AstralENERGY. The Company will issue an aggregate 2,500,000 shares of common stock of the Company as consideration for the acquisition. AstralENERGY is a manufacturer of architecturally designed solar panels for residential and commercial solar production and has also developed integrated multi-function LED street lighting systems. Consummation of the acquisition is subject to the completion of certain conditions specified in the agreement. As of May 20, 2019, this transaction has not closed.

XML 19 R8.htm IDEA: XBRL DOCUMENT

Note 2 - New Accounting Standard	3 Months Ended
Note 2 - New Accounting Standard	Mar. 31, 2019
Notes to Financial Statements
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]	NOTE 2 – NEW ACCOUNTING STANDARD Adoption of New Accounting Standard The Company adopted Accounting Standards Codification (ASC) 842, “ Leases ” using the modified retrospective approach, effective January 1, 2019, on its condensed consolidated financial statements. The comparative information has not been restated and continues to be reported under the lease accounting standard in effect for those periods. The new lease standard requires all leases to be reported on the balance sheet as right-of-use assets and lease obligations. We elected the practical expedients permitted under the transition guidance of the new standard.

XML 20 R9.htm IDEA: XBRL DOCUMENT

Note 3 - Going Concern Uncertainty / Management Plans	3 Months Ended
Note 3 - Going Concern Uncertainty / Management Plans	Mar. 31, 2019
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	NOTE 3 – GOING CONCERN UNCERTAINTY / MANAGEMENT PLANS The accompanying condensed consolidated financial statements have been prepared in contemplating continuation of the Company as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. However, a substantial doubt has been raised with regard to the ability of the Company to continue as a going concern. The Company has incurred significant operating losses and negative cash flows from operations since inception. The Company had an accumulated deficit of $36,897,830 at March 31, 2019 and had no committed source of additional debt or equity financing. The Company has not had any operating revenue and does not foresee any operating revenue in the near term. The Company has relied on the issuance of loans payable and convertible debt instruments to finance its expenses, including notes that are in default, as described in Notes 7, 8, 9, and 10. The Company will be dependent upon raising additional capital through placement of our common stock, notes or other securities in order to implement its business plan or additional borrowings, including from related parties. There can be no assurance that the Company will be successful in either situation in order to continue as a going concern. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties. The Company’s cash position may not be sufficient to support the Company’s daily operations or its ability to undertake any business activity that will generate net revenue.

XML 21 R10.htm IDEA: XBRL DOCUMENT

Note 4 - Property, Plant and Improvements, Net

3 Months Ended

Mar. 31, 2019

Notes to Financial Statements

Property, Plant and Equipment Disclosure [Text Block]

NOTE

– PROPERTY, PLANT AND IMPROVEMENTS, NET

Property and equipment, net consists of the following as of:

	March 31, 2019			December 31, 2018
Leasehold improvements	$	166,163		$	166,163
Furniture and equipment		17,668			17,668
Accumulated depreciation and amortization		(21,918	)		(17,322	)

Net property, plant and improvements	$	161,913		$	166,509

Depreciation and amortization expense was

$4,596

and

$442

for the

three

-months ended

March 31, 2019

and

2018,

respectively.

XML 22 R11.htm IDEA: XBRL DOCUMENT

Note 5 - Advances to CEN Biotech Ukraine	3 Months Ended
Note 5 - Advances to CEN Biotech Ukraine	Mar. 31, 2019
Notes to Financial Statements
Advances to Related Party [Text Block]	NOTE 5 – ADVANCES TO CEN BIOTECH UKRAINE At March 31, 2019 and December 31, 2018, the Company had advances of $905,328 and $875,328, respectively, to CEN Biotech Ukraine, LLC, a related party, (see Note 13 ). The advances were for the purpose of funding the operations of CEN Biotech Ukraine, LLC and are unsecured, non-interest bearing, and are due on demand.

XML 23 R12.htm IDEA: XBRL DOCUMENT

Note 6 - Intangible Assets

3 Months Ended

Mar. 31, 2019

Notes to Financial Statements

Intangible Assets Disclosure [Text Block]

NOTE

– INTANGIBLE ASSETS

September 12, 2016,

the Company executed an agreement dated

August 31, 2016,

to acquire assets, including a patent related to LED Lighting, from Tesla Digital, Inc., a Canadian Corporation, and Stevan (Steve) Pokrajac (the “Sellers”).

Material consideration given by Company was: (a) Shares of CEN common stock equal to

million upon commencement of public trading (b) The transfer of real properties located at

135

North Rear Road, Lakeshore, Ontario, Canada having a fair value of

$2,161,467

and

1517

1525

Ridge Road having a purchase cost (including other related disbursements) to the Company of

$202,666.

The patent remains in the name of Tesla Digital, Inc. until full settlement of the terms of the agreement. In the interim, pursuant to an updated agreement executed on

April 15, 2019

between the Company and the Sellers, CEN has reaffirmed the rights to use the patented technology.

In addition, the Company agreed to employ Stevan Pokrajac, by an LED subsidiary that the Company plans to form, but which has

not

yet been formed, in connection with the development of the acquired technology with compensation equal to

$200,000

per year, commencing with the start of operations of the planned subsidiary after the acquisition is completed.

March 2018,

the Tesla agreement was amended to replace the

million stock consideration commitment with a commitment to issue

one million

registered shares of CEN common stock with a closing date of

September 30, 2018.

October 4, 2018,

this agreement was amended to extend the closing date to

December 15, 2018.

April 3, 2019,

the Company entered into an amendment which extended the closing date of the agreement to

December 31, 2019.

The modification of the agreement converted a fixed value of shares to a fixed number of shares. Accordingly, the liability was reduced and additional paid in capital was increased by

$4,380,000

to reflect the fair value of the shares committed at the date of the amendment. As of

March 31, 2019

and

December 31, 2018,

the fair value of this liability was

$1,010,000

This liability will be remeasured at each reporting date using the current fair value of CEN’s common shares.

fair value.

The intangible assets consists of the following as of:

	March 31, 2019			December 31, 2018

Lighting patent	$	6,797,000		$	6,797,000
Accumulated amortization		(1,097,432	)		(991,229	)

Net	$	5,699,568		$	5,805,771

As of

March 31, 2019

and

December 31, 2018,

there is

impairment expense recognized based on the Company’s expectations that it will be able to monetize the patent.

The lighting patent is being amortized straight-line over

years. Expected amortization expense is

$424,812

per year through

2031,

with the remaining

$283,215

to be amortized in

2032.

XML 24 R13.htm IDEA: XBRL DOCUMENT

Note 7 - Loans Payable

3 Months Ended

Mar. 31, 2019

Notes to Financial Statements

Short-term Debt [Text Block]

NOTE

– LOANS PAYABLE

Loans payable consist of the following at:

	March 31, 2019		December 31, 2018
Loan payable to Global Holdings International, LLC, which bears interest at 15% per annum after defaulting on the maturity date of June 30, 2016. This note is secured by the Company's equipment.	$	9,675,000	$	9,675,000

Mortgage payable in default to ARG & Pals, Inc., for the original amount of CAD $385,000. The mortgage bears interest at 22% per annum, and matured on November 21, 2018.		288,095		282,205

Loan payable in default to an individual, issued January 17, 2018 with a 30-day maturity, bearing share interest of 2,000 common shares per 30-day period. This is an unsecured loan which matured on April 16, 2019.		50,000		50,000

Loan payable in default to an individual, issued April 13, 2018, with a 30-day maturity, bearing share interest of 4,000 common shares per 30-day period. This is an unsecured loan which matured on April 16, 2019.		100,000		100,000

Total loans payable (all current)	$	10,113,095	$	10,107,205

We are in default of

$9,675,000

of debt that is secured by certain equipment that we value at approximately

$9,000.

The remainder of our debt that is in default is

not

secured.

During the

three

-month periods ended

March 31, 2019

and

2018,

18,000

and

16,400

common shares were issued to individuals for loans made to CEN, respectively. Accordingly, during the

three

-month periods ended

March 31, 2019

and

2018,

$18,180

and

$10,168

in interest expense and additional paid-in capital was recorded, respectively.

XML 25 R14.htm IDEA: XBRL DOCUMENT

Note 8 - Loans Payable - Related Party

3 Months Ended

Mar. 31, 2019

Notes to Financial Statements

Loans Payable to Related Party [Text Block]

NOTE

– LOANS PAYABLE- RELATED PARTY

Loans payable - related party consists of the following at:

	March 31, 2019		December 31, 2018
Loan payable in default to the spouse of Bill Chaaban, President of CEN, bears an interest at 10% per annum. This is an unsecured loan that matured on December 31, 2018.	$	235,050	$	234,306

Loan payable in default to a former director of Creative, former parent company, bears interest at 10% per annum. This is an unsecured loan that matured on December 31, 2018.		601,500		601,500

Loan payable to R&D Labs Canada, Inc., whose president is Bill Chaaban, also the President of CEN, bearing interest at 8% per annum. This is an unsecured loan with a maturity date of October 2, 2019. R&D Labs Canada is a company owned by Bill Chaaban’s spouse.		300,000		300,000

Loan payable in default to the spouse of Joseph Byrne, CEO of CEN, issued January 12, 2018 with a 30-day maturity, bearing share interest of 4,000 common shares per 30-day period. This is an unsecured loan that matured on May 16, 2019.		100,000		100,000

Loan payable in default to Alex Tarrabain, a Director of CEN, issued January 17, 2018 with a 30-day maturity, bearing share interest of 3,000 common shares per 30-day period. This is an unsecured loan that matured on May 16, 2019.		75,000		75,000

Loan payable in default to Joseph Byrne, CEO of CEN, issued January 24, 2018 with a 30-day maturity, bearing share interest of 2,000 common shares per 30-day period. This is an unsecured loan that matured on May 16, 2019.		50,000		50,000

Total loans payable - related party		1,361,550		1,360,806
Less: current portion		1,361,550		1,360,806

Long-term portion loans payable - related party	$	-	$	-

Attributable related party accrued interest was

$384,187

and

$357,373

as of

March 31, 2019

and

December 31, 2018,

respectively. Interest expense attributable to related party loans was

$26,814

and

$43,042

for the

three

-months ended

March 31, 2019

and

2018,

respectively.

During both

three

-month periods ended

March 31, 2019

and

2018,

27,000

common shares were issued to related parties in connection with interest terms of the above loans made to CEN. Accordingly, during the

three

-month periods ended

March 31, 2019

and

2018,

$27,270

and

$16,740

in related party interest expense, which is included above, and additional paid-in capital was recorded, respectively.

XML 26 R15.htm IDEA: XBRL DOCUMENT

Note 9 - Convertible Notes

3 Months Ended

Mar. 31, 2019

Notes to Financial Statements

Long-term Debt [Text Block]

NOTE

– CONVERTIBLE NOTES

Convertible notes payable consists of the following at:

	March 31, 2019		December 31, 2018

Convertible note payable, due on demand, bearing interest at 7% per annum with conversion rights for 335,833 common shares.	$	826,657	$	809,755

Convertible notes payable to multiple private investors, including certain notes in default, bearing interest at 5% per annum with conversion rights for 2,775,690 common shares, maturing at various dates between May 2018 and March 2021.		4,480,927		4,333,892

Total convertible notes payable		5,307,584		5,143,647
Less current portion		4,190,461		3,597,760

Convertible notes payable, less current portion	$	1,117,123	$	1,545,887

These notes

may

be converted at the option of the note holder at any time after registration of CEN’s common stock upon written notice by the note holder. These notes are convertible into a total of

3,111,523

common shares.

As of

May 20, 2019,

we are currently in default of

$1,329,287

of convertible notes payable, which are convertible into

834,277

shares of common stock.

XML 27 R16.htm IDEA: XBRL DOCUMENT

Note 10 - Convertible Notes - Related Party

3 Months Ended

Mar. 31, 2019

Notes to Financial Statements

Long-term Convertible Notes Related Party [Text Block]

NOTE

– CONVERTIBLE NOTES - RELATED PARTY

Convertible notes - related party consists of the following at:

	March 31, 2019		December 31, 2018
Convertible note due to the spouse of Bill Chaaban, President of CEN, which bears an interest at 12% per annum. This note is convertible to 867,576 common shares with a maturity date of August 17, 2020.	$	1,388,122	$	1,388,122

Convertible notes in default due to Harold Aubrey de Lavenu, a Director of CEN, bearing interest at 5% per annum. These notes are convertible to 548,980 common shares with maturity dates of March 31, 2019.		878,368		878,368

Convertible note in default due to Alex Tarrabain, a Director of CEN, bearing interest at 5% per annum. This note is convertible to 30,000 common shares with a maturity date of March 31, 2019.		48,000		48,000

Convertible notes due to Joseph Byrne, CEO of CEN, bearing interest at 12% per annum. This note is convertible to 140,120 common shares with a maturity date of August 17, 2020.		224,191		224,191

Total convertible notes payable - related party		2,538,681		2,538,681
Less current portion		926,368		926,368

Convertible notes payable - related party, less current portion	$	1,612,313	$	1,612,313

Attributable related party accrued interest was

$647,984

and

$588,854

as of

March 31, 2019

and

December 31, 2018,

respectively. Interest expense attributable to related party convertible notes was

$59,129

and

$61,244

for the

three

-months ended

March 31, 2019

and

2018,

respectively.

These notes

may

be converted at the option of the note holder at any time after registration of CEN’s common stock upon written notice by the note holder. These notes are convertible into a total of

1,586,676

common shares.

As of

May 20, 2019,

we are currently in default of

$926,368

of convertible notes payable, which are convertible into

578,980

shares of common stock.

XML 28 R17.htm IDEA: XBRL DOCUMENT

Note 11 - Income Taxes

3 Months Ended

Mar. 31, 2019

Notes to Financial Statements

Income Tax Disclosure [Text Block]

NOTE

– INCOME TAXES

A reconciliation of the effective tax rate of the income tax benefit and the statutory income tax rates applied to the loss before income taxes is as follows for the

three

-months ended

March

31:

	2019			2018

Income tax benefit at Canadian statutory rate		26.5	%		26.5	%
Valuation allowance		(26.5	%)		(26.5	%)

Effective income tax rate		0	%		0	%

As of

March 31, 2019,

the Company has net operating loss carry forwards of approximately

$37,800,000

that

may

be available to reduce future years’ taxable income. Such carry forwards typically expire after

years. The Company currently has carry forwards that begin to expire in

2034.

Future tax benefits which

may

arise as a result of these losses have

not

been recognized in these condensed consolidated financial statements, because the Company believes that it is more likely than

not

that the carryforwards will expire unused and accordingly, the Company has recorded a valuation allowance for the deferred tax asset relating to these tax loss carry-forwards. The deferred tax asset and associated valuation allowance are as follows for the period ended

March 31, 2019

and the year ended

December 31, 2018:

	2019			2018

Deferred tax asset - net operating losses	$	10,000,000		$	9,700,000
Deferred tax asset valuation allowance		(10,000,000	)		(9,700,000	)

Net deferred tax asset	$	-		$	-

The change in the valuation allowance amounted to

$300,000

and

$400,000

for the

three

-months ended

March 31, 2019

and

2018,

respectively. All other temporary differences are immaterial both individually and in the aggregate to the condensed consolidated financial statements.

March 31, 2019,

there are

uncertain income tax positions taken or expected to be taken that would require recognition of a liability or disclosure in the condensed consolidated financial statements. The Company is subject to routing audits by taxing jurisdictions; however, there are currently

audits for any tax periods in progress. Generally, the Company is

longer subject to income tax examinations for years prior to

2015.

XML 29 R18.htm IDEA: XBRL DOCUMENT

Note 12 - Shareholders' Deficit / Stock Activity	3 Months Ended
Note 12 - Shareholders' Deficit / Stock Activity	Mar. 31, 2019
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 12 – SHAREHOLDERS’ DEFICIT / STOCK ACTIVITY The Company is authorized to issue an unlimited number of common shares and an unlimited number of special voting shares. Common shares have no stated par value. As of March 31, 2019, 4,698,199 shares of common stock are committed to the holders of the convertible notes.

XML 30 R19.htm IDEA: XBRL DOCUMENT

Note 13 - Related Party Transactions	3 Months Ended
Note 13 - Related Party Transactions	Mar. 31, 2019
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 13 – RELATED PARTY TRANSACTIONS The Company has received loans from several related parties, as described above in Notes 8 and 10. There are advances of $905,328 and $875,328 to CEN Ukraine as of March 31, 2019 and December 31, 2018, respectively, which such advances were made for the purpose of funding the operations of CEN Ukraine. CEN Ukraine was founded by Bill Chaaban. Prior to December 3, 2017, Bill Chaaban directly owned 51% of CEN Ukraine. Subsequent to December 3, 2017, Mr. Chaaban directly owned 25.5% of CEN Ukraine. CEN Ukraine was founded to seek agricultural and pharmaceutical opportunities in Ukraine. Bill Chaaban personally funded the establishment and initial phases of CEN Ukraine. On December 14, 2017, the Company entered into a controlling interest purchase agreement with Bill Chaaban and another shareholder of CEN Ukraine for 51% of the outstanding equity interests of CEN Ukraine. The consideration will be paid by issuing common shares of the Company. The agreement, which is subject to certain conditions, has not closed as of May 20, 2019, as the Company needs to raise additional funds in order to proceed with the closing. On July 12, 2017, the Company’s Shareholders elected individuals to serve as Directors on the Board. These individuals hold long-term convertible notes payable issued prior to the election. All notes payable bear interest at 5% per annum and are convertible to common shares with various maturity dates. They became related parties when they were elected. During each of the three -months ended March 31, 2019 and 2018, the Company incurred payroll expenses with certain Board Members and Officers totaling $31,200 . As of March 31, 2019 and December 31, 2018, $156,000 and $124,800, respectively, were payable for such services. During 2017, the Company purchased equipment from R&D Labs Canada, Inc., whose president is Bill Chaaban, in exchange for a $300,000 note payable. This equipment was then sold to CEN Ukraine for a loss of $255,141 in exchange for a $44,859 note receivable, payable in 10 equal installments beginning in 2017 through 2026. No payments have been received as of March 31, 2019, however, management expects this balance to be collectible. The Company leases 20 North Rear Road, a 10.4 acre site of land in Canada, through a sublease from a relative of the Company’s President. There are two buildings on the site – one of 27,000 square feet and one of 53,000 square feet. There is also a 4,000 square foot vault for security purposes. The Company constructed improvements to this property, including structures and equipment for growing marijuana, security fencing required for licensing as a marijuana producer, and other infrastructure. These improvements were fully impaired during the 4 th quarter of 2018. The 20 North Rear Road lease agreement began on September 1, 2013 and required annual rent payments of CAD $339,000, including tax. At December 31, 2016, the balance sheet included accrued rent of $552,934, owed to Jamaal Shaban (“Lessor”), cousin of Bill Chaaban. Concurrently, the Lessor had fallen behind on a mortgage payable on the property. Effective January 2017, the Company entered into agreements to terminate the initial lease, enter into a convertible debt note with the Lessor’s creditor, and begin a new lease agreement for the same property. The new lease agreement calls for monthly rental payments of CAD $4,000 plus taxes for a period of five years. In exchange, the Company issued convertible notes payable of $824,446 in satisfaction of the accrued rent and future rent. The lease has been accounted for as an operating lease, and the amount of the note in excess of the accrued rent was treated as a deferred lease asset amortized over the 5 -year lease. However, in conjunction with the impairment in the 4 th quarter of 2018, the remaining deferred lease asset was fully expensed. As of March 31, 2019, the operating right of use asset was $88,992 and the associated liability was $85,998, utilizing an 8% discount rate. During the three -months ended March 31, 2019 and 2018, lease expenses of $19,562 and $22,883 related to this agreement were recognized within general and administrative expenses. The Company also leases office space in Windsor, Ontario from R&D Labs Canada, Inc., whose president is Bill Chaaban. Under the lease agreement effective October 1, 2017, monthly rents of CAD $2,608 are due through September 2022, at which point monthly rents of CAD $3,390 are due. As of March 31, 2019, the operating right of use asset was $162,118 and the associated liability was $165,523, utilizing an 8% discount rate. During the three -months ended March 31, 2019 and 2018, lease expenses of $9,259 and $6,068 related to this agreement were recognized within general and administrative expenses. As of March 31, 2019, the weighted average remaining lease term was approximately 6.8 years and the weighted average discount rate used to determine operating lease liabilities was 8%.

XML 31 R20.htm IDEA: XBRL DOCUMENT

Note 14 - Stock Based Compensation

3 Months Ended

Mar. 31, 2019

Notes to Financial Statements

Share-based Payment Arrangement [Text Block]

NOTE

– STOCK BASED COMPENSATION

Adoption of Equity Compensation Plan

November 29, 2017,

the Board adopted the

2017

Equity Compensation Plan (the “Plan”) providing for the granting of options to purchase shares of common stock, restricted stock awards and other stock-based awards to directors, officers, employees, advisors and consultants. The Company reserved

20,000,000

shares of common stock for issuance under the Plan. The Plan is intended to provide equity incentives to persons retained by our Company.

Equity Compensation Grants

November 30, 2017,

the Company granted a

one

-time equity award (“Equity Award”) of

20,000

restricted shares of the Company’s common stock pursuant to a Restricted Stock Agreement, to each of the following executives and directors of the Company: Bahige “Bill” Chaaban, Chairman of the Board and President of the Company; Joseph Byrne, Chief Executive Officer and Director; Richard Boswell, Senior Executive Vice President, Chief Financial Officer and Director; Brian Payne, Vice President and Director; Donald Strilchuck, Director; Harold Aubrey de Lavenu, Director; Alex Tarrabain, Director; and Ameen Ferris, Director. The Equity Awards vested immediately.

In addition, as part of this

one

-time equity award, Donald Strilchuck, Director, received an additional

1,000,000

restricted shares of the Company's common stock for security consulting services, of which

550,000

vested immediately and the remaining vesting ratably each month over the next

months. Other individuals received a total of

1,870,000

restricted shares of the Company's common stock for consulting services performed, of which

1,330,000

vested immediately and the remaining vesting ratably each month over the next

months. The expense related to the restricted stock awarded to non-employees for services rendered was recognized on the grant date.

June 7, 2018,

the Company elected Dr. Usamakh Saadikh to serve as a director of the Company. As compensation for his role as a Director, the company granted a

one

-time equity award of

20,000

shares of the Company’s common stock. This award vested immediately.

June 19, 2018,

the Company entered into an agreement with a law firm for the payment of its services under which the Company issued

125,000

shares of its common stock. This award vested immediately. The expense related to the restricted stock awarded to non-employees for services rendered was recognized on the grant date.

December 31, 2018,

the Company issued

12,120

shares of its common stock to individuals for the payment of their services. These awards vested immediately. The expense related to the stock awarded to non-employees for services rendered was recognized on the grant date.

Employment Agreements

November 30, 2017,

employment agreements were entered into with

four

key members of management:

•

Under the Employment Agreement with Bahige (Bill) Chaaban, President of the Company, Mr. Chaaban will receive compensation in the form of a base annual salary of

$31,200

and a grant of

8,750,000

shares of restricted stock of the Company, of which

7,400,000

vested immediately and the remaining vesting ratably each month over the next

months.

•

Under the Employment Agreement with Joseph Byrne, Chief Executive Officer of the Company, Mr. Byrne will receive compensation in the form of a base annual salary of

$31,200

and a grant of

1,250,000

shares of restricted stock of the Company, of which

325,000

vested immediately and the remaining vesting ratably each month over the next

months.

•

$31,200

and a grant of

4,500,000

shares of restricted stock of the Company, of which

4,140,000

vested immediately and the remaining vesting ratably each month over the next

months.

•

Under the Employment Agreement with Brian Payne, Vice President of the Company, Mr. Payne will receive compensation in the form of a base annual salary of

$31,200

and a grant of

750,000

shares of restricted stock of the Company, of which

300,000

vested immediately and the remaining vesting ratably each month over the next

months.

Restricted Stock Awards

The grant-date fair value of the restricted shares noted in the employment agreements and equity compensation grants sections above was

$11,435,741

2018

and prior.

such grants were made during the

three

-month periods ended

March 31, 2019

and

2018.

The grant-date fair value is calculated utilizing an enterprise valuation model as of the date the awards are granted. During

2017,

14,317,500

of these shares vested, with the remaining restricted stock units of

3,962,500

shares vesting pro-rata over the requisite service period, which is generally

three

years from the grant-date. During each of the

three

-months ended

March 31, 2019

and

2018,

an additional

337,500

of these shares vested. Non-vested restricted stock awards participate in dividends and recipients are entitled to vote these restricted shares during the vesting period.

Compensation expense recognized in connection with the restricted stock awards was

$167,400

for each of the

three

-months ended

March 31, 2019

and

2018.

The fair value of the restricted stock which vested amounted to

$340,875

and

$209,250

for the

three

-months ended

March 31, 2019

and

2018,

respectively.

Non-vested restricted stock award activity for the

three

-months ended

March 31, 2019

and

2018

are as follows:

	Number of Shares			Weighted- Average Grant Date Fair Value per Share		Weighted- Average Remaining Contractual Term (Years)
Non-vested at January 1, 2018		3,962,500		$	0.62		2.92
Granted		-			-		-
Vested		(337,500	)		0.62		-
Forfeited		-			-		-
Non-vested at March 31, 2018		3,625,000		$	0.62		2.75

Non-vested at December 31, 2018		2,612,500		$	0.62		2.00
Granted		-			-		-
Vested		(337,500	)		0.62		-
Forfeited		-			-		-
Non-vested at March 31, 2019		2,275,000		$	0.62		1.75

The fair value of the restricted stock grants was based on the valuation of a

third

-party specialist. Unrecognized compensation expense related to restricted stock amounted to approximately

$1,131,500

as of

March 31, 2019.

This expense will be recognized over vesting period of the respective awards.

XML 32 R21.htm IDEA: XBRL DOCUMENT

Note 15 - Net Loss Per Share

3 Months Ended

Mar. 31, 2019

Notes to Financial Statements

Earnings Per Share [Text Block]

NOTE

– NET LOSS PER SHARE

March 31, 2019

and

2018.

Common stock equivalents that were excluded for the

three

-month periods ended

March 31, 2019

and

2018

are as follows:

		2019				2018
Convertible debt			4,628,234				3,919,160

XML 33 R22.htm IDEA: XBRL DOCUMENT

Note 16 - Contingency	3 Months Ended
Note 16 - Contingency	Mar. 31, 2019
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 16 – CONTINGENCY In connection with the distribution by Creative of CEN’s common stock on February 29, 2016 and the Form 10 registration statement filed by CEN to register its shares of common stock under the Exchange Act, CEN received comments by the Staff of the Securities and Exchange Commission, including a letter dated May 4, 2016 in which the Staff noted that they “…continue to question the absence of Securities Act registration of the spin-off distribution”. In the event that the distribution of shares of CEN’s common stock was a distribution that required registration under the Securities Act, then the Company could be subject to enforcement action by the SEC that claims a violation of Section 5 of the Securities Act and could be subject to a private right of action for rescission or damages. Based on management’s estimate, any potential liability related to this matter would not be material.

XML 34 R23.htm IDEA: XBRL DOCUMENT

Note 17 - Fair Value Disclosures

3 Months Ended

Mar. 31, 2019

Notes to Financial Statements

Fair Value Disclosures [Text Block]

NOTE

– FAIR VALUE DISCLOSURES

The fair value of the Company’s financial instruments are as follows:

			Fair Value Measured at Reporting Date Using
	Carrying Amount		Level 1		Level 2		Level 3		Fair Value
At March 31, 2019:
Cash and cash equivalents	$	39,752	$	-	$	39,752	$	-	$	39,752
Other receivables	$	417,904	$	-	$	-	$	417,904	$	417,904
Note receivable - related party	$	44,859	$	-	$	-	$	44,859	$	44,859
Advances to CEN Biotech Ukraine, LLC - related party	$	905,328	$	-	$	-	$	905,328	$	905,328
Loans payable	$	10,113,095	$	-	$	-	$	10,113,095	$	10,113,095
Loans payable - related parties	$	1,361,550	$	-	$	-	$	-	$	-
Patent acquisition liability	$	1,010,000	$	-	$	-	$	1,010,000	$	1,010,000
Convertible notes payable	$	5,307,584	$	-	$	-	$	5,768,525	$	5,768,525
Convertible notes payable - related parties	$	2,538,681	$	-	$	-	$	-	$	-

	Carrying Amount		Level 1		Level 2		Level 3		Fair Value
At December 31, 2018:
Cash and cash equivalents	$	3,193	$	-	$	3,193	$	-	$	3,193
Other receivables	$	418,905	$	-	$	-	$	418,905	$	418,905
Note receivable - related party	$	44,859	$	-	$	-	$	44,859	$	44,859
Advances to CEN Biotech Ukraine, LLC - related party	$	875,328	$	-	$	-	$	875,328	$	875,328
Loans payable	$	10,107,205	$	-	$	-	$	10,107,205	$	10,107,205
Loans payable - related parties	$	1,360,806	$	-	$	-	$	-	$	-
Patent acquisition liability	$	1,010,000	$	-	$	-	$	1,010,000	$	1,010,000
Convertible notes payable	$	5,143,647	$	-	$	-	$	5,534,810	$	5,534,810
Convertible notes payable - related parties	$	2,538,681	$	-	$	-	$	-	$	-

The fair value of the loans payable approximates carrying value due to the terms of such instruments and applicable interest rates.

The fair value of convertible notes payable is based on the par value plus accrued interest through the date of reporting due to the terms of such instruments and interest rates.

It is

not

practicable to estimate the fair value of loans payable – related parties and convertible notes payable – related parties due to their related party nature.

The fair value of the patent acquisition liability is based upon a valuation report obtained from a

party valuation specialist. This valuation report utilized a cash-free asset value model to estimate enterprise value based upon similar companies.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 35 R24.htm IDEA: XBRL DOCUMENT

Note 18 - Subsequent Event	3 Months Ended
Note 18 - Subsequent Event	Mar. 31, 2019
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 18 – SUBSEQUENT EVENT. On April 3, 2019, the Company entered into an amendment to the Share Purchase Agreement dated August 31, 2016, and executed September 12, 2016, as amended, between CEN Biotech, Inc. and Stevan Pokrajac and Tesla Digital Inc. and Tesla Digital Global Group Inc., which extended the closing date of the agreement to December 31, 2019. On May 15, 2019, the Company entered into a Non-Binding (other than as set forth therein) Term Sheet (the “Term Sheet”) with Caduceus Software Systems Corp., a Wyoming corporation (“CSOC”), which was reviewed and approved by the Board of Directors of the Company (the “Board”) on May 15, 2019. Pursuant to the Term Sheet, the Company and CSOC agreed to undertake a merger transaction to combine the two companies’ operations and negotiate and enter into a definite agreement to effect the transaction. On May 16, 2019, the Board appointed Alex Tarrabain, one of the members of the Company’s Board to serve as the Company’s Chief Financial Officer and as one of the Vice Presidents of the Company effective May 21, 2019 ( the “Effective Date”). Richard Boswell, who served as the Company’s Chief Financial Officer since July 2017, resigned from his position as the Company’s Chief Financial Officer as of the Effective Date, and will continue to serve in his position as the Company’s Senior Executive Vice President going forward focusing on the Company’s strategic activities and will also continue to serve as a member of the Company’s Board. In connection with the foregoing, on May 16, 2019, the Company entered into an Executive Employment Agreement (the “Employment Agreement”) with Mr. Tarrabain pursuant to which Mr. Tarrabain agreed to serve as the Company’s Vice President and Chief Financial Officer and the Company agreed to issue to Mr. Tarrabain 1,250,000 shares (the “Shares’) of the Company’s common stock in accordance with a Restricted Stock Agreement (the “RSA”). The Employment Agreement has an indefinite term. Additionally, pursuant to the Employment Agreement, the Company agreed to pay Mr. Tarrabain an annual base salary of $31,200. Further, pursuant to the Employment Agreement in the event of an occurrence of a “Change in Control” (as defined in the Employment Agreement) or a strategic transaction, the Board may, but is not obligated to, provide Mr. Tarrabain with additional compensation, including additional stock options or restricted stock, for services outside of his general scope of duties and responsibilities. Pursuant to the RSA, entered into by Mr. Tarrabain and the Company on May 16, 2019, 350,000 of the Shares will vest immediately (the “Grant Date”) and the balance 900,000 of the Shares will vest over a three ( 3 ) year period with 25,000 of the Shares versing on the one ( 1 ) month anniversary of the Grant Date and an additional 25,000 of the Shares vesting at the end of each one ( 1 ) month anniversary of the Grant Date thereafter, provided that Mr. Tarrabain continues to be an employee of the Company.

XML 36 R25.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)	3 Months Ended
Significant Accounting Policies (Policies)	Mar. 31, 2019
Accounting Policies [Abstract]
Earnings Per Share, Policy [Policy Text Block]	Loss per Share Net loss per common share is computed pursuant to ASC 260 - 10 - 45. Basic loss per share is computed based on the weighted average number of common shares outstanding during the period. Diluted net loss per share is calculated by dividing net loss by the diluted weighted average common shares outstanding, which includes the effect of potentially dilutive securities. During periods when there is a net loss, all potentially dilutive shares are anti-dilutive and are excluded from the calculation of net loss per share. Diluted earnings per share is similarly computed except that the denominator includes the effect, using the treasury stock method, of unvested restricted stock and convertible notes, if including such potential shares of common stock is dilutive. For the three -months ended March 31, 2019 and 2018, the common stock equivalents of the convertible note agreements were not included in diluted earnings per share computations because their effect was antidilutive.
Business Combinations Policy [Policy Text Block]	Share Purchase Agreement On July 31, 2018, the Company entered into a Share Purchase Agreement with AstralENERGY Solar Manufacturing Corporation, LTD. (“AstralENERGY”) to acquire 70% of the outstanding common stock of AstralENERGY. The Company will issue an aggregate 2,500,000 shares of common stock of the Company as consideration for the acquisition. AstralENERGY is a manufacturer of architecturally designed solar panels for residential and commercial solar production and has also developed integrated multi-function LED street lighting systems. Consummation of the acquisition is subject to the completion of certain conditions specified in the agreement. As of May 20, 2019, this transaction has not closed.

XML 37 R26.htm IDEA: XBRL DOCUMENT

Note 4 - Property, Plant and Improvements, Net (Tables)

3 Months Ended

Mar. 31, 2019

Notes Tables

Property, Plant and Equipment [Table Text Block]

	March 31, 2019			December 31, 2018
Leasehold improvements	$	166,163		$	166,163
Furniture and equipment		17,668			17,668
Accumulated depreciation and amortization		(21,918	)		(17,322	)

Net property, plant and improvements	$	161,913		$	166,509

XML 38 R27.htm IDEA: XBRL DOCUMENT

Note 6 - Intangible Assets (Tables)

3 Months Ended

Mar. 31, 2019

Notes Tables

Schedule of Finite-Lived Intangible Assets [Table Text Block]

	March 31, 2019			December 31, 2018

Lighting patent	$	6,797,000		$	6,797,000
Accumulated amortization		(1,097,432	)		(991,229	)

Net	$	5,699,568		$	5,805,771

XML 39 R28.htm IDEA: XBRL DOCUMENT

Note 7 - Loans Payable (Tables)

3 Months Ended

Mar. 31, 2019

Notes Tables

Schedule of Short-term Debt [Table Text Block]

	March 31, 2019		December 31, 2018
Loan payable to Global Holdings International, LLC, which bears interest at 15% per annum after defaulting on the maturity date of June 30, 2016. This note is secured by the Company's equipment.	$	9,675,000	$	9,675,000

Mortgage payable in default to ARG & Pals, Inc., for the original amount of CAD $385,000. The mortgage bears interest at 22% per annum, and matured on November 21, 2018.		288,095		282,205

Loan payable in default to an individual, issued January 17, 2018 with a 30-day maturity, bearing share interest of 2,000 common shares per 30-day period. This is an unsecured loan which matured on April 16, 2019.		50,000		50,000

Loan payable in default to an individual, issued April 13, 2018, with a 30-day maturity, bearing share interest of 4,000 common shares per 30-day period. This is an unsecured loan which matured on April 16, 2019.		100,000		100,000

Total loans payable (all current)	$	10,113,095	$	10,107,205

XML 40 R29.htm IDEA: XBRL DOCUMENT

Note 8 - Loans Payable - Related Party (Tables)

3 Months Ended

Mar. 31, 2019

Notes Tables

Schedule of Loans Payable to Related Party [Table Text Block]

	March 31, 2019		December 31, 2018
Loan payable in default to the spouse of Bill Chaaban, President of CEN, bears an interest at 10% per annum. This is an unsecured loan that matured on December 31, 2018.	$	235,050	$	234,306

Loan payable in default to a former director of Creative, former parent company, bears interest at 10% per annum. This is an unsecured loan that matured on December 31, 2018.		601,500		601,500

Loan payable to R&D Labs Canada, Inc., whose president is Bill Chaaban, also the President of CEN, bearing interest at 8% per annum. This is an unsecured loan with a maturity date of October 2, 2019. R&D Labs Canada is a company owned by Bill Chaaban’s spouse.		300,000		300,000

Loan payable in default to the spouse of Joseph Byrne, CEO of CEN, issued January 12, 2018 with a 30-day maturity, bearing share interest of 4,000 common shares per 30-day period. This is an unsecured loan that matured on May 16, 2019.		100,000		100,000

Loan payable in default to Alex Tarrabain, a Director of CEN, issued January 17, 2018 with a 30-day maturity, bearing share interest of 3,000 common shares per 30-day period. This is an unsecured loan that matured on May 16, 2019.		75,000		75,000

Loan payable in default to Joseph Byrne, CEO of CEN, issued January 24, 2018 with a 30-day maturity, bearing share interest of 2,000 common shares per 30-day period. This is an unsecured loan that matured on May 16, 2019.		50,000		50,000

Total loans payable - related party		1,361,550		1,360,806
Less: current portion		1,361,550		1,360,806

Long-term portion loans payable - related party	$	-	$	-

XML 41 R30.htm IDEA: XBRL DOCUMENT

Note 9 - Convertible Notes (Tables)

3 Months Ended

Mar. 31, 2019

Notes Tables

Schedule of Long-term Debt Instruments [Table Text Block]

	March 31, 2019		December 31, 2018

Convertible note payable, due on demand, bearing interest at 7% per annum with conversion rights for 335,833 common shares.	$	826,657	$	809,755

Convertible notes payable to multiple private investors, including certain notes in default, bearing interest at 5% per annum with conversion rights for 2,775,690 common shares, maturing at various dates between May 2018 and March 2021.		4,480,927		4,333,892

Total convertible notes payable		5,307,584		5,143,647
Less current portion		4,190,461		3,597,760

Convertible notes payable, less current portion	$	1,117,123	$	1,545,887

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

+ Details

XML 42 R31.htm IDEA: XBRL DOCUMENT

Note 10 - Convertible Notes - Related Party (Tables)

3 Months Ended

Mar. 31, 2019

Notes Tables

Schedule of Convertible Notes Payable to Related Party [Table Text Block]

	March 31, 2019		December 31, 2018
Convertible note due to the spouse of Bill Chaaban, President of CEN, which bears an interest at 12% per annum. This note is convertible to 867,576 common shares with a maturity date of August 17, 2020.	$	1,388,122	$	1,388,122

Convertible notes in default due to Harold Aubrey de Lavenu, a Director of CEN, bearing interest at 5% per annum. These notes are convertible to 548,980 common shares with maturity dates of March 31, 2019.		878,368		878,368

Convertible note in default due to Alex Tarrabain, a Director of CEN, bearing interest at 5% per annum. This note is convertible to 30,000 common shares with a maturity date of March 31, 2019.		48,000		48,000

Convertible notes due to Joseph Byrne, CEO of CEN, bearing interest at 12% per annum. This note is convertible to 140,120 common shares with a maturity date of August 17, 2020.		224,191		224,191

Total convertible notes payable - related party		2,538,681		2,538,681
Less current portion		926,368		926,368

Convertible notes payable - related party, less current portion	$	1,612,313	$	1,612,313

XML 43 R32.htm IDEA: XBRL DOCUMENT

Note 11 - Income Taxes (Tables)

3 Months Ended

Mar. 31, 2019

Notes Tables

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

	2019			2018

Income tax benefit at Canadian statutory rate		26.5	%		26.5	%
Valuation allowance		(26.5	%)		(26.5	%)

Effective income tax rate		0	%		0	%

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]

	2019			2018

Deferred tax asset - net operating losses	$	10,000,000		$	9,700,000
Deferred tax asset valuation allowance		(10,000,000	)		(9,700,000	)

Net deferred tax asset	$	-		$	-

XML 44 R33.htm IDEA: XBRL DOCUMENT

Note 14 - Stock Based Compensation (Tables)

3 Months Ended

Mar. 31, 2019

Notes Tables

Nonvested Restricted Stock Shares Activity [Table Text Block]

	Number of Shares			Weighted- Average Grant Date Fair Value per Share		Weighted- Average Remaining Contractual Term (Years)
Non-vested at January 1, 2018		3,962,500		$	0.62		2.92
Granted		-			-		-
Vested		(337,500	)		0.62		-
Forfeited		-			-		-
Non-vested at March 31, 2018		3,625,000		$	0.62		2.75

Non-vested at December 31, 2018		2,612,500		$	0.62		2.00
Granted		-			-		-
Vested		(337,500	)		0.62		-
Forfeited		-			-		-
Non-vested at March 31, 2019		2,275,000		$	0.62		1.75

XML 45 R34.htm IDEA: XBRL DOCUMENT

Note 15 - Net Loss Per Share (Tables)

3 Months Ended

Mar. 31, 2019

Notes Tables

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

		2019				2018
Convertible debt			4,628,234				3,919,160

XML 46 R35.htm IDEA: XBRL DOCUMENT

Note 17 - Fair Value Disclosures (Tables)

3 Months Ended

Mar. 31, 2019

Notes Tables

Fair Value, by Balance Sheet Grouping [Table Text Block]

			Fair Value Measured at Reporting Date Using
	Carrying Amount		Level 1		Level 2		Level 3		Fair Value
At March 31, 2019:
Cash and cash equivalents	$	39,752	$	-	$	39,752	$	-	$	39,752
Other receivables	$	417,904	$	-	$	-	$	417,904	$	417,904
Note receivable - related party	$	44,859	$	-	$	-	$	44,859	$	44,859
Advances to CEN Biotech Ukraine, LLC - related party	$	905,328	$	-	$	-	$	905,328	$	905,328
Loans payable	$	10,113,095	$	-	$	-	$	10,113,095	$	10,113,095
Loans payable - related parties	$	1,361,550	$	-	$	-	$	-	$	-
Patent acquisition liability	$	1,010,000	$	-	$	-	$	1,010,000	$	1,010,000
Convertible notes payable	$	5,307,584	$	-	$	-	$	5,768,525	$	5,768,525
Convertible notes payable - related parties	$	2,538,681	$	-	$	-	$	-	$	-

	Carrying Amount		Level 1		Level 2		Level 3		Fair Value
At December 31, 2018:
Cash and cash equivalents	$	3,193	$	-	$	3,193	$	-	$	3,193
Other receivables	$	418,905	$	-	$	-	$	418,905	$	418,905
Note receivable - related party	$	44,859	$	-	$	-	$	44,859	$	44,859
Advances to CEN Biotech Ukraine, LLC - related party	$	875,328	$	-	$	-	$	875,328	$	875,328
Loans payable	$	10,107,205	$	-	$	-	$	10,107,205	$	10,107,205
Loans payable - related parties	$	1,360,806	$	-	$	-	$	-	$	-
Patent acquisition liability	$	1,010,000	$	-	$	-	$	1,010,000	$	1,010,000
Convertible notes payable	$	5,143,647	$	-	$	-	$	5,534,810	$	5,534,810
Convertible notes payable - related parties	$	2,538,681	$	-	$	-	$	-	$	-

XML 47 R36.htm IDEA: XBRL DOCUMENT

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) - AstralENERGY [Member]	Jul. 31, 2018 shares
Sale of Stock, Percentage of Ownership after Transaction	70.00%
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	2,500,000

XML 48 R37.htm IDEA: XBRL DOCUMENT

Note 3 - Going Concern Uncertainty / Management Plans (Details Textual) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Retained Earnings (Accumulated Deficit), Ending Balance	$ (36,897,830)	$ (35,655,053)

XML 49 R38.htm IDEA: XBRL DOCUMENT

Note 4 - Property, Plant and Improvements, Net (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Depreciation, Total	$ 4,596	$ 442

XML 50 R39.htm IDEA: XBRL DOCUMENT

Note 4 - Property, Plant and Improvements, Net - Property, Plant and Improvement Placed in Service (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Accumulated depreciation and amortization	$ (21,918)	$ (17,322)
Net property, plant and improvements	161,913	166,509
Leasehold Improvements [Member]
Property, plant and equipment, gross	166,163	166,163
Furniture and Equipment [Member]
Property, plant and equipment, gross	$ 17,668	$ 17,668

XML 51 R40.htm IDEA: XBRL DOCUMENT

Note 5 - Advances to CEN Biotech Ukraine (Details Textual) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
CEN Biotech Ukraine [Member]
Payments to Fund Long-term Loans to Related Parties	$ 905,328	$ 875,328

XML 52 R41.htm IDEA: XBRL DOCUMENT

Note 6 - Intangible Assets (Details Textual) - USD ($)		1 Months Ended	3 Months Ended		7 Months Ended	12 Months Ended
Note 6 - Intangible Assets (Details Textual) - USD ($)	Sep. 12, 2016	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018	Sep. 30, 2018	Dec. 31, 2018
Stock Issued During Period, Value, Purchase of Assets		$ 5,000,000
Development of Acquired Technology, Annual Compensation for Specialist	$ 200,000
Noncash or Part Noncash Acquisition, Noncash Consideration, Liability Incurred		4,380,000		$ 4,380,000
Contingent Consideration Classified as Equity, Fair Value Disclosure			1,010,000			$ 1,010,000
Impairment of Real Estate			$ 0			$ 0
Finite-Lived Intangible Asset, Useful Life			16 years
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months			$ 424,812
Finite-Lived Intangible Assets, Amortization Expense, After Year Thirteen			$ 283,215
Adjustments to Additional Paid in Capital, Patent Acquisition Liability Modification		$ 4,380,000		$ 4,380,000
Tesla Digital [Member]
Stock Issued During Period, Shares, Purchase of Assets					1,000,000
Patented Technology [Member]
Stock Issued During Period, Value, Purchase of Assets	5,000,000
Noncash or Part Noncash Acquisition, Noncash Consideration, Carrying Value of Properties to be Transferred	2,161,467
Noncash or Part Noncash Acquisition, Noncash Consideration, Original Cost of Property Transferred	$ 202,666

XML 53 R42.htm IDEA: XBRL DOCUMENT

Note 6 - Intangible Assets - Intangible Assets (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Lighting patent	$ 6,797,000	$ 6,797,000
Accumulated amortization	(1,097,432)	(991,229)
Net	$ 5,699,568	$ 5,805,771

XML 54 R43.htm IDEA: XBRL DOCUMENT

Note 7 - Loans Payable (Details Textual) - USD ($)	3 Months Ended
Note 7 - Loans Payable (Details Textual) - USD ($)	Mar. 31, 2019	Mar. 31, 2018
Debt Instrument, Debt Default, Amount	$ 9,675,000
Equipment Pledged as Collateral	9,000
Stock Issued During Period, Value, New Issues	$ 45,450	$ 26,908
Individual Lenders [Member]
Stock Issued During Period, Shares, New Issues	18,000	16,400
Stock Issued During Period, Value, New Issues	$ 18,180	$ 10,168

XML 55 R44.htm IDEA: XBRL DOCUMENT

Note 7 - Loans Payable - Loans Payable (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Loans payable	$ 10,113,095	$ 10,107,205
Short-term Loan Payable to Global Holdings International, LLC [Member]
Loans payable	9,675,000	9,675,000
Short-term Mortgage Payable to ARG & Pals, Inc. [Member]
Loans payable	288,095	282,205
Short-term Loan Payable to an Individual [Member]
Loans payable	50,000	50,000
Second Short-term Loan Payable to an Individual [Member]
Loans payable	$ 100,000	$ 100,000

XML 56 R45.htm IDEA: XBRL DOCUMENT

Note 7 - Loans Payable - Loans Payable (Details) (Parentheticals) - CAD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Short-term Loan Payable to Global Holdings International, LLC [Member]
Interest Rate	15.00%	15.00%
Maturity Date	Jun. 30, 2016	Jun. 30, 2016
Short-term Mortgage Payable to ARG & Pals, Inc. [Member]
Interest Rate	22.00%	22.00%
Maturity Date	Nov. 21, 2018	Nov. 21, 2018
Original Amount	$ 385,000	$ 385,000
Short-term Loan Payable to an Individual [Member]
Maturity Date	Apr. 16, 2019	Apr. 16, 2019
Share Interest (in shares)	2,000	2,000
Second Short-term Loan Payable to an Individual [Member]
Maturity Date	Apr. 16, 2019	Apr. 16, 2019
Share Interest (in shares)	4,000	4,000

XML 57 R46.htm IDEA: XBRL DOCUMENT

Note 8 - Loans Payable - Related Party (Details Textual) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Interest Expense, Related Party	$ 113,213	$ 104,286
Stock Issued During Period, Value, New Issues	$ 45,450	$ 26,908
Related Parties Lenders [Member]
Stock Issued During Period, Shares, New Issues	27,000	27,000
Stock Issued During Period, Value, New Issues	$ 27,270	$ 16,740
Loans Payable to Related Party [Member]
Interest Payable, Related Party	384,187		$ 357,373
Interest Expense, Related Party	$ 26,814		$ 43,042

XML 58 R47.htm IDEA: XBRL DOCUMENT

Note 8 - Loans Payable - Related Party - Loans Payable to Related Parties (Details) - Loans Payable to Related Party [Member] - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Long-term Debt	$ 1,361,550	$ 1,360,806
Less: current portion	1,361,550	1,360,806
Long-term portion loans payable - related party
Bill Chaaban, President of Cen Biotech [Member]
Long-term Debt	235,050	234,306
Creative Edge [Member]
Long-term Debt	601,500	601,500
R&D Labs Canada, Inc [Member]
Long-term Debt	300,000	300,000
Spouse of Joseph Byrne, CEO of CEN Biotech [Member]
Long-term Debt	100,000	100,000
Director, Alex Tarrabain [Member]
Long-term Debt	75,000	75,000
Joseph Byrne [Member]
Long-term Debt	$ 50,000	$ 50,000

XML 59 R48.htm IDEA: XBRL DOCUMENT

Note 8 - Loans Payable - Related Party - Loans Payable to Related Parties (Details) (Parentheticals) - Loans Payable to Related Party [Member] - shares	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Bill Chaaban, President of Cen Biotech [Member]
Interest Rate	10.00%	10.00%
Maturity Date	Dec. 31, 2018	Dec. 31, 2018
Creative Edge [Member]
Interest Rate	10.00%	10.00%
Maturity Date	Dec. 31, 2018	Dec. 31, 2018
R&D Labs Canada, Inc [Member]
Interest Rate	8.00%	8.00%
Maturity Date	Oct. 02, 2019	Oct. 02, 2019
Spouse of Joseph Byrne, CEO of CEN Biotech [Member]
Maturity Date	Mar. 16, 2019	Mar. 16, 2019
Share Interest (in shares)	4,000	4,000
Director, Alex Tarrabain [Member]
Maturity Date	May 16, 2019	May 16, 2019
Share Interest (in shares)	3,000	3,000
Joseph Byrne [Member]
Maturity Date	May 16, 2019	May 16, 2019
Share Interest (in shares)	2,000	2,000

XML 60 R49.htm IDEA: XBRL DOCUMENT

Note 9 - Convertible Notes (Details Textual)		3 Months Ended
Note 9 - Convertible Notes (Details Textual)	May 20, 2019 USD ($)	Mar. 31, 2019
Convertible Debt [Member]
Debt Instrument, Convertible, Number of Equity Instruments		3,111,523
Convertible Debt in Default [Member] \| Subsequent Event [Member]
Debt Instrument, Convertible, Number of Equity Instruments	834,277
Convertible Debt, Total	$ 1,329,287

XML 61 R50.htm IDEA: XBRL DOCUMENT

Note 9 - Convertible Notes - Convertible Notes (Details) - Convertible Debt [Member] - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Long-term Debt	$ 5,307,584	$ 5,143,647
Less: current portion	4,190,461	3,597,760
Long-term portion loans payable - related party	1,117,123	1,545,887
Convertible Notes 1[Member]
Long-term Debt	826,657	809,755
Convertible Notes 2 [Member]
Long-term Debt	$ 4,480,927	$ 4,333,892

XML 62 R51.htm IDEA: XBRL DOCUMENT

Note 9 - Convertible Notes - Convertible Notes (Details) (Parentheticals)	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Convertible Notes 1[Member]
Interest Rate	7.00%	7.00%
Conversion Rights	335,833	335,833
Convertible Notes 2 [Member]
Interest Rate	5.00%	5.00%
Conversion Rights	2,775,690	2,775,690
Maturing Dates Range	May 2018 and March 2021	May 2018 and March 2021

XML 63 R52.htm IDEA: XBRL DOCUMENT

Note 10 - Convertible Notes - Related Party (Details Textual)		3 Months Ended
	May 20, 2019 USD ($)	Mar. 31, 2019 USD ($)	Mar. 31, 2018 USD ($)	Dec. 31, 2018 USD ($)
Interest Expense, Related Party		$ 113,213	$ 104,286
Convertible Debt Payable to Related Party [Member]
Interest Payable, Related Party		647,984		$ 588,854
Interest Expense, Related Party		$ 59,129	$ 61,244
Debt Instrument, Convertible, Number of Equity Instruments		1,586,676
Convertible Debt Payable to Related Party [Member] \| Subsequent Event [Member]
Convertible Debt, Total	$ 926,368
Convertible Debt to Related Party in Default [Member] \| Subsequent Event [Member]
Debt Instrument, Convertible, Number of Equity Instruments	578,980

XML 64 R53.htm IDEA: XBRL DOCUMENT

Note 10 - Convertible Notes - Related Party - Convertible Notes Payable to Related Parties (Details) - Convertible Debt Payable to Related Party [Member] - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Long-term Debt	$ 2,538,681	$ 2,538,681
Less: current portion	926,368	926,368
Long-term portion loans payable - related party	1,612,313	1,612,313
Bill Chaaban, President of Cen Biotech [Member]
Long-term Debt	1,388,122	1,388,122
Director, Harold Aubrey de Lavenu [Member]
Long-term Debt	878,368	878,368
Director, Alex Tarrabain [Member]
Long-term Debt	48,000	48,000
Joseph Byrne [Member]
Long-term Debt	$ 224,191	$ 224,191

XML 65 R54.htm IDEA: XBRL DOCUMENT

Note 10 - Convertible Notes - Related Party - Convertible Notes Payable to Related Parties (Details) (Parentheticals) - Convertible Debt Payable to Related Party [Member]	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Conversion Rights	1,586,676
Bill Chaaban, President of Cen Biotech [Member]
Interest Rate	12.00%	12.00%
Conversion Rights	867,576	867,576
Maturing Dates	Aug. 17, 2020	Aug. 17, 2020
Director, Harold Aubrey de Lavenu [Member]
Interest Rate	5.00%	5.00%
Conversion Rights	548,980	548,980
Maturing Dates	Mar. 31, 2019	Mar. 31, 2019
Director, Alex Tarrabain [Member]
Interest Rate	5.00%	5.00%
Conversion Rights	30,000	30,000
Maturing Dates	Mar. 31, 2019	Mar. 31, 2019
Joseph Byrne [Member]
Interest Rate	12.00%	12.00%
Conversion Rights	140,120	140,120
Maturing Dates	Aug. 17, 2020	Aug. 17, 2020

XML 66 R55.htm IDEA: XBRL DOCUMENT

Note 11 - Income Taxes (Details Textual) - USD ($)	3 Months Ended
Note 11 - Income Taxes (Details Textual) - USD ($)	Mar. 31, 2019	Mar. 31, 2018
Operating Loss Carryforwards, Total	$ 37,800,000
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$ 300,000	$ 400,000
Domestic Tax Authority [Member] \| Canada Revenue Agency [Member]
Open Tax Year	2015 2016 2017 2018

XML 67 R56.htm IDEA: XBRL DOCUMENT

Note 11 - Income Taxes - Reconciliation of Effective Tax Rate (Details)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Income tax benefit at Canadian statutory rate	26.50%	26.50%
Valuation allowance	(26.50%)	(26.50%)
Effective income tax rate	0.00%	0.00%

XML 68 R57.htm IDEA: XBRL DOCUMENT

Note 11 - Income Taxes - Deferred Tax Assets (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Deferred tax asset - net operating losses	$ 10,000,000	$ 9,700,000
Deferred tax asset valuation allowance	(10,000,000)	(9,700,000)
Net deferred tax asset

XML 69 R58.htm IDEA: XBRL DOCUMENT

Note 12 - Shareholders' Deficit / Stock Activity (Details Textual) - $ / shares $ / shares in Thousands	Mar. 31, 2019	Dec. 31, 2018
Common Stock, No Par Value	$ 0	$ 0
Convertible Debt [Member]
Common Stock, Capital Shares Reserved for Future Issuance	4,698,199

XML 70 R59.htm IDEA: XBRL DOCUMENT

Note 13 - Related Party Transactions (Details Textual)				1 Months Ended	3 Months Ended		12 Months Ended
Note 13 - Related Party Transactions (Details Textual)	Sep. 01, 2022 CAD ($)	Oct. 01, 2017 CAD ($)	Sep. 01, 2013 USD ($)	Jan. 31, 2017 CAD ($)	Mar. 31, 2019 USD ($) a	Mar. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	May 20, 2019	Dec. 31, 2018 USD ($)	Dec. 03, 2017	Dec. 02, 2017	Jul. 12, 2017	Jan. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)
Operating Lease, Right-of-Use Asset					$ 251,110
Operating Lease, Weighted Average Remaining Lease Term					6 years 292 days
Operating Lease, Weighted Average Discount Rate, Percent					8.00%
General and Administrative Expense [Member]
Operating Lease, Expense					$ 19,562	$ 22,883
Lease Arrangement, 20 North Rear Road [Member]
Area of Land \| a					10.4
Operating Lease Annual Rent			$ 339,000
Accrued Rent														$ 552,934
Operating Lease, Monthly Rent				$ 4,000
Lessee, Operating Lease, Term of Contract													5 years
Operating Lease, Right-of-Use Asset					$ 88,992
Operating Lease, Liability, Total					$ 85,998
Lessee, Operating Lease, Discount Rate					8.00%
Leases Office Space from R&D Labs Canada, Inc [Member]
Operating Lease, Monthly Rent	$ 3,390	$ 2,608
Operating Lease, Right-of-Use Asset					$ 162,118
Operating Lease, Liability, Total					$ 165,523
Lessee, Operating Lease, Discount Rate					8.00%
Operating Lease, Expense					$ 9,259	6,068
Long-term Convertible Notes Payable to Multiple Private Investors [Member]
Debt Instrument, Interest Rate, Stated Percentage												5.00%
Convertible Debt Issued to Lessor's Creditor [Member]
Convertible Debt, Total													$ 824,446
CEN Biotech Ukraine [Member] \| Forecast [Member]
Business Acquisition, Percentage of Voting Interests Acquired								51.00%
CEN Biotech Ukraine [Member]
Due from Related Parties, Total					905,328				875,328
Percentage of Related Party's Equity Interest Owned by Director										25.50%	51.00%
CEN Biotech Ukraine [Member] \| Equipment Sold to Related Party in Exchange for Note Receivable [Member]
Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings							$ 255,141
Notes Receivable, Related Parties							44,859
Board Members and Officers [Member] \| Consulting Fees [Member]
Related Party Transaction, Amounts of Transaction					31,200	$ 31,200
Due to Related Parties, Total					$ 156,000				$ 124,800
R&D Labs Canada, Inc [Member] \| Purchased Equipment in Exchange for Note Payable [Member]
Notes Payable, Related Parties							$ 300,000

XML 71 R60.htm IDEA: XBRL DOCUMENT

Note 14 - Stock Based Compensation (Details Textual) - USD ($)					3 Months Ended		12 Months Ended	24 Months Ended
	Dec. 31, 2018	Jun. 19, 2018	Jun. 07, 2018	Nov. 30, 2017	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Nov. 29, 2017
Stock Issued During Period, Shares, Issued for Services	12,120	125,000
President [Member]
Employment Agreement, Base Annual Salary				$ 31,200
Employment Agreement, Compensation, Shares of Restricted Stock				8,750,000
President [Member] \| Vested Immediately [Member]
Employment Agreement, Compensation, Shares of Restricted Stock				7,400,000
Chief Executive Officer [Member]
Employment Agreement, Base Annual Salary				$ 31,200
Employment Agreement, Compensation, Shares of Restricted Stock				1,250,000
Chief Executive Officer [Member] \| Vested Immediately [Member]
Employment Agreement, Compensation, Shares of Restricted Stock				325,000
Senior Executive Vice President and Chief Financial Officer [Member]
Employment Agreement, Base Annual Salary				$ 31,200
Employment Agreement, Compensation, Shares of Restricted Stock				4,500,000
Senior Executive Vice President and Chief Financial Officer [Member] \| Vested Immediately [Member]
Employment Agreement, Compensation, Shares of Restricted Stock				4,140,000
Vice President [Member]
Employment Agreement, Base Annual Salary				$ 31,200
Employment Agreement, Compensation, Shares of Restricted Stock				750,000
Vice President [Member] \| Vested Immediately [Member]
Employment Agreement, Compensation, Shares of Restricted Stock				300,000
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period					0	0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period					337,500	337,500	14,317,500
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grant DateFair Value								$ 11,435,741
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance	2,612,500				2,275,000	3,625,000	3,962,500	2,612,500
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period							3 years
Share-based Payment Arrangement, Expense					$ 167,400	$ 167,400
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value					340,875	$ 209,250
Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount					$ 1,131,500
Restricted Stock [Member] \| Vesting Pro-rate Over the Requisite Service Period [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance							3,962,500
Restricted Stock [Member] \| President [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period				20,000
Restricted Stock [Member] \| Director,Donald Strilchuck [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period				20,000
Restricted Stock [Member] \| Director Usamakh Saadikh [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period			20,000
Restricted Stock [Member] \| Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period				20,000
Restricted Stock [Member] \| Senior Executive Vice President and Chief Financial Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period				20,000
Restricted Stock [Member] \| Vice President [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period				20,000
Restricted Stock [Member] \| Director, Harold Aubrey de Lavenu [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period				20,000
Restricted Stock [Member] \| Director, Alex Tarrabain [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period				20,000
Restricted Stock [Member] \| Director, Ameen Ferris [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period				20,000
Restricted Shares Issued for Security Consulting Services [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period				1,870,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period				1,330,000
Restricted Shares Issued for Security Consulting Services [Member] \| Director,Donald Strilchuck [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period				1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period				550,000
2017 Equity Compensation Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance									20,000,000

XML 72 R61.htm IDEA: XBRL DOCUMENT

Note 14 - Stock Based Compensation - Restricted Stock Award Activity (Details) - Restricted Stock [Member] - $ / shares	3 Months Ended		12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	Dec. 31, 2017
Non-vested, number of share (in shares)	2,612,500	3,962,500	3,962,500
Non-vested, weighted average grant date fair value (in dollars per share)	$ 0.62	$ 0.62	$ 0.62
Non-vested, weighted average remaining contractual term (Year)	1 year 273 days	2 years 273 days	2 years	2 years 335 days
Granted, number of share (in shares)	0	0
Granted, weighted average grant date fair value (in dollars per share)
Vested, number of share (in shares)	(337,500)	(337,500)		(14,317,500)
Vested, weighted average grant date fair value (in dollars per share)	$ 0.62	$ 0.62
Forfeited, number of share (in shares)
Forfeited, weighted average grant date fair value (in dollars per share)
Non-vested, number of share (in shares)	2,275,000	3,625,000	2,612,500	3,962,500
Non-vested, weighted average grant date fair value (in dollars per share)	$ 0.62	$ 0.62	$ 0.62	$ 0.62

XML 73 R62.htm IDEA: XBRL DOCUMENT

Note 15 - Net Loss Per Share - Antidilutive Securities (Details) - shares	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Convertible Debt Securities [Member]
Antidilutive Securities (in shares)	4,628,234	3,919,160

XML 74 R63.htm IDEA: XBRL DOCUMENT

Note 17 - Fair Value Disclosures - Fair Value of Financial Instruments (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Reported Value Measurement [Member]
Cash and cash equivalents	$ 39,752	$ 3,193
Other receivables	417,904	418,905
Note receivable - related party	44,859	44,859
Advances to CEN Biotech Ukraine, LLC - related party	905,328	875,328
Loans payable	10,113,095	10,107,205
Loans payable - related parties	1,361,550	1,360,806
Patent acquisition liability	1,010,000	1,010,000
Convertible notes payable	5,307,584	5,143,647
Convertible notes payable - related parties	2,538,681	2,538,681
Estimate of Fair Value Measurement [Member]
Cash and cash equivalents	39,752	3,193
Other receivables	417,904	418,905
Note receivable - related party	44,859	44,859
Advances to CEN Biotech Ukraine, LLC - related party	905,328	875,328
Loans payable	10,113,095	10,107,205
Loans payable - related parties
Patent acquisition liability	1,010,000	1,010,000
Convertible notes payable	5,768,525	5,534,810
Convertible notes payable - related parties
Estimate of Fair Value Measurement [Member] \| Fair Value, Inputs, Level 1 [Member]
Cash and cash equivalents
Other receivables
Note receivable - related party
Advances to CEN Biotech Ukraine, LLC - related party
Loans payable
Loans payable - related parties
Patent acquisition liability
Convertible notes payable
Convertible notes payable - related parties
Estimate of Fair Value Measurement [Member] \| Fair Value, Inputs, Level 2 [Member]
Cash and cash equivalents	39,752	3,193
Other receivables
Note receivable - related party
Advances to CEN Biotech Ukraine, LLC - related party
Loans payable
Loans payable - related parties
Patent acquisition liability
Convertible notes payable
Convertible notes payable - related parties
Estimate of Fair Value Measurement [Member] \| Fair Value, Inputs, Level 3 [Member]
Cash and cash equivalents
Other receivables	417,904	418,905
Note receivable - related party	44,859	44,859
Advances to CEN Biotech Ukraine, LLC - related party	905,328	875,328
Loans payable	10,113,095	10,107,205
Loans payable - related parties
Patent acquisition liability	1,010,000	1,010,000
Convertible notes payable	5,768,525	5,534,810
Convertible notes payable - related parties

XML 75 R64.htm IDEA: XBRL DOCUMENT

Note 18 - Subsequent Event (Details Textual) - USD ($)		12 Months Ended
Note 18 - Subsequent Event (Details Textual) - USD ($)	May 16, 2019	Dec. 31, 2017
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		3 years
Subsequent Event [Member] \| Vice President and Chief Financial Officer [Member]
Employment Agreement, Compensation, Shares of Common Stock	1,250,000
Employment Agreement, Base Annual Salary	$ 31,200
Subsequent Event [Member] \| Vice President and Chief Financial Officer [Member] \| Share-based Payment Arrangement, Tranche One [Member]
Employment Agreement, Compensation, Shares of Restricted Stock	350,000
Subsequent Event [Member] \| Vice President and Chief Financial Officer [Member] \| Share-based Payment Arrangement, Tranche Two [Member]
Employment Agreement, Compensation, Shares of Restricted Stock	900,000
Subsequent Event [Member] \| Vice President and Chief Financial Officer [Member] \| Share-based Payment Arrangement, Tranche Two [Member] \| Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	3 years
Subsequent Event [Member] \| Vice President and Chief Financial Officer [Member] \| Vesting One Month After Grant [Member]
Employment Agreement, Compensation, Shares of Restricted Stock	25,000
Subsequent Event [Member] \| Vice President and Chief Financial Officer [Member] \| Vesting One Month After Grant [Member] \| Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	30 days
Subsequent Event [Member] \| Vice President and Chief Financial Officer [Member] \| Vesting at The End of Each One Month Anniversary of rant Date [Member]
Employment Agreement, Compensation, Shares of Restricted Stock	25,000

EXCEL 76 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 77 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 78 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 79 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.1 html 202 211 1 false 68 0 false 6 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.cenbiotechinc.com/20190331/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) Sheet http://www.cenbiotechinc.com/20190331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited Condensed Consolidated Balance Sheets (Current Period Unaudited) Statements 2 false false R3.htm 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Sheet http://www.cenbiotechinc.com/20190331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://www.cenbiotechinc.com/20190331/role/statement-condensed-consolidated-statements-of-operations-unaudited Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Consolidated Statements of Shareholders' Deficit (Unaudited) Sheet http://www.cenbiotechinc.com/20190331/role/statement-condensed-consolidated-statements-of-shareholders-deficit-unaudited Condensed Consolidated Statements of Shareholders' Deficit (Unaudited) Statements 5 false false R6.htm 005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.cenbiotechinc.com/20190331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 006 - Disclosure - Note 1 - Basis of Presentation and Summary of Significant Accounting Policies Sheet http://www.cenbiotechinc.com/20190331/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies Note 1 - Basis of Presentation and Summary of Significant Accounting Policies Notes 7 false false R8.htm 007 - Disclosure - Note 2 - New Accounting Standard Sheet http://www.cenbiotechinc.com/20190331/role/statement-note-2-new-accounting-standard Note 2 - New Accounting Standard Notes 8 false false R9.htm 008 - Disclosure - Note 3 - Going Concern Uncertainty / Management Plans Sheet http://www.cenbiotechinc.com/20190331/role/statement-note-3-going-concern-uncertainty-management-plans Note 3 - Going Concern Uncertainty / Management Plans Notes 9 false false R10.htm 009 - Disclosure - Note 4 - Property, Plant and Improvements, Net Sheet http://www.cenbiotechinc.com/20190331/role/statement-note-4-property-plant-and-improvements-net Note 4 - Property, Plant and Improvements, Net Notes 10 false false R11.htm 010 - Disclosure - Note 5 - Advances to CEN Biotech Ukraine Sheet http://www.cenbiotechinc.com/20190331/role/statement-note-5-advances-to-cen-biotech-ukraine Note 5 - Advances to CEN Biotech Ukraine Notes 11 false false R12.htm 011 - Disclosure - Note 6 - Intangible Assets Sheet http://www.cenbiotechinc.com/20190331/role/statement-note-6-intangible-assets Note 6 - Intangible Assets Notes 12 false false R13.htm 012 - Disclosure - Note 7 - Loans Payable Sheet http://www.cenbiotechinc.com/20190331/role/statement-note-7-loans-payable Note 7 - Loans Payable Notes 13 false false R14.htm 013 - Disclosure - Note 8 - Loans Payable - Related Party Sheet http://www.cenbiotechinc.com/20190331/role/statement-note-8-loans-payable-related-party Note 8 - Loans Payable - Related Party Notes 14 false false R15.htm 014 - Disclosure - Note 9 - Convertible Notes Notes http://www.cenbiotechinc.com/20190331/role/statement-note-9-convertible-notes Note 9 - Convertible Notes Notes 15 false false R16.htm 015 - Disclosure - Note 10 - Convertible Notes - Related Party Notes http://www.cenbiotechinc.com/20190331/role/statement-note-10-convertible-notes-related-party Note 10 - Convertible Notes - Related Party Notes 16 false false R17.htm 016 - Disclosure - Note 11 - Income Taxes Sheet http://www.cenbiotechinc.com/20190331/role/statement-note-11-income-taxes Note 11 - Income Taxes Notes 17 false false R18.htm 017 - Disclosure - Note 12 - Shareholders' Deficit / Stock Activity Sheet http://www.cenbiotechinc.com/20190331/role/statement-note-12-shareholders-deficit-stock-activity Note 12 - Shareholders' Deficit / Stock Activity Notes 18 false false R19.htm 018 - Disclosure - Note 13 - Related Party Transactions Sheet http://www.cenbiotechinc.com/20190331/role/statement-note-13-related-party-transactions Note 13 - Related Party Transactions Notes 19 false false R20.htm 019 - Disclosure - Note 14 - Stock Based Compensation Sheet http://www.cenbiotechinc.com/20190331/role/statement-note-14-stock-based-compensation Note 14 - Stock Based Compensation Notes 20 false false R21.htm 020 - Disclosure - Note 15 - Net Loss Per Share Sheet http://www.cenbiotechinc.com/20190331/role/statement-note-15-net-loss-per-share Note 15 - Net Loss Per Share Notes 21 false false R22.htm 021 - Disclosure - Note 16 - Contingency Sheet http://www.cenbiotechinc.com/20190331/role/statement-note-16-contingency Note 16 - Contingency Notes 22 false false R23.htm 022 - Disclosure - Note 17 - Fair Value Disclosures Sheet http://www.cenbiotechinc.com/20190331/role/statement-note-17-fair-value-disclosures Note 17 - Fair Value Disclosures Notes 23 false false R24.htm 023 - Disclosure - Note 18 - Subsequent Event Sheet http://www.cenbiotechinc.com/20190331/role/statement-note-18-subsequent-event Note 18 - Subsequent Event Notes 24 false false R25.htm 024 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.cenbiotechinc.com/20190331/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://www.cenbiotechinc.com/20190331/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies 25 false false R26.htm 025 - Disclosure - Note 4 - Property, Plant and Improvements, Net (Tables) Sheet http://www.cenbiotechinc.com/20190331/role/statement-note-4-property-plant-and-improvements-net-tables Note 4 - Property, Plant and Improvements, Net (Tables) Tables http://www.cenbiotechinc.com/20190331/role/statement-note-4-property-plant-and-improvements-net 26 false false R27.htm 026 - Disclosure - Note 6 - Intangible Assets (Tables) Sheet http://www.cenbiotechinc.com/20190331/role/statement-note-6-intangible-assets-tables Note 6 - Intangible Assets (Tables) Tables http://www.cenbiotechinc.com/20190331/role/statement-note-6-intangible-assets 27 false false R28.htm 027 - Disclosure - Note 7 - Loans Payable (Tables) Sheet http://www.cenbiotechinc.com/20190331/role/statement-note-7-loans-payable-tables Note 7 - Loans Payable (Tables) Tables http://www.cenbiotechinc.com/20190331/role/statement-note-7-loans-payable 28 false false R29.htm 028 - Disclosure - Note 8 - Loans Payable - Related Party (Tables) Sheet http://www.cenbiotechinc.com/20190331/role/statement-note-8-loans-payable-related-party-tables Note 8 - Loans Payable - Related Party (Tables) Tables http://www.cenbiotechinc.com/20190331/role/statement-note-8-loans-payable-related-party 29 false false R30.htm 029 - Disclosure - Note 9 - Convertible Notes (Tables) Notes http://www.cenbiotechinc.com/20190331/role/statement-note-9-convertible-notes-tables Note 9 - Convertible Notes (Tables) Tables http://www.cenbiotechinc.com/20190331/role/statement-note-9-convertible-notes 30 false false R31.htm 030 - Disclosure - Note 10 - Convertible Notes - Related Party (Tables) Notes http://www.cenbiotechinc.com/20190331/role/statement-note-10-convertible-notes-related-party-tables Note 10 - Convertible Notes - Related Party (Tables) Tables http://www.cenbiotechinc.com/20190331/role/statement-note-10-convertible-notes-related-party 31 false false R32.htm 031 - Disclosure - Note 11 - Income Taxes (Tables) Sheet http://www.cenbiotechinc.com/20190331/role/statement-note-11-income-taxes-tables Note 11 - Income Taxes (Tables) Tables http://www.cenbiotechinc.com/20190331/role/statement-note-11-income-taxes 32 false false R33.htm 032 - Disclosure - Note 14 - Stock Based Compensation (Tables) Sheet http://www.cenbiotechinc.com/20190331/role/statement-note-14-stock-based-compensation-tables Note 14 - Stock Based Compensation (Tables) Tables http://www.cenbiotechinc.com/20190331/role/statement-note-14-stock-based-compensation 33 false false R34.htm 033 - Disclosure - Note 15 - Net Loss Per Share (Tables) Sheet http://www.cenbiotechinc.com/20190331/role/statement-note-15-net-loss-per-share-tables Note 15 - Net Loss Per Share (Tables) Tables http://www.cenbiotechinc.com/20190331/role/statement-note-15-net-loss-per-share 34 false false R35.htm 034 - Disclosure - Note 17 - Fair Value Disclosures (Tables) Sheet http://www.cenbiotechinc.com/20190331/role/statement-note-17-fair-value-disclosures-tables Note 17 - Fair Value Disclosures (Tables) Tables http://www.cenbiotechinc.com/20190331/role/statement-note-17-fair-value-disclosures 35 false false R36.htm 035 - Disclosure - Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) Sheet http://www.cenbiotechinc.com/20190331/role/statement-note-1-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) Details 36 false false R37.htm 036 - Disclosure - Note 3 - Going Concern Uncertainty / Management Plans (Details Textual) Sheet http://www.cenbiotechinc.com/20190331/role/statement-note-3-going-concern-uncertainty-management-plans-details-textual Note 3 - Going Concern Uncertainty / Management Plans (Details Textual) Details http://www.cenbiotechinc.com/20190331/role/statement-note-3-going-concern-uncertainty-management-plans 37 false false R38.htm 037 - Disclosure - Note 4 - Property, Plant and Improvements, Net (Details Textual) Sheet http://www.cenbiotechinc.com/20190331/role/statement-note-4-property-plant-and-improvements-net-details-textual Note 4 - Property, Plant and Improvements, Net (Details Textual) Details http://www.cenbiotechinc.com/20190331/role/statement-note-4-property-plant-and-improvements-net-tables 38 false false R39.htm 038 - Disclosure - Note 4 - Property, Plant and Improvements, Net - Property, Plant and Improvement Placed in Service (Details) Sheet http://www.cenbiotechinc.com/20190331/role/statement-note-4-property-plant-and-improvements-net-property-plant-and-improvement-placed-in-service-details Note 4 - Property, Plant and Improvements, Net - Property, Plant and Improvement Placed in Service (Details) Details 39 false false R40.htm 039 - Disclosure - Note 5 - Advances to CEN Biotech Ukraine (Details Textual) Sheet http://www.cenbiotechinc.com/20190331/role/statement-note-5-advances-to-cen-biotech-ukraine-details-textual Note 5 - Advances to CEN Biotech Ukraine (Details Textual) Details http://www.cenbiotechinc.com/20190331/role/statement-note-5-advances-to-cen-biotech-ukraine 40 false false R41.htm 040 - Disclosure - Note 6 - Intangible Assets (Details Textual) Sheet http://www.cenbiotechinc.com/20190331/role/statement-note-6-intangible-assets-details-textual Note 6 - Intangible Assets (Details Textual) Details http://www.cenbiotechinc.com/20190331/role/statement-note-6-intangible-assets-tables 41 false false R42.htm 041 - Disclosure - Note 6 - Intangible Assets - Intangible Assets (Details) Sheet http://www.cenbiotechinc.com/20190331/role/statement-note-6-intangible-assets-intangible-assets-details Note 6 - Intangible Assets - Intangible Assets (Details) Details 42 false false R43.htm 042 - Disclosure - Note 7 - Loans Payable (Details Textual) Sheet http://www.cenbiotechinc.com/20190331/role/statement-note-7-loans-payable-details-textual Note 7 - Loans Payable (Details Textual) Details http://www.cenbiotechinc.com/20190331/role/statement-note-7-loans-payable-tables 43 false false R44.htm 043 - Disclosure - Note 7 - Loans Payable - Loans Payable (Details) Sheet http://www.cenbiotechinc.com/20190331/role/statement-note-7-loans-payable-loans-payable-details Note 7 - Loans Payable - Loans Payable (Details) Details 44 false false R45.htm 044 - Disclosure - Note 7 - Loans Payable - Loans Payable (Details) (Parentheticals) Sheet http://www.cenbiotechinc.com/20190331/role/statement-note-7-loans-payable-loans-payable-details-parentheticals Note 7 - Loans Payable - Loans Payable (Details) (Parentheticals) Details 45 false false R46.htm 045 - Disclosure - Note 8 - Loans Payable - Related Party (Details Textual) Sheet http://www.cenbiotechinc.com/20190331/role/statement-note-8-loans-payable-related-party-details-textual Note 8 - Loans Payable - Related Party (Details Textual) Details http://www.cenbiotechinc.com/20190331/role/statement-note-8-loans-payable-related-party-tables 46 false false R47.htm 046 - Disclosure - Note 8 - Loans Payable - Related Party - Loans Payable to Related Parties (Details) Sheet http://www.cenbiotechinc.com/20190331/role/statement-note-8-loans-payable-related-party-loans-payable-to-related-parties-details Note 8 - Loans Payable - Related Party - Loans Payable to Related Parties (Details) Details 47 false false R48.htm 047 - Disclosure - Note 8 - Loans Payable - Related Party - Loans Payable to Related Parties (Details) (Parentheticals) Sheet http://www.cenbiotechinc.com/20190331/role/statement-note-8-loans-payable-related-party-loans-payable-to-related-parties-details-parentheticals Note 8 - Loans Payable - Related Party - Loans Payable to Related Parties (Details) (Parentheticals) Details 48 false false R49.htm 048 - Disclosure - Note 9 - Convertible Notes (Details Textual) Notes http://www.cenbiotechinc.com/20190331/role/statement-note-9-convertible-notes-details-textual Note 9 - Convertible Notes (Details Textual) Details http://www.cenbiotechinc.com/20190331/role/statement-note-9-convertible-notes-tables 49 false false R50.htm 049 - Disclosure - Note 9 - Convertible Notes - Convertible Notes (Details) Notes http://www.cenbiotechinc.com/20190331/role/statement-note-9-convertible-notes-convertible-notes-details Note 9 - Convertible Notes - Convertible Notes (Details) Details 50 false false R51.htm 050 - Disclosure - Note 9 - Convertible Notes - Convertible Notes (Details) (Parentheticals) Notes http://www.cenbiotechinc.com/20190331/role/statement-note-9-convertible-notes-convertible-notes-details-parentheticals Note 9 - Convertible Notes - Convertible Notes (Details) (Parentheticals) Details 51 false false R52.htm 051 - Disclosure - Note 10 - Convertible Notes - Related Party (Details Textual) Notes http://www.cenbiotechinc.com/20190331/role/statement-note-10-convertible-notes-related-party-details-textual Note 10 - Convertible Notes - Related Party (Details Textual) Details http://www.cenbiotechinc.com/20190331/role/statement-note-10-convertible-notes-related-party-tables 52 false false R53.htm 052 - Disclosure - Note 10 - Convertible Notes - Related Party - Convertible Notes Payable to Related Parties (Details) Notes http://www.cenbiotechinc.com/20190331/role/statement-note-10-convertible-notes-related-party-convertible-notes-payable-to-related-parties-details Note 10 - Convertible Notes - Related Party - Convertible Notes Payable to Related Parties (Details) Details 53 false false R54.htm 053 - Disclosure - Note 10 - Convertible Notes - Related Party - Convertible Notes Payable to Related Parties (Details) (Parentheticals) Notes http://www.cenbiotechinc.com/20190331/role/statement-note-10-convertible-notes-related-party-convertible-notes-payable-to-related-parties-details-parentheticals Note 10 - Convertible Notes - Related Party - Convertible Notes Payable to Related Parties (Details) (Parentheticals) Details 54 false false R55.htm 054 - Disclosure - Note 11 - Income Taxes (Details Textual) Sheet http://www.cenbiotechinc.com/20190331/role/statement-note-11-income-taxes-details-textual Note 11 - Income Taxes (Details Textual) Details http://www.cenbiotechinc.com/20190331/role/statement-note-11-income-taxes-tables 55 false false R56.htm 055 - Disclosure - Note 11 - Income Taxes - Reconciliation of Effective Tax Rate (Details) Sheet http://www.cenbiotechinc.com/20190331/role/statement-note-11-income-taxes-reconciliation-of-effective-tax-rate-details Note 11 - Income Taxes - Reconciliation of Effective Tax Rate (Details) Details 56 false false R57.htm 056 - Disclosure - Note 11 - Income Taxes - Deferred Tax Assets (Details) Sheet http://www.cenbiotechinc.com/20190331/role/statement-note-11-income-taxes-deferred-tax-assets-details Note 11 - Income Taxes - Deferred Tax Assets (Details) Details 57 false false R58.htm 057 - Disclosure - Note 12 - Shareholders' Deficit / Stock Activity (Details Textual) Sheet http://www.cenbiotechinc.com/20190331/role/statement-note-12-shareholders-deficit-stock-activity-details-textual Note 12 - Shareholders' Deficit / Stock Activity (Details Textual) Details http://www.cenbiotechinc.com/20190331/role/statement-note-12-shareholders-deficit-stock-activity 58 false false R59.htm 058 - Disclosure - Note 13 - Related Party Transactions (Details Textual) Sheet http://www.cenbiotechinc.com/20190331/role/statement-note-13-related-party-transactions-details-textual Note 13 - Related Party Transactions (Details Textual) Details http://www.cenbiotechinc.com/20190331/role/statement-note-13-related-party-transactions 59 false false R60.htm 059 - Disclosure - Note 14 - Stock Based Compensation (Details Textual) Sheet http://www.cenbiotechinc.com/20190331/role/statement-note-14-stock-based-compensation-details-textual Note 14 - Stock Based Compensation (Details Textual) Details http://www.cenbiotechinc.com/20190331/role/statement-note-14-stock-based-compensation-tables 60 false false R61.htm 060 - Disclosure - Note 14 - Stock Based Compensation - Restricted Stock Award Activity (Details) Sheet http://www.cenbiotechinc.com/20190331/role/statement-note-14-stock-based-compensation-restricted-stock-award-activity-details Note 14 - Stock Based Compensation - Restricted Stock Award Activity (Details) Details 61 false false R62.htm 061 - Disclosure - Note 15 - Net Loss Per Share - Antidilutive Securities (Details) Sheet http://www.cenbiotechinc.com/20190331/role/statement-note-15-net-loss-per-share-antidilutive-securities-details Note 15 - Net Loss Per Share - Antidilutive Securities (Details) Details 62 false false R63.htm 062 - Disclosure - Note 17 - Fair Value Disclosures - Fair Value of Financial Instruments (Details) Sheet http://www.cenbiotechinc.com/20190331/role/statement-note-17-fair-value-disclosures-fair-value-of-financial-instruments-details Note 17 - Fair Value Disclosures - Fair Value of Financial Instruments (Details) Details 63 false false R64.htm 063 - Disclosure - Note 18 - Subsequent Event (Details Textual) Sheet http://www.cenbiotechinc.com/20190331/role/statement-note-18-subsequent-event-details-textual Note 18 - Subsequent Event (Details Textual) Details http://www.cenbiotechinc.com/20190331/role/statement-note-18-subsequent-event 64 false false All Reports Book All Reports cenb-20190331.xml cenb-20190331.xsd cenb-20190331_cal.xml cenb-20190331_def.xml cenb-20190331_lab.xml cenb-20190331_pre.xml http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/srt/2019-01-31 true true ZIP 81 0001437749-19-010466-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-19-010466-xbrl.zip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end